[{"id": 10000, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.adcetris", "type": "Document", "subtype": "Regulatory approval", "name": "Adcetris (brentuximab vedotin) [product information]. EMA.", "citation": "Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Adcetris", "drug_name_generic": "brentuximab vedotin", "first_published": "2012-11-22", "access_date": null, "publication_date": "2023-12-01", "url": "https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.adcetris:0", "indication": "ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL).", "raw_biomarkers": null, "raw_cancer_type": "Hodgkin Lymphoma (HL)", "raw_therapeutics": "Adcetris (brentuximab vedotin) in combination with doxorubicin, vinblastine, and dacarbazine", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.adcetris", "type": "Document", "subtype": "Regulatory approval", "name": "Adcetris (brentuximab vedotin) [product information]. EMA.", "citation": "Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Adcetris", "drug_name_generic": "brentuximab vedotin", "first_published": "2012-11-22", "access_date": null, "publication_date": "2023-12-01", "url": "https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 532, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 0, "name": "CD30 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD30"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 80, "conceptType": "Disease", "name": "Hodgkin Lymphoma", "primaryCoding": {"id": "oncotree:HL", "code": "HL", "name": "Hodgkin Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HL"]}, "mappings": []}, "objectTherapeutic": {"id": 104, "membership_operator": "AND", "therapies": [{"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 1, "conceptType": "Drug", "name": "Dacarbazine", "primaryCoding": {"id": "ncit:C411", "code": "C411", "name": "Dacarbazine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Nonclassical alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 3, "conceptType": "Drug", "name": "Vinblastine", "primaryCoding": {"id": "ncit:C930", "code": "C930", "name": "Vinblastine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C930"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Vinca alkaloid chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 0, "conceptType": "Drug", "name": "Brentuximab vedotin", "primaryCoding": {"id": "ncit:C66944", "code": "C66944", "name": "Brentuximab Vedotin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["target CD30 antigens"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10001, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ Hodgkin lymphoma (HL) at increased risk of relapase or progression following autologous stemc ell transplant (ASCT).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.adcetris", "type": "Document", "subtype": "Regulatory approval", "name": "Adcetris (brentuximab vedotin) [product information]. EMA.", "citation": "Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Adcetris", "drug_name_generic": "brentuximab vedotin", "first_published": "2012-11-22", "access_date": null, "publication_date": "2023-12-01", "url": "https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.adcetris:1", "indication": "ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ Hodgkin lymphoma (HL) at increased risk of relapase or progression following autologous stemc ell transplant (ASCT).", "raw_biomarkers": null, "raw_cancer_type": "Hodgkin Lymphoma (HL)", "raw_therapeutics": "Adcetris (brentuximab vedotin)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.adcetris", "type": "Document", "subtype": "Regulatory approval", "name": "Adcetris (brentuximab vedotin) [product information]. EMA.", "citation": "Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Adcetris", "drug_name_generic": "brentuximab vedotin", "first_published": "2012-11-22", "access_date": null, "publication_date": "2023-12-01", "url": "https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 533, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 0, "name": "CD30 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD30"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 80, "conceptType": "Disease", "name": "Hodgkin Lymphoma", "primaryCoding": {"id": "oncotree:HL", "code": "HL", "name": "Hodgkin Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HL"]}, "mappings": []}, "objectTherapeutic": {"id": 0, "conceptType": "Drug", "name": "Brentuximab vedotin", "primaryCoding": {"id": "ncit:C66944", "code": "C66944", "name": "Brentuximab Vedotin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["target CD30 antigens"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10002, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) either following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.adcetris", "type": "Document", "subtype": "Regulatory approval", "name": "Adcetris (brentuximab vedotin) [product information]. EMA.", "citation": "Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Adcetris", "drug_name_generic": "brentuximab vedotin", "first_published": "2012-11-22", "access_date": null, "publication_date": "2023-12-01", "url": "https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.adcetris:2", "indication": "ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): (i) following ASCT, or (ii) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) either following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.", "raw_biomarkers": null, "raw_cancer_type": "Hodgkin Lymphoma (HL)", "raw_therapeutics": "Adcetris (brentuximab vedotin)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.adcetris", "type": "Document", "subtype": "Regulatory approval", "name": "Adcetris (brentuximab vedotin) [product information]. EMA.", "citation": "Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Adcetris", "drug_name_generic": "brentuximab vedotin", "first_published": "2012-11-22", "access_date": null, "publication_date": "2023-12-01", "url": "https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 533, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 0, "name": "CD30 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD30"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 80, "conceptType": "Disease", "name": "Hodgkin Lymphoma", "primaryCoding": {"id": "oncotree:HL", "code": "HL", "name": "Hodgkin Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HL"]}, "mappings": []}, "objectTherapeutic": {"id": 0, "conceptType": "Drug", "name": "Brentuximab vedotin", "primaryCoding": {"id": "ncit:C66944", "code": "C66944", "name": "Brentuximab Vedotin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["target CD30 antigens"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10003, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.adcetris", "type": "Document", "subtype": "Regulatory approval", "name": "Adcetris (brentuximab vedotin) [product information]. EMA.", "citation": "Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Adcetris", "drug_name_generic": "brentuximab vedotin", "first_published": "2012-11-22", "access_date": null, "publication_date": "2023-12-01", "url": "https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.adcetris:3", "indication": "ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Cutaneous T-cell lymphoma (CTCL)", "raw_therapeutics": "Adcetris (brentuximab vedotin)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.adcetris", "type": "Document", "subtype": "Regulatory approval", "name": "Adcetris (brentuximab vedotin) [product information]. EMA.", "citation": "Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Adcetris", "drug_name_generic": "brentuximab vedotin", "first_published": "2012-11-22", "access_date": null, "publication_date": "2023-12-01", "url": "https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 534, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 0, "name": "CD30 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD30"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 30, "conceptType": "Disease", "name": "Cutaneous T-cell Lymphoma", "primaryCoding": {"id": "ncit:C3467", "code": "C3467", "name": "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3467"]}, "mappings": []}, "objectTherapeutic": {"id": 0, "conceptType": "Drug", "name": "Brentuximab vedotin", "primaryCoding": {"id": "ncit:C66944", "code": "C66944", "name": "Brentuximab Vedotin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["target CD30 antigens"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10004, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.afinitor", "type": "Document", "subtype": "Regulatory approval", "name": "Afinitor (everolimus) [product information]. EMA.", "citation": "Novartis Europharm Limited. Afinitor (everolimus) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf. Revised June 2022. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Afinitor", "drug_name_generic": "everolimus", "first_published": "2009-09-02", "access_date": null, "publication_date": "2022-06-27", "url": "https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.afinitor:0", "indication": "Afinitor is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Afinitor (everolimus) in combination with exemestane", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.afinitor", "type": "Document", "subtype": "Regulatory approval", "name": "Afinitor (everolimus) [product information]. EMA.", "citation": "Novartis Europharm Limited. Afinitor (everolimus) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf. Revised June 2022. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Afinitor", "drug_name_generic": "everolimus", "first_published": "2009-09-02", "access_date": null, "publication_date": "2022-06-27", "url": "https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 131, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 26, "membership_operator": "AND", "therapies": [{"id": 5, "conceptType": "Drug", "name": "Exemestane", "primaryCoding": {"id": "ncit:C1097", "code": "C1097", "name": "Exemestane", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 4, "conceptType": "Drug", "name": "Everolimus", "primaryCoding": {"id": "ncit:C48387", "code": "C48387", "name": "Everolimus", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10005, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.afinitor", "type": "Document", "subtype": "Regulatory approval", "name": "Afinitor (everolimus) [product information]. EMA.", "citation": "Novartis Europharm Limited. Afinitor (everolimus) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf. Revised June 2022. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Afinitor", "drug_name_generic": "everolimus", "first_published": "2009-09-02", "access_date": null, "publication_date": "2022-06-27", "url": "https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.afinitor:0", "indication": "Afinitor is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Afinitor (everolimus) in combination with exemestane", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.afinitor", "type": "Document", "subtype": "Regulatory approval", "name": "Afinitor (everolimus) [product information]. EMA.", "citation": "Novartis Europharm Limited. Afinitor (everolimus) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf. Revised June 2022. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Afinitor", "drug_name_generic": "everolimus", "first_published": "2009-09-02", "access_date": null, "publication_date": "2022-06-27", "url": "https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 132, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 26, "membership_operator": "AND", "therapies": [{"id": 5, "conceptType": "Drug", "name": "Exemestane", "primaryCoding": {"id": "ncit:C1097", "code": "C1097", "name": "Exemestane", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 4, "conceptType": "Drug", "name": "Everolimus", "primaryCoding": {"id": "ncit:C48387", "code": "C48387", "name": "Everolimus", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10006, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.afinitor", "type": "Document", "subtype": "Regulatory approval", "name": "Afinitor (everolimus) [product information]. EMA.", "citation": "Novartis Europharm Limited. Afinitor (everolimus) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf. Revised June 2022. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Afinitor", "drug_name_generic": "everolimus", "first_published": "2009-09-02", "access_date": null, "publication_date": "2022-06-27", "url": "https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.afinitor:0", "indication": "Afinitor is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized everolimus in combination with exemestane for the treatment of adult patients with hormone receptor-positive, HER2/neu negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Afinitor (everolimus) in combination with exemestane", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.afinitor", "type": "Document", "subtype": "Regulatory approval", "name": "Afinitor (everolimus) [product information]. EMA.", "citation": "Novartis Europharm Limited. Afinitor (everolimus) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf. Revised June 2022. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Afinitor", "drug_name_generic": "everolimus", "first_published": "2009-09-02", "access_date": null, "publication_date": "2022-06-27", "url": "https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 133, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 26, "membership_operator": "AND", "therapies": [{"id": 5, "conceptType": "Drug", "name": "Exemestane", "primaryCoding": {"id": "ncit:C1097", "code": "C1097", "name": "Exemestane", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 4, "conceptType": "Drug", "name": "Everolimus", "primaryCoding": {"id": "ncit:C48387", "code": "C48387", "name": "Everolimus", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10007, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.akeega", "type": "Document", "subtype": "Regulatory approval", "name": "Akeega (abiraterone acetate and niraparib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Akeega (abiraterone acetate and niraparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf. Revised June 2023. Accessed March 5, 2024.", "company": "", "drug_name_brand": "Akeega", "drug_name_generic": "abiraterone acetate and niraparib", "first_published": "2023-06-02", "access_date": null, "publication_date": "2023-06-02", "url": "https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.akeega:0", "indication": "Akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.", "raw_biomarkers": null, "raw_cancer_type": "Metastatic castration-resistant prostate cancer", "raw_therapeutics": "Akeega (abiraterone acetate and niraparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.akeega", "type": "Document", "subtype": "Regulatory approval", "name": "Akeega (abiraterone acetate and niraparib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Akeega (abiraterone acetate and niraparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf. Revised June 2023. Accessed March 5, 2024.", "company": "", "drug_name_brand": "Akeega", "drug_name_generic": "abiraterone acetate and niraparib", "first_published": "2023-06-02", "access_date": null, "publication_date": "2023-06-02", "url": "https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 537, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 47, "name": "BRCA1 oncogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 55, "conceptType": "Disease", "name": "Prostate Adenocarcinoma", "primaryCoding": {"id": "oncotree:PRAD", "code": "PRAD", "name": "Prostate Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD"]}, "mappings": []}, "objectTherapeutic": {"id": 105, "membership_operator": "AND", "therapies": [{"id": 8, "conceptType": "Drug", "name": "Prednisolone", "primaryCoding": {"id": "ncit:C769", "code": "C769", "name": "Prednisolone", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Corticosteroid"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 6, "conceptType": "Drug", "name": "Niraparib", "primaryCoding": {"id": "ncit:C80059", "code": "C80059", "name": "Niraparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 7, "conceptType": "Drug", "name": "Abiraterone acetate", "primaryCoding": {"id": "ncit:C68845", "code": "C68845", "name": "Abiraterone Acetate", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antiandrogen"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10008, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.akeega", "type": "Document", "subtype": "Regulatory approval", "name": "Akeega (abiraterone acetate and niraparib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Akeega (abiraterone acetate and niraparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf. Revised June 2023. Accessed March 5, 2024.", "company": "", "drug_name_brand": "Akeega", "drug_name_generic": "abiraterone acetate and niraparib", "first_published": "2023-06-02", "access_date": null, "publication_date": "2023-06-02", "url": "https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.akeega:0", "indication": "Akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.", "raw_biomarkers": null, "raw_cancer_type": "Metastatic castration-resistant prostate cancer", "raw_therapeutics": "Akeega (abiraterone acetate and niraparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.akeega", "type": "Document", "subtype": "Regulatory approval", "name": "Akeega (abiraterone acetate and niraparib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Akeega (abiraterone acetate and niraparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf. Revised June 2023. Accessed March 5, 2024.", "company": "", "drug_name_brand": "Akeega", "drug_name_generic": "abiraterone acetate and niraparib", "first_published": "2023-06-02", "access_date": null, "publication_date": "2023-06-02", "url": "https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 538, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 49, "name": "BRCA2 oncogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 55, "conceptType": "Disease", "name": "Prostate Adenocarcinoma", "primaryCoding": {"id": "oncotree:PRAD", "code": "PRAD", "name": "Prostate Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD"]}, "mappings": []}, "objectTherapeutic": {"id": 105, "membership_operator": "AND", "therapies": [{"id": 8, "conceptType": "Drug", "name": "Prednisolone", "primaryCoding": {"id": "ncit:C769", "code": "C769", "name": "Prednisolone", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Corticosteroid"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 6, "conceptType": "Drug", "name": "Niraparib", "primaryCoding": {"id": "ncit:C80059", "code": "C80059", "name": "Niraparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 7, "conceptType": "Drug", "name": "Abiraterone acetate", "primaryCoding": {"id": "ncit:C68845", "code": "C68845", "name": "Abiraterone Acetate", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antiandrogen"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10009, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.akeega", "type": "Document", "subtype": "Regulatory approval", "name": "Akeega (abiraterone acetate and niraparib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Akeega (abiraterone acetate and niraparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf. Revised June 2023. Accessed March 5, 2024.", "company": "", "drug_name_brand": "Akeega", "drug_name_generic": "abiraterone acetate and niraparib", "first_published": "2023-06-02", "access_date": null, "publication_date": "2023-06-02", "url": "https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.akeega:0", "indication": "Akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.", "raw_biomarkers": null, "raw_cancer_type": "Metastatic castration-resistant prostate cancer", "raw_therapeutics": "Akeega (abiraterone acetate and niraparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.akeega", "type": "Document", "subtype": "Regulatory approval", "name": "Akeega (abiraterone acetate and niraparib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Akeega (abiraterone acetate and niraparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf. Revised June 2023. Accessed March 5, 2024.", "company": "", "drug_name_brand": "Akeega", "drug_name_generic": "abiraterone acetate and niraparib", "first_published": "2023-06-02", "access_date": null, "publication_date": "2023-06-02", "url": "https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 539, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 48, "name": "BRCA1 pathogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 55, "conceptType": "Disease", "name": "Prostate Adenocarcinoma", "primaryCoding": {"id": "oncotree:PRAD", "code": "PRAD", "name": "Prostate Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD"]}, "mappings": []}, "objectTherapeutic": {"id": 105, "membership_operator": "AND", "therapies": [{"id": 8, "conceptType": "Drug", "name": "Prednisolone", "primaryCoding": {"id": "ncit:C769", "code": "C769", "name": "Prednisolone", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Corticosteroid"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 6, "conceptType": "Drug", "name": "Niraparib", "primaryCoding": {"id": "ncit:C80059", "code": "C80059", "name": "Niraparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 7, "conceptType": "Drug", "name": "Abiraterone acetate", "primaryCoding": {"id": "ncit:C68845", "code": "C68845", "name": "Abiraterone Acetate", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antiandrogen"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10010, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.akeega", "type": "Document", "subtype": "Regulatory approval", "name": "Akeega (abiraterone acetate and niraparib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Akeega (abiraterone acetate and niraparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf. Revised June 2023. Accessed March 5, 2024.", "company": "", "drug_name_brand": "Akeega", "drug_name_generic": "abiraterone acetate and niraparib", "first_published": "2023-06-02", "access_date": null, "publication_date": "2023-06-02", "url": "https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.akeega:0", "indication": "Akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized niraparib with abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.", "raw_biomarkers": null, "raw_cancer_type": "Metastatic castration-resistant prostate cancer", "raw_therapeutics": "Akeega (abiraterone acetate and niraparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.akeega", "type": "Document", "subtype": "Regulatory approval", "name": "Akeega (abiraterone acetate and niraparib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Akeega (abiraterone acetate and niraparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf. Revised June 2023. Accessed March 5, 2024.", "company": "", "drug_name_brand": "Akeega", "drug_name_generic": "abiraterone acetate and niraparib", "first_published": "2023-06-02", "access_date": null, "publication_date": "2023-06-02", "url": "https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 540, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 50, "name": "BRCA2 pathogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 55, "conceptType": "Disease", "name": "Prostate Adenocarcinoma", "primaryCoding": {"id": "oncotree:PRAD", "code": "PRAD", "name": "Prostate Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD"]}, "mappings": []}, "objectTherapeutic": {"id": 105, "membership_operator": "AND", "therapies": [{"id": 8, "conceptType": "Drug", "name": "Prednisolone", "primaryCoding": {"id": "ncit:C769", "code": "C769", "name": "Prednisolone", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Corticosteroid"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 6, "conceptType": "Drug", "name": "Niraparib", "primaryCoding": {"id": "ncit:C80059", "code": "C80059", "name": "Niraparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 7, "conceptType": "Drug", "name": "Abiraterone acetate", "primaryCoding": {"id": "ncit:C68845", "code": "C68845", "name": "Abiraterone Acetate", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antiandrogen"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10011, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.alecensa", "type": "Document", "subtype": "Regulatory approval", "name": "Alecensa (alectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Alecensa (alectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Revised June 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Alecensa", "drug_name_generic": "alectinib", "first_published": "2017-04-11", "access_date": null, "publication_date": "2024-06-19", "url": "https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.alecensa:0", "indication": "Alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Alecensa (alectinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.alecensa", "type": "Document", "subtype": "Regulatory approval", "name": "Alecensa (alectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Alecensa (alectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Revised June 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Alecensa", "drug_name_generic": "alectinib", "first_published": "2017-04-11", "access_date": null, "publication_date": "2024-06-19", "url": "https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 22, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 9, "conceptType": "Drug", "name": "Alectinib", "primaryCoding": {"id": "ncit:C101790", "code": "C101790", "name": "Alectinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C101790"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10012, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.alecensa", "type": "Document", "subtype": "Regulatory approval", "name": "Alecensa (alectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Alecensa (alectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Revised June 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Alecensa", "drug_name_generic": "alectinib", "first_published": "2017-04-11", "access_date": null, "publication_date": "2024-06-19", "url": "https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.alecensa:1", "indication": "Alecensa as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Alecensa (alectinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.alecensa", "type": "Document", "subtype": "Regulatory approval", "name": "Alecensa (alectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Alecensa (alectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Revised June 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Alecensa", "drug_name_generic": "alectinib", "first_published": "2017-04-11", "access_date": null, "publication_date": "2024-06-19", "url": "https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 22, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 9, "conceptType": "Drug", "name": "Alectinib", "primaryCoding": {"id": "ncit:C101790", "code": "C101790", "name": "Alectinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C101790"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10013, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the adjuvant treatment following complete tumor resection for adult patients with ALK-positive non-small cell lung cancer (NSCLC) at high risk of recurrence.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.alecensa", "type": "Document", "subtype": "Regulatory approval", "name": "Alecensa (alectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Alecensa (alectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Revised June 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Alecensa", "drug_name_generic": "alectinib", "first_published": "2017-04-11", "access_date": null, "publication_date": "2024-06-19", "url": "https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.alecensa:2", "indication": "Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK-positive non-small cell lung cancer (NSCLC) at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the adjuvant treatment following complete tumor resection for adult patients with ALK-positive non-small cell lung cancer (NSCLC) at high risk of recurrence.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Alecensa (alectinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.alecensa", "type": "Document", "subtype": "Regulatory approval", "name": "Alecensa (alectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Alecensa (alectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Revised June 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Alecensa", "drug_name_generic": "alectinib", "first_published": "2017-04-11", "access_date": null, "publication_date": "2024-06-19", "url": "https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 22, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 9, "conceptType": "Drug", "name": "Alectinib", "primaryCoding": {"id": "ncit:C101790", "code": "C101790", "name": "Alectinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C101790"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10014, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who were previously not treated with an ALK inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.alunbrig", "type": "Document", "subtype": "Regulatory approval", "name": "Alunbrig (brigatinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Alunbrig (brigatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf. Revised September 2023. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Alunbrig", "drug_name_generic": "brigatinib", "first_published": "2018-11-26", "access_date": null, "publication_date": "2023-09-22", "url": "https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.alunbrig:0", "indication": "Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who were previously not treated with an ALK inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Alunbrig (brigatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.alunbrig", "type": "Document", "subtype": "Regulatory approval", "name": "Alunbrig (brigatinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Alunbrig (brigatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf. Revised September 2023. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Alunbrig", "drug_name_generic": "brigatinib", "first_published": "2018-11-26", "access_date": null, "publication_date": "2023-09-22", "url": "https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 50, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 10, "conceptType": "Drug", "name": "Brigatinib", "primaryCoding": {"id": "ncit:C98831", "code": "C98831", "name": "Brigatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98831"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10015, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.alunbrig", "type": "Document", "subtype": "Regulatory approval", "name": "Alunbrig (brigatinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Alunbrig (brigatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf. Revised September 2023. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Alunbrig", "drug_name_generic": "brigatinib", "first_published": "2018-11-26", "access_date": null, "publication_date": "2023-09-22", "url": "https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.alunbrig:1", "indication": "Alunbrig is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Alunbrig (brigatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.alunbrig", "type": "Document", "subtype": "Regulatory approval", "name": "Alunbrig (brigatinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Alunbrig (brigatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf. Revised September 2023. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Alunbrig", "drug_name_generic": "brigatinib", "first_published": "2018-11-26", "access_date": null, "publication_date": "2023-09-22", "url": "https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 50, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 10, "conceptType": "Drug", "name": "Brigatinib", "primaryCoding": {"id": "ncit:C98831", "code": "C98831", "name": "Brigatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98831"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10016, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized bevacizumab in combination with erlotinib for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating variants. This indication is based on JO25567, a randomized, open-label, multi-centre phase 2 study that defined EGFR activating variants as either exon 19 deletions or exon 21 p.L858R.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.avastin", "type": "Document", "subtype": "Regulatory approval", "name": "Avastin (bevacizumab) [product information]. EMA.", "citation": "Mabxience Research SL. Avastin (bevacizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Revised March 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Avastin", "drug_name_generic": "bevacizumab", "first_published": "2009-09-17", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.avastin:0", "indication": "Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized bevacizumab in combination with erlotinib for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating variants. This indication is based on JO25567, a randomized, open-label, multi-centre phase 2 study that defined EGFR activating variants as either exon 19 deletions or exon 21 p.L858R.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Avastin (bevacizumab) in combination with erlotinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.avastin", "type": "Document", "subtype": "Regulatory approval", "name": "Avastin (bevacizumab) [product information]. EMA.", "citation": "Mabxience Research SL. Avastin (bevacizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Revised March 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Avastin", "drug_name_generic": "bevacizumab", "first_published": "2009-09-17", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 541, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 9, "name": "EGFR p.L858R", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 55259515}, {"name": "end_position", "value": 55259515}, {"name": "reference_allele", "value": "T"}, {"name": "alternate_allele", "value": "G"}, {"name": "cdna_change", "value": "c.2573T>G"}, {"name": "protein_change", "value": "p.L858R"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "21"}, {"name": "rsid", "value": "rs121434568"}, {"name": "hgvsg", "value": "7:g.55259515T>G"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 106, "membership_operator": "AND", "therapies": [{"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 12, "conceptType": "Drug", "name": "Erlotinib", "primaryCoding": {"id": "ncit:C65530", "code": "C65530", "name": "Erlotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C65530"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10017, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized bevacizumab in combination with erlotinib for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating variants. This indication is based on JO25567, a randomized, open-label, multi-centre phase 2 study that defined EGFR activating variants as either exon 19 deletions or exon 21 p.L858R.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.avastin", "type": "Document", "subtype": "Regulatory approval", "name": "Avastin (bevacizumab) [product information]. EMA.", "citation": "Mabxience Research SL. Avastin (bevacizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Revised March 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Avastin", "drug_name_generic": "bevacizumab", "first_published": "2009-09-17", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.avastin:0", "indication": "Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized bevacizumab in combination with erlotinib for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating variants. This indication is based on JO25567, a randomized, open-label, multi-centre phase 2 study that defined EGFR activating variants as either exon 19 deletions or exon 21 p.L858R.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Avastin (bevacizumab) in combination with erlotinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.avastin", "type": "Document", "subtype": "Regulatory approval", "name": "Avastin (bevacizumab) [product information]. EMA.", "citation": "Mabxience Research SL. Avastin (bevacizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Revised March 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Avastin", "drug_name_generic": "bevacizumab", "first_published": "2009-09-17", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 542, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 10, "name": "EGFR Exon 19 (Deletion)", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "variant_annotation", "value": "Deletion"}, {"name": "exon", "value": "19"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 106, "membership_operator": "AND", "therapies": [{"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 12, "conceptType": "Drug", "name": "Erlotinib", "primaryCoding": {"id": "ncit:C65530", "code": "C65530", "name": "Erlotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C65530"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10018, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized avapritinib as a monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring the platelet-derived growth factor receptor alpha (PDGFRA) p.D842V variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.ayvakyt", "type": "Document", "subtype": "Regulatory approval", "name": "Ayvakyt (avapritinib) [product information]. EMA.", "citation": "Blueprint Medicines (Netherlands) B.V. Ayvakyt (avapritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf. Revised February 2024. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Ayvakyt", "drug_name_generic": "avapritinib", "first_published": "2020-09-30", "access_date": null, "publication_date": "2024-02-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.ayvakyt:0", "indication": "AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized avapritinib as a monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring the platelet-derived growth factor receptor alpha (PDGFRA) p.D842V variant.", "raw_biomarkers": null, "raw_cancer_type": "Gastrointestinal stromal tumours (GIST)", "raw_therapeutics": "Ayvakyt (avapritinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.ayvakyt", "type": "Document", "subtype": "Regulatory approval", "name": "Ayvakyt (avapritinib) [product information]. EMA.", "citation": "Blueprint Medicines (Netherlands) B.V. Ayvakyt (avapritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf. Revised February 2024. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Ayvakyt", "drug_name_generic": "avapritinib", "first_published": "2020-09-30", "access_date": null, "publication_date": "2024-02-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 40, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 11, "name": "PDGFRA p.D842V", "genes": [{"id": 39, "name": "PDGFRA", "primaryCoding": {"id": "hgnc:8803", "code": "HGNC:8803", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8803"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_006206.6", "code": "NM_006206.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_006206.6"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000134853", "code": "ENSG00000134853", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000134853"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5156", "code": "5156", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5156"]}}], "extensions": [{"name": "location", "value": "4q12"}, {"name": "location_sortable", "value": "04q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "4"}, {"name": "start_position", "value": 55152093}, {"name": "end_position", "value": 55152093}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.2525A>T"}, {"name": "protein_change", "value": "p.D842V"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "18"}, {"name": "rsid", "value": "rs121908585"}, {"name": "hgvsg", "value": "4:g.55152093A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 22, "conceptType": "Disease", "name": "Gastrointestinal Stromal Tumor", "primaryCoding": {"id": "oncotree:GIST", "code": "GIST", "name": "Gastrointestinal Stromal Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GIST"]}, "mappings": []}, "objectTherapeutic": {"id": 13, "conceptType": "Drug", "name": "Avapritinib", "primaryCoding": {"id": "ncit:C123827", "code": "C123827", "name": "Avapritinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C123827"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["KIT inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10019, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Besponsa (inotuzumab ozogamicin) as a monotherapy for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). Adult patients with Philidelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor (TKI).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.besponsa", "type": "Document", "subtype": "Regulatory approval", "name": "Besponsa (inotuzumab ozogamicin) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Besponsa (inotuzumab ozogamicin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf. Revised February 2024. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Besponsa", "drug_name_generic": "inotuzumab ozogamicin", "first_published": "2017-07-13", "access_date": null, "publication_date": "2024-02-14", "url": "https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.besponsa:0", "indication": "BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Besponsa (inotuzumab ozogamicin) as a monotherapy for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). Adult patients with Philidelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor (TKI).", "raw_biomarkers": null, "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)", "raw_therapeutics": "Besponsa (inotuzumab ozogamicin)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.besponsa", "type": "Document", "subtype": "Regulatory approval", "name": "Besponsa (inotuzumab ozogamicin) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Besponsa (inotuzumab ozogamicin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf. Revised February 2024. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Besponsa", "drug_name_generic": "inotuzumab ozogamicin", "first_published": "2017-07-13", "access_date": null, "publication_date": "2024-02-14", "url": "https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 543, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}, {"id": 13, "name": "CD22 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD22"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 14, "conceptType": "Drug", "name": "Inotuzumab ozogamicin", "primaryCoding": {"id": "ncit:C71542", "code": "C71542", "name": "Inotuzumab Ozogamicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71542"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10020, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Besponsa (inotuzumab ozogamicin) as a monotherapy for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). Adult patients with Philidelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor (TKI).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.besponsa", "type": "Document", "subtype": "Regulatory approval", "name": "Besponsa (inotuzumab ozogamicin) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Besponsa (inotuzumab ozogamicin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf. Revised February 2024. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Besponsa", "drug_name_generic": "inotuzumab ozogamicin", "first_published": "2017-07-13", "access_date": null, "publication_date": "2024-02-14", "url": "https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.besponsa:0", "indication": "BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Besponsa (inotuzumab ozogamicin) as a monotherapy for the treatment of adult patients with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL). Adult patients with Philidelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor (TKI).", "raw_biomarkers": null, "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)", "raw_therapeutics": "Besponsa (inotuzumab ozogamicin)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.besponsa", "type": "Document", "subtype": "Regulatory approval", "name": "Besponsa (inotuzumab ozogamicin) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Besponsa (inotuzumab ozogamicin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf. Revised February 2024. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Besponsa", "drug_name_generic": "inotuzumab ozogamicin", "first_published": "2017-07-13", "access_date": null, "publication_date": "2024-02-14", "url": "https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 168, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 13, "name": "CD22 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD22"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 14, "conceptType": "Drug", "name": "Inotuzumab ozogamicin", "primaryCoding": {"id": "ncit:C71542", "code": "C71542", "name": "Inotuzumab Ozogamicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71542"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10021, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.blincyto", "type": "Document", "subtype": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Blincyto", "drug_name_generic": "blinatumomab", "first_published": "2015-12-07", "access_date": null, "publication_date": "2025-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.blincyto:0", "indication": "BLINCYTO is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome-positive B-cell precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.", "raw_biomarkers": null, "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)", "raw_therapeutics": "Blincyto (blinatumomab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.blincyto", "type": "Document", "subtype": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Blincyto", "drug_name_generic": "blinatumomab", "first_published": "2015-12-07", "access_date": null, "publication_date": "2025-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 45, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 14, "name": "CD19 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD19"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 15, "conceptType": "Drug", "name": "Blinatumomab", "primaryCoding": {"id": "ncit:C62528", "code": "C62528", "name": "Blinatumomab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62528"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD19 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10022, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.blincyto", "type": "Document", "subtype": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Blincyto", "drug_name_generic": "blinatumomab", "first_published": "2015-12-07", "access_date": null, "publication_date": "2025-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.blincyto:0", "indication": "BLINCYTO is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome-positive B-cell precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.", "raw_biomarkers": null, "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)", "raw_therapeutics": "Blincyto (blinatumomab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.blincyto", "type": "Document", "subtype": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Blincyto", "drug_name_generic": "blinatumomab", "first_published": "2015-12-07", "access_date": null, "publication_date": "2025-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 46, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}, {"id": 14, "name": "CD19 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD19"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 15, "conceptType": "Drug", "name": "Blinatumomab", "primaryCoding": {"id": "ncit:C62528", "code": "C62528", "name": "Blinatumomab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62528"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD19 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10023, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with Philadelphia chromosome negative CD19 positive B-cell precusor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.blincyto", "type": "Document", "subtype": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Blincyto", "drug_name_generic": "blinatumomab", "first_published": "2015-12-07", "access_date": null, "publication_date": "2025-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.blincyto:1", "indication": "BLINCYTO is indicated as monotherapy for the treatment of adults with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of adult patients with Philadelphia chromosome negative CD19 positive B-cell precusor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.", "raw_biomarkers": "Philadelphia chromosome negative CD19 positive", "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)", "raw_therapeutics": "Blincyto (blinatumomab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.blincyto", "type": "Document", "subtype": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Blincyto", "drug_name_generic": "blinatumomab", "first_published": "2015-12-07", "access_date": null, "publication_date": "2025-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 46, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}, {"id": 14, "name": "CD19 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD19"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 15, "conceptType": "Drug", "name": "Blinatumomab", "primaryCoding": {"id": "ncit:C62528", "code": "C62528", "name": "Blinatumomab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62528"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD19 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10024, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 year or older with Philidelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.blincyto", "type": "Document", "subtype": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Blincyto", "drug_name_generic": "blinatumomab", "first_published": "2015-12-07", "access_date": null, "publication_date": "2025-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.blincyto:2", "indication": "BLINCYTO is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation.", "initial_approval_date": "2025-02-10", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0056-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 month or older with Philidelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplants.", "raw_biomarkers": "Philadelphia chromosome negative CD19 positive", "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)", "raw_therapeutics": "Blincyto (blinatumomab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.blincyto", "type": "Document", "subtype": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Blincyto", "drug_name_generic": "blinatumomab", "first_published": "2015-12-07", "access_date": null, "publication_date": "2025-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 46, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}, {"id": 14, "name": "CD19 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD19"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 15, "conceptType": "Drug", "name": "Blinatumomab", "primaryCoding": {"id": "ncit:C62528", "code": "C62528", "name": "Blinatumomab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62528"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD19 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10025, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 year or older with high-risk first relapsed Philidelphia chromosome negative CD19 positive B-cell precursor ALL as part of the consolidation therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.blincyto", "type": "Document", "subtype": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Blincyto", "drug_name_generic": "blinatumomab", "first_published": "2015-12-07", "access_date": null, "publication_date": "2025-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.blincyto:3", "indication": "BLINCYTO is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with high-risk first relapsed Philadelphia chromosome-negative CD19 positive B-cell precursor ALL as part of the consolidation therapy.", "initial_approval_date": "2025-02-10", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0056-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 month or older with high-risk first relapsed Philidelphia chromosome negative CD19 positive B-cell precursor ALL as part of the consolidation therapy.", "raw_biomarkers": "Philadelphia chromosome negative CD19 positive", "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)", "raw_therapeutics": "Blincyto (blinatumomab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.blincyto", "type": "Document", "subtype": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Blincyto", "drug_name_generic": "blinatumomab", "first_published": "2015-12-07", "access_date": null, "publication_date": "2025-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 46, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}, {"id": 14, "name": "CD19 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD19"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 15, "conceptType": "Drug", "name": "Blinatumomab", "primaryCoding": {"id": "ncit:C62528", "code": "C62528", "name": "Blinatumomab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62528"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD19 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10026, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.bosulif", "type": "Document", "subtype": "Regulatory approval", "name": "Bosulif (bosutinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Bosulif", "drug_name_generic": "bosutinib", "first_published": "2013-04-09", "access_date": null, "publication_date": "2025-08-26", "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.bosulif:0", "indication": "Bosulif is indicated for the treatment of adult and paediatric patients aged 6 years and older with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).", "initial_approval_date": "2025-08-26", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult and pediatric patients aged 6 years and older with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).", "raw_biomarkers": "Philadelphia chromosome-positive", "raw_cancer_type": "Chronic Myelogenous Leukemia", "raw_therapeutics": "Bosulif (bosutinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.bosulif", "type": "Document", "subtype": "Regulatory approval", "name": "Bosulif (bosutinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Bosulif", "drug_name_generic": "bosutinib", "first_published": "2013-04-09", "access_date": null, "publication_date": "2025-08-26", "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 47, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 12, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 16, "conceptType": "Drug", "name": "Bosutinib", "primaryCoding": {"id": "ncit:C60809", "code": "C60809", "name": "Bosutinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C60809"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10027, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with chronic phase, accelerated phase, and blast phase Ph+ CML previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are no considered appropriate treatment options.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.bosulif", "type": "Document", "subtype": "Regulatory approval", "name": "Bosulif (bosutinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Bosulif", "drug_name_generic": "bosutinib", "first_published": "2013-04-09", "access_date": null, "publication_date": "2025-08-26", "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.bosulif:1", "indication": "Bosulif is indicated for the treatment of adult patients with accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.", "initial_approval_date": "2025-08-26", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with accelerated phase, and blast phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options.", "raw_biomarkers": "Philadelphia chromosome-positive", "raw_cancer_type": "Chronic Myelogenous Leukemia", "raw_therapeutics": "Bosulif (bosutinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.bosulif", "type": "Document", "subtype": "Regulatory approval", "name": "Bosulif (bosutinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Bosulif", "drug_name_generic": "bosutinib", "first_published": "2013-04-09", "access_date": null, "publication_date": "2025-08-26", "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 47, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 12, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 16, "conceptType": "Drug", "name": "Bosutinib", "primaryCoding": {"id": "ncit:C60809", "code": "C60809", "name": "Bosutinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C60809"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10028, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.braftovi", "type": "Document", "subtype": "Regulatory approval", "name": "Braftovi (encorafenib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Braftovi (encorafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Braftovi", "drug_name_generic": "encorafenib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.braftovi:0", "indication": "Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Encorafenib and Binimetinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.braftovi", "type": "Document", "subtype": "Regulatory approval", "name": "Braftovi (encorafenib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Braftovi (encorafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Braftovi", "drug_name_generic": "encorafenib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 41, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 10, "membership_operator": "AND", "therapies": [{"id": 17, "conceptType": "Drug", "name": "Binimetinib", "primaryCoding": {"id": "ncit:C84865", "code": "C84865", "name": "Binimetinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 18, "conceptType": "Drug", "name": "Encorafenib", "primaryCoding": {"id": "ncit:C98283", "code": "C98283", "name": "Encorafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10029, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.braftovi", "type": "Document", "subtype": "Regulatory approval", "name": "Braftovi (encorafenib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Braftovi (encorafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Braftovi", "drug_name_generic": "encorafenib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.braftovi:0", "indication": "Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Encorafenib and Binimetinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.braftovi", "type": "Document", "subtype": "Regulatory approval", "name": "Braftovi (encorafenib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Braftovi (encorafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Braftovi", "drug_name_generic": "encorafenib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 42, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 17, "name": "BRAF p.V600K", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453137}, {"name": "reference_allele", "value": "AC"}, {"name": "alternate_allele", "value": "TT"}, {"name": "cdna_change", "value": "c.1798_1799GT>AA"}, {"name": "protein_change", "value": "p.V600K"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs121913227"}, {"name": "hgvsg", "value": "7:g.140453136_140453137delinsTT"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 10, "membership_operator": "AND", "therapies": [{"id": 17, "conceptType": "Drug", "name": "Binimetinib", "primaryCoding": {"id": "ncit:C84865", "code": "C84865", "name": "Binimetinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 18, "conceptType": "Drug", "name": "Encorafenib", "primaryCoding": {"id": "ncit:C98283", "code": "C98283", "name": "Encorafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10030, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF p.V600E variant, who have received prior systemic therapy. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.braftovi", "type": "Document", "subtype": "Regulatory approval", "name": "Braftovi (encorafenib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Braftovi (encorafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Braftovi", "drug_name_generic": "encorafenib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.braftovi:1", "indication": "Encorafenib is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF p.V600E variant, who have received prior systemic therapy. The efficacy and safety of encorafenib have been established only in patients with melanoma tumours expressing BRAF V600E and V600K variants or colorectal tumours expressing BRAF V600E.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Encorafenib and Cetuximab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.braftovi", "type": "Document", "subtype": "Regulatory approval", "name": "Braftovi (encorafenib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Braftovi (encorafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Braftovi", "drug_name_generic": "encorafenib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 81, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 16, "membership_operator": "AND", "therapies": [{"id": 19, "conceptType": "Drug", "name": "Cetuximab", "primaryCoding": {"id": "ncit:C1723", "code": "C1723", "name": "Cetuximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 18, "conceptType": "Drug", "name": "Encorafenib", "primaryCoding": {"id": "ncit:C98283", "code": "C98283", "name": "Encorafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10031, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.braftovi", "type": "Document", "subtype": "Regulatory approval", "name": "Braftovi (encorafenib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Braftovi (encorafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Braftovi", "drug_name_generic": "encorafenib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.braftovi:2", "indication": "Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized encorafenib in combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Braftovi (encorafenib) in combination with binimetinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.braftovi", "type": "Document", "subtype": "Regulatory approval", "name": "Braftovi (encorafenib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Braftovi (encorafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Braftovi", "drug_name_generic": "encorafenib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 43, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 10, "membership_operator": "AND", "therapies": [{"id": 17, "conceptType": "Drug", "name": "Binimetinib", "primaryCoding": {"id": "ncit:C84865", "code": "C84865", "name": "Binimetinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 18, "conceptType": "Drug", "name": "Encorafenib", "primaryCoding": {"id": "ncit:C98283", "code": "C98283", "name": "Encorafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10032, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized vandetanib for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is indicated in adults, children, and adolescents aged 5 years and older.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.caprelsa", "type": "Document", "subtype": "Regulatory approval", "name": "Caprelsa (vandetanib) [product information]. EMA.", "citation": "Sanofi B.V. Caprelsa (vandetanib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf. Revised August 2023. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Caprelsa", "drug_name_generic": "vandetanib", "first_published": "2012-03-02", "access_date": null, "publication_date": "2023-08-16", "url": "https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.caprelsa:0", "indication": "Caprelsa is indicated for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized vandetanib for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is indicated in adults, children, and adolescents aged 5 years and older.", "raw_biomarkers": null, "raw_cancer_type": "Medullary thyroid cancer", "raw_therapeutics": "Caprelsa (vandetanib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.caprelsa", "type": "Document", "subtype": "Regulatory approval", "name": "Caprelsa (vandetanib) [product information]. EMA.", "citation": "Sanofi B.V. Caprelsa (vandetanib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf. Revised August 2023. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Caprelsa", "drug_name_generic": "vandetanib", "first_published": "2012-03-02", "access_date": null, "publication_date": "2023-08-16", "url": "https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 547, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 18, "name": "v::RET", "genes": [{"id": 49, "name": "RET", "primaryCoding": {"id": "hgnc:9967", "code": "HGNC:9967", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_020975.6", "code": "NM_020975.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000165731", "code": "ENSG00000165731", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000165731"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5979", "code": "5979", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5979"]}}], "extensions": [{"name": "location", "value": "10q11.21"}, {"name": "location_sortable", "value": "10q11.21"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 38, "conceptType": "Disease", "name": "Medullary Thyroid Cancer", "primaryCoding": {"id": "oncotree:THME", "code": "THME", "name": "Medullary Thyroid Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THME"]}, "mappings": []}, "objectTherapeutic": {"id": 20, "conceptType": "Drug", "name": "Vandetanib", "primaryCoding": {"id": "ncit:C2737", "code": "C2737", "name": "Vandetanib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2737"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["RET inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10033, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.cotellic", "type": "Document", "subtype": "Regulatory approval", "name": "Cotellic (cobimetinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Cotellic (cobimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf. Revised March 2023. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Cotellic", "drug_name_generic": "cobimetinib", "first_published": "2015-12-10", "access_date": null, "publication_date": "2023-03-06", "url": "https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.cotellic:0", "indication": "Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 variant.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Cobimetinib and vemurafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.cotellic", "type": "Document", "subtype": "Regulatory approval", "name": "Cotellic (cobimetinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Cotellic (cobimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf. Revised March 2023. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Cotellic", "drug_name_generic": "cobimetinib", "first_published": "2015-12-10", "access_date": null, "publication_date": "2023-03-06", "url": "https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 82, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 17, "membership_operator": "AND", "therapies": [{"id": 22, "conceptType": "Drug", "name": "Vemurafenib", "primaryCoding": {"id": "ncit:C64768", "code": "C64768", "name": "Vemurafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 21, "conceptType": "Drug", "name": "Cobimetinib", "primaryCoding": {"id": "ncit:C68923", "code": "C68923", "name": "Cobimetinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68923"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10034, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.cotellic", "type": "Document", "subtype": "Regulatory approval", "name": "Cotellic (cobimetinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Cotellic (cobimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf. Revised March 2023. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Cotellic", "drug_name_generic": "cobimetinib", "first_published": "2015-12-10", "access_date": null, "publication_date": "2023-03-06", "url": "https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.cotellic:0", "indication": "Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF p.V600 variant.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Cobimetinib and vemurafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.cotellic", "type": "Document", "subtype": "Regulatory approval", "name": "Cotellic (cobimetinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Cotellic (cobimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf. Revised March 2023. Accessed March 6, 2024.", "company": "", "drug_name_brand": "Cotellic", "drug_name_generic": "cobimetinib", "first_published": "2015-12-10", "access_date": null, "publication_date": "2023-03-06", "url": "https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 83, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 17, "name": "BRAF p.V600K", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453137}, {"name": "reference_allele", "value": "AC"}, {"name": "alternate_allele", "value": "TT"}, {"name": "cdna_change", "value": "c.1798_1799GT>AA"}, {"name": "protein_change", "value": "p.V600K"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs121913227"}, {"name": "hgvsg", "value": "7:g.140453136_140453137delinsTT"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 17, "membership_operator": "AND", "therapies": [{"id": 22, "conceptType": "Drug", "name": "Vemurafenib", "primaryCoding": {"id": "ncit:C64768", "code": "C64768", "name": "Vemurafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 21, "conceptType": "Drug", "name": "Cobimetinib", "primaryCoding": {"id": "ncit:C68923", "code": "C68923", "name": "Cobimetinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68923"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10035, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ramucirumab in combination with erlotinib as a first-line treatment for adult patients with metastatic non-small cell lung cancer with activating EGFR variants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.cyramza", "type": "Document", "subtype": "Regulatory approval", "name": "Cyramza (ramucirumab) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Cyramza (ramucirumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf. Revised December 2022. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Cyramza", "drug_name_generic": "ramucirumab", "first_published": "2015-01-21", "access_date": null, "publication_date": "2022-12-13", "url": "https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.cyramza:0", "indication": "Cyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ramucirumab in combination with erlotinib as a first-line treatment for adult patients with metastatic non-small cell lung cancer with activating EGFR variants.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Cyramza (ramucirumab) and erlotinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.cyramza", "type": "Document", "subtype": "Regulatory approval", "name": "Cyramza (ramucirumab) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Cyramza (ramucirumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf. Revised December 2022. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Cyramza", "drug_name_generic": "ramucirumab", "first_published": "2015-01-21", "access_date": null, "publication_date": "2022-12-13", "url": "https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 548, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 19, "name": "EGFR oncogenic variants", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 76, "membership_operator": "AND", "therapies": [{"id": 12, "conceptType": "Drug", "name": "Erlotinib", "primaryCoding": {"id": "ncit:C65530", "code": "C65530", "name": "Erlotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C65530"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 23, "conceptType": "Drug", "name": "Ramucirumab", "primaryCoding": {"id": "ncit:C70792", "code": "C70792", "name": "Ramucirumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C70792"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF/VEGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10036, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.taxotere", "type": "Document", "subtype": "Regulatory approval", "name": "Taxotere (docetaxel) [product information]. EMA.", "citation": "Sanofi Winthrop Industrie. Taxotere (docetaxel) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Taxotere", "drug_name_generic": "docetaxel", "first_published": "2009-01-13", "access_date": null, "publication_date": "2023-12-14", "url": "https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.taxotere:0", "indication": "TAXOTERE in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.", "raw_biomarkers": "HER2 overexpression", "raw_cancer_type": "breast cancer", "raw_therapeutics": "Taxotere (docetaxel)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.taxotere", "type": "Document", "subtype": "Regulatory approval", "name": "Taxotere (docetaxel) [product information]. EMA.", "citation": "Sanofi Winthrop Industrie. Taxotere (docetaxel) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Taxotere", "drug_name_generic": "docetaxel", "first_published": "2009-01-13", "access_date": null, "publication_date": "2023-12-14", "url": "https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 549, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 108, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10037, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.taxotere", "type": "Document", "subtype": "Regulatory approval", "name": "Taxotere (docetaxel) [product information]. EMA.", "citation": "Sanofi Winthrop Industrie. Taxotere (docetaxel) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Taxotere", "drug_name_generic": "docetaxel", "first_published": "2009-01-13", "access_date": null, "publication_date": "2023-12-14", "url": "https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.taxotere:0", "indication": "TAXOTERE in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized docetaxel in combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors over express HER2 and who previously have not received chemotherapy for metastatic disease.", "raw_biomarkers": "HER2 overexpression", "raw_cancer_type": "breast cancer", "raw_therapeutics": "Taxotere (docetaxel)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.taxotere", "type": "Document", "subtype": "Regulatory approval", "name": "Taxotere (docetaxel) [product information]. EMA.", "citation": "Sanofi Winthrop Industrie. Taxotere (docetaxel) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.", "company": "", "drug_name_brand": "Taxotere", "drug_name_generic": "docetaxel", "first_published": "2009-01-13", "access_date": null, "publication_date": "2023-12-14", "url": "https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 550, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 108, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10040, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimes.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:0", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimes.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 420, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 26, "conceptType": "Drug", "name": "Trastuzumab deruxtecan", "primaryCoding": {"id": "ncit:C128799", "code": "C128799", "name": "Trastuzumab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10041, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimes.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:0", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimes.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 551, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 26, "conceptType": "Drug", "name": "Trastuzumab deruxtecan", "primaryCoding": {"id": "ncit:C128799", "code": "C128799", "name": "Trastuzumab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10042, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. For the purposes of this indication, HER2-low is defined as a score of IHC 1+ or IHC 2+/ISH-, as assessed by a CE-marked IVD medical device or alternative valid test.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:1", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. For the purposes of this indication, HER2-low is defined as a score of IHC 1+ or IHC 2+/ISH-, as assessed by a CE-marked IVD medical device or alternative valid test.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 421, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 22, "name": "HER2-low", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Low"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 26, "conceptType": "Drug", "name": "Trastuzumab deruxtecan", "primaryCoding": {"id": "ncit:C128799", "code": "C128799", "name": "Trastuzumab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10043, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) variant and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:2", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) variant and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 552, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 26, "conceptType": "Drug", "name": "Trastuzumab deruxtecan", "primaryCoding": {"id": "ncit:C128799", "code": "C128799", "name": "Trastuzumab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10044, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) variant and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:2", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) variant and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 422, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 23, "name": "ERBB2 oncogenic variants", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 26, "conceptType": "Drug", "name": "Trastuzumab deruxtecan", "primaryCoding": {"id": "ncit:C128799", "code": "C128799", "name": "Trastuzumab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10045, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:3", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.", "raw_biomarkers": null, "raw_cancer_type": "Gastric or gastroesophageal junction (GEJ) adenocarcinoma", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 423, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 2, "conceptType": "Disease", "name": "Adenocarcinoma of the Gastroesophageal Junction", "primaryCoding": {"id": "oncotree:GEJ", "code": "GEJ", "name": "Adenocarcinoma of the Gastroesophageal Junction", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ"]}, "mappings": []}, "objectTherapeutic": {"id": 26, "conceptType": "Drug", "name": "Trastuzumab deruxtecan", "primaryCoding": {"id": "ncit:C128799", "code": "C128799", "name": "Trastuzumab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10046, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:3", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.", "raw_biomarkers": null, "raw_cancer_type": "Gastric or gastroesophageal junction (GEJ) adenocarcinoma", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 553, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 2, "conceptType": "Disease", "name": "Adenocarcinoma of the Gastroesophageal Junction", "primaryCoding": {"id": "oncotree:GEJ", "code": "GEJ", "name": "Adenocarcinoma of the Gastroesophageal Junction", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ"]}, "mappings": []}, "objectTherapeutic": {"id": 26, "conceptType": "Drug", "name": "Trastuzumab deruxtecan", "primaryCoding": {"id": "ncit:C128799", "code": "C128799", "name": "Trastuzumab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10047, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized cetuximab as a single agent for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.erbitux", "type": "Document", "subtype": "Regulatory approval", "name": "Erbitux (cetuximab) [product information]. EMA.", "citation": "Merck Europe B.V. Erbitux (cetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf. Revised May 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Erbitux", "drug_name_generic": "cetuximab", "first_published": "2009-07-14", "access_date": null, "publication_date": "2022-05-25", "url": "https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.erbitux:0", "indication": "Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized cetuximab as a single agent for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Erbitux (cetuximab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.erbitux", "type": "Document", "subtype": "Regulatory approval", "name": "Erbitux (cetuximab) [product information]. EMA.", "citation": "Merck Europe B.V. Erbitux (cetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf. Revised May 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Erbitux", "drug_name_generic": "cetuximab", "first_published": "2009-07-14", "access_date": null, "publication_date": "2022-05-25", "url": "https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 554, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 24, "name": "EGFR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "EGFR"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 25, "name": "Wild type KRAS", "genes": [{"id": 31, "name": "KRAS", "primaryCoding": {"id": "hgnc:6407", "code": "HGNC:6407", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_004985.5", "code": "NM_004985.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000133703", "code": "ENSG00000133703", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000133703"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3845", "code": "3845", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3845"]}}], "extensions": [{"name": "location", "value": "12p12.1"}, {"name": "location_sortable", "value": "12p12.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 26, "name": "Wild type HRAS", "genes": [{"id": 27, "name": "HRAS", "primaryCoding": {"id": "hgnc:5173", "code": "HGNC:5173", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5173"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005343.4", "code": "NM_005343.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005343.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000174775", "code": "ENSG00000174775", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000174775"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3265", "code": "3265", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3265"]}}], "extensions": [{"name": "location", "value": "11p15.5"}, {"name": "location_sortable", "value": "11p15.5"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 27, "name": "Wild type NRAS", "genes": [{"id": 33, "name": "NRAS", "primaryCoding": {"id": "hgnc:7989", "code": "HGNC:7989", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7989"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_002524.5", "code": "NM_002524.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_002524.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000213281", "code": "ENSG00000213281", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000213281"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4893", "code": "4893", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4893"]}}], "extensions": [{"name": "location", "value": "1p13.2"}, {"name": "location_sortable", "value": "01p13.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 19, "conceptType": "Drug", "name": "Cetuximab", "primaryCoding": {"id": "ncit:C1723", "code": "C1723", "name": "Cetuximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10048, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized cetuximab in combination with irinotecan-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.erbitux", "type": "Document", "subtype": "Regulatory approval", "name": "Erbitux (cetuximab) [product information]. EMA.", "citation": "Merck Europe B.V. Erbitux (cetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf. Revised May 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Erbitux", "drug_name_generic": "cetuximab", "first_published": "2009-07-14", "access_date": null, "publication_date": "2022-05-25", "url": "https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.erbitux:1", "indication": "Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized cetuximab in combination with irinotecan-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Erbitux (cetuximab) in combination with irinotecan", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.erbitux", "type": "Document", "subtype": "Regulatory approval", "name": "Erbitux (cetuximab) [product information]. EMA.", "citation": "Merck Europe B.V. Erbitux (cetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf. Revised May 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Erbitux", "drug_name_generic": "cetuximab", "first_published": "2009-07-14", "access_date": null, "publication_date": "2022-05-25", "url": "https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 555, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 24, "name": "EGFR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "EGFR"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 25, "name": "Wild type KRAS", "genes": [{"id": 31, "name": "KRAS", "primaryCoding": {"id": "hgnc:6407", "code": "HGNC:6407", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_004985.5", "code": "NM_004985.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000133703", "code": "ENSG00000133703", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000133703"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3845", "code": "3845", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3845"]}}], "extensions": [{"name": "location", "value": "12p12.1"}, {"name": "location_sortable", "value": "12p12.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 26, "name": "Wild type HRAS", "genes": [{"id": 27, "name": "HRAS", "primaryCoding": {"id": "hgnc:5173", "code": "HGNC:5173", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5173"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005343.4", "code": "NM_005343.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005343.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000174775", "code": "ENSG00000174775", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000174775"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3265", "code": "3265", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3265"]}}], "extensions": [{"name": "location", "value": "11p15.5"}, {"name": "location_sortable", "value": "11p15.5"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 27, "name": "Wild type NRAS", "genes": [{"id": 33, "name": "NRAS", "primaryCoding": {"id": "hgnc:7989", "code": "HGNC:7989", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7989"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_002524.5", "code": "NM_002524.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_002524.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000213281", "code": "ENSG00000213281", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000213281"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4893", "code": "4893", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4893"]}}], "extensions": [{"name": "location", "value": "1p13.2"}, {"name": "location_sortable", "value": "01p13.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 15, "membership_operator": "AND", "therapies": [{"id": 27, "conceptType": "Drug", "name": "Irinotecan", "primaryCoding": {"id": "ncit:C62040", "code": "C62040", "name": "Irinotecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62040"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase I inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 19, "conceptType": "Drug", "name": "Cetuximab", "primaryCoding": {"id": "ncit:C1723", "code": "C1723", "name": "Cetuximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10049, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized cetuximab in combination with FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) for the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.erbitux", "type": "Document", "subtype": "Regulatory approval", "name": "Erbitux (cetuximab) [product information]. EMA.", "citation": "Merck Europe B.V. Erbitux (cetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf. Revised May 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Erbitux", "drug_name_generic": "cetuximab", "first_published": "2009-07-14", "access_date": null, "publication_date": "2022-05-25", "url": "https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.erbitux:2", "indication": "Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in first-line in combination with FOLFOX.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized cetuximab in combination with FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) for the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Erbitux (cetuximab) in combination with 5-fluorouracil and oxaliplatin", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.erbitux", "type": "Document", "subtype": "Regulatory approval", "name": "Erbitux (cetuximab) [product information]. EMA.", "citation": "Merck Europe B.V. Erbitux (cetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf. Revised May 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Erbitux", "drug_name_generic": "cetuximab", "first_published": "2009-07-14", "access_date": null, "publication_date": "2022-05-25", "url": "https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 556, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 24, "name": "EGFR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "EGFR"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 25, "name": "Wild type KRAS", "genes": [{"id": 31, "name": "KRAS", "primaryCoding": {"id": "hgnc:6407", "code": "HGNC:6407", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_004985.5", "code": "NM_004985.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000133703", "code": "ENSG00000133703", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000133703"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3845", "code": "3845", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3845"]}}], "extensions": [{"name": "location", "value": "12p12.1"}, {"name": "location_sortable", "value": "12p12.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 26, "name": "Wild type HRAS", "genes": [{"id": 27, "name": "HRAS", "primaryCoding": {"id": "hgnc:5173", "code": "HGNC:5173", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5173"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005343.4", "code": "NM_005343.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005343.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000174775", "code": "ENSG00000174775", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000174775"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3265", "code": "3265", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3265"]}}], "extensions": [{"name": "location", "value": "11p15.5"}, {"name": "location_sortable", "value": "11p15.5"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 27, "name": "Wild type NRAS", "genes": [{"id": 33, "name": "NRAS", "primaryCoding": {"id": "hgnc:7989", "code": "HGNC:7989", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7989"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_002524.5", "code": "NM_002524.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_002524.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000213281", "code": "ENSG00000213281", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000213281"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4893", "code": "4893", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4893"]}}], "extensions": [{"name": "location", "value": "1p13.2"}, {"name": "location_sortable", "value": "01p13.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 109, "membership_operator": "AND", "therapies": [{"id": 28, "conceptType": "Drug", "name": "Oxaliplatin", "primaryCoding": {"id": "ncit:C1181", "code": "C1181", "name": "Oxaliplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 19, "conceptType": "Drug", "name": "Cetuximab", "primaryCoding": {"id": "ncit:C1723", "code": "C1723", "name": "Cetuximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10050, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized fulvestrant as a monotherapy for the treatment of patients who are postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer. These patients should not have been previously treated with endocrine therapy, or have had disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.faslodex", "type": "Document", "subtype": "Regulatory approval", "name": "Faslodex (fulvestrant) [product information]. EMA.", "citation": "AstraZeneca AB. Faslodex (fulvestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf. Revised August 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Faslodex", "drug_name_generic": "fulvestrant", "first_published": "2009-02-18", "access_date": null, "publication_date": "2022-08-31", "url": "https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.faslodex:0", "indication": "Faslodex is indicated as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized fulvestrant as a monotherapy for the treatment of patients who are postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer. These patients should not have been previously treated with endocrine therapy, or have had disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Faslodex (fulvestrant)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.faslodex", "type": "Document", "subtype": "Regulatory approval", "name": "Faslodex (fulvestrant) [product information]. EMA.", "citation": "AstraZeneca AB. Faslodex (fulvestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf. Revised August 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Faslodex", "drug_name_generic": "fulvestrant", "first_published": "2009-02-18", "access_date": null, "publication_date": "2022-08-31", "url": "https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 137, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10052, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.faslodex", "type": "Document", "subtype": "Regulatory approval", "name": "Faslodex (fulvestrant) [product information]. EMA.", "citation": "AstraZeneca AB. Faslodex (fulvestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf. Revised August 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Faslodex", "drug_name_generic": "fulvestrant", "first_published": "2009-02-18", "access_date": null, "publication_date": "2022-08-31", "url": "https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.faslodex:1", "indication": "Faslodex is indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Faslodex (fulvestrant) in combination with palbociclib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.faslodex", "type": "Document", "subtype": "Regulatory approval", "name": "Faslodex (fulvestrant) [product information]. EMA.", "citation": "AstraZeneca AB. Faslodex (fulvestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf. Revised August 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Faslodex", "drug_name_generic": "fulvestrant", "first_published": "2009-02-18", "access_date": null, "publication_date": "2022-08-31", "url": "https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 143, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 28, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 31, "conceptType": "Drug", "name": "Palbociclib", "primaryCoding": {"id": "ncit:C49176", "code": "C49176", "name": "Palbociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10053, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.faslodex", "type": "Document", "subtype": "Regulatory approval", "name": "Faslodex (fulvestrant) [product information]. EMA.", "citation": "AstraZeneca AB. Faslodex (fulvestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf. Revised August 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Faslodex", "drug_name_generic": "fulvestrant", "first_published": "2009-02-18", "access_date": null, "publication_date": "2022-08-31", "url": "https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.faslodex:1", "indication": "Faslodex is indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Faslodex (fulvestrant) in combination with palbociclib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.faslodex", "type": "Document", "subtype": "Regulatory approval", "name": "Faslodex (fulvestrant) [product information]. EMA.", "citation": "AstraZeneca AB. Faslodex (fulvestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf. Revised August 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Faslodex", "drug_name_generic": "fulvestrant", "first_published": "2009-02-18", "access_date": null, "publication_date": "2022-08-31", "url": "https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 144, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 28, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 31, "conceptType": "Drug", "name": "Palbociclib", "primaryCoding": {"id": "ncit:C49176", "code": "C49176", "name": "Palbociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10054, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.faslodex", "type": "Document", "subtype": "Regulatory approval", "name": "Faslodex (fulvestrant) [product information]. EMA.", "citation": "AstraZeneca AB. Faslodex (fulvestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf. Revised August 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Faslodex", "drug_name_generic": "fulvestrant", "first_published": "2009-02-18", "access_date": null, "publication_date": "2022-08-31", "url": "https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.faslodex:1", "indication": "Faslodex is indicated in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized fulvestrant in combination with palbociclib for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Faslodex (fulvestrant) in combination with palbociclib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.faslodex", "type": "Document", "subtype": "Regulatory approval", "name": "Faslodex (fulvestrant) [product information]. EMA.", "citation": "AstraZeneca AB. Faslodex (fulvestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf. Revised August 2022. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Faslodex", "drug_name_generic": "fulvestrant", "first_published": "2009-02-18", "access_date": null, "publication_date": "2022-08-31", "url": "https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 145, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 28, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 31, "conceptType": "Drug", "name": "Palbociclib", "primaryCoding": {"id": "ncit:C49176", "code": "C49176", "name": "Palbociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10058, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pralsetinib as a monotherapy treatment for adult patients with RET fusion-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with a RET inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.gavreto", "type": "Document", "subtype": "Regulatory approval", "name": "Gavreto (pralsetinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Gavreto (pralsetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf. Revised January 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Gavreto", "drug_name_generic": "pralsetinib", "first_published": "2021-12-09", "access_date": null, "publication_date": "2025-01-17", "url": "https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.gavreto:0", "indication": "Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pralsetinib as a monotherapy treatment for adult patients with RET fusion-positive advanced non-small cell lung cancer (NSCLC) who have not previously been treated with a RET inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Gavreto (pralsetinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.gavreto", "type": "Document", "subtype": "Regulatory approval", "name": "Gavreto (pralsetinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Gavreto (pralsetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf. Revised January 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Gavreto", "drug_name_generic": "pralsetinib", "first_published": "2021-12-09", "access_date": null, "publication_date": "2025-01-17", "url": "https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 364, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 18, "name": "v::RET", "genes": [{"id": 49, "name": "RET", "primaryCoding": {"id": "hgnc:9967", "code": "HGNC:9967", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_020975.6", "code": "NM_020975.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000165731", "code": "ENSG00000165731", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000165731"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5979", "code": "5979", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5979"]}}], "extensions": [{"name": "location", "value": "10q11.21"}, {"name": "location_sortable", "value": "10q11.21"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 32, "conceptType": "Drug", "name": "Pralsetinib", "primaryCoding": {"id": "ncit:C132295", "code": "C132295", "name": "Pralsetinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132295"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["RET inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10059, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized gefitinib as a monotherapy treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating variants of EGFR-TK.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.iressa", "type": "Document", "subtype": "Regulatory approval", "name": "Iressa (gefitinib) [product information]. EMA.", "citation": "AstraZeneca AB. Iressa (gefitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf. Revised July 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Iressa", "drug_name_generic": "gefitinib", "first_published": "2009-07-22", "access_date": null, "publication_date": "2023-07-17", "url": "https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.iressa:0", "indication": "IRESSA is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized gefitinib as a monotherapy treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating variants of EGFR-TK.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Iressa (gefitinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.iressa", "type": "Document", "subtype": "Regulatory approval", "name": "Iressa (gefitinib) [product information]. EMA.", "citation": "AstraZeneca AB. Iressa (gefitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf. Revised July 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Iressa", "drug_name_generic": "gefitinib", "first_published": "2009-07-22", "access_date": null, "publication_date": "2023-07-17", "url": "https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 559, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 19, "name": "EGFR oncogenic variants", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 33, "conceptType": "Drug", "name": "Gefitinib", "primaryCoding": {"id": "ncit:C1855", "code": "C1855", "name": "Gefitinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1855"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10060, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized afatinib as a monotherapy indicated for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR variants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.giotrif", "type": "Document", "subtype": "Regulatory approval", "name": "Giotrif (afatinib) [product information]. EMA.", "citation": "Boehringer Ingelheim International GmbH. Giotrif (afatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf. Revised June 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Giotrif", "drug_name_generic": "afatinib", "first_published": "2013-10-16", "access_date": null, "publication_date": "2023-06-21", "url": "https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.giotrif:0", "indication": "GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized afatinib as a monotherapy indicated for the treatment of EGFR TKI-naive adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR variants.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Giotrif (afatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.giotrif", "type": "Document", "subtype": "Regulatory approval", "name": "Giotrif (afatinib) [product information]. EMA.", "citation": "Boehringer Ingelheim International GmbH. Giotrif (afatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf. Revised June 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Giotrif", "drug_name_generic": "afatinib", "first_published": "2013-10-16", "access_date": null, "publication_date": "2023-06-21", "url": "https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 560, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 19, "name": "EGFR oncogenic variants", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 34, "conceptType": "Drug", "name": "Afatinib", "primaryCoding": {"id": "ncit:C66940", "code": "C66940", "name": "Afatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66940"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10061, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:0", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "metastatic breast cancer (MBC)", "raw_therapeutics": "Herceptin (trastuzumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 418, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10063, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:1", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "metastatic breast cancer (MBC)", "raw_therapeutics": "Herceptin (trastuzumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 561, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 110, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10065, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:2", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "metastatic breast cancer (MBC)", "raw_therapeutics": "Herceptin (trastuzumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 549, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 108, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10067, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:3", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "metastatic breast cancer (MBC)", "raw_therapeutics": "Herceptin (trastuzumab) in combination with an aromatase inhibitor", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 562, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 111, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 36, "conceptType": "Drug", "name": "Anastrozole", "primaryCoding": {"id": "ncit:C1607", "code": "C1607", "name": "Anastrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10069, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:4", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "breast cancer", "raw_therapeutics": "Herceptin (trastuzumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 418, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10070, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:5", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "breast cancer", "raw_therapeutics": "Herceptin (trastuzumab) in combination with paclitaxel or docetaxel", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 561, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 110, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10071, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:5", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "breast cancer", "raw_therapeutics": "Herceptin (trastuzumab) in combination with paclitaxel or docetaxel", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 549, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 108, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10072, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin for the treatment of adult patients with HER2 positive early breast cancer (EBC). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:6", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin for the treatment of adult patients with HER2 positive early breast cancer (EBC). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "breast cancer", "raw_therapeutics": "Herceptin (trastuzumab) in combination with adjuvant chemotherapy containing docetaxel and carboplatin", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 563, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 112, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10073, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) whose tumors are locally advanced (including inflammatory) disease or > 2 cm in diameter. This indication is based on the multicenter randomized trial MO16432 which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:7", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) in combination with neoadjuvant chemotherapy followed by adjuvant Herceptin therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) whose tumors are locally advanced (including inflammatory) disease or > 2 cm in diameter. This indication is based on the multicenter randomized trial MO16432 which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "breast cancer", "raw_therapeutics": "Herceptin (trastuzumab) in combination with neoadjuvant chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 564, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 114, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10074, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:0", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab as a monotherapy for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have received at least two chemotherapy regimes for their metastatic disease. Prior chemotherapy must have been included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must have also failed hormonal therapy, unless a patient is unsuitable for those treatments. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "metastatic breast cancer (MBC)", "raw_therapeutics": "Herceptin (trastuzumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 565, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10076, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:1", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "metastatic breast cancer (MBC)", "raw_therapeutics": "Herceptin (trastuzumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 566, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 110, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10078, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:2", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with docetaxel for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) that have not received chemotherapy for their metastatic disease. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "metastatic breast cancer (MBC)", "raw_therapeutics": "Herceptin (trastuzumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 550, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 108, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10080, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:3", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "metastatic breast cancer (MBC)", "raw_therapeutics": "Herceptin (trastuzumab) in combination with an aromatase inhibitor", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 567, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 111, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 36, "conceptType": "Drug", "name": "Anastrozole", "primaryCoding": {"id": "ncit:C1607", "code": "C1607", "name": "Anastrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10082, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:4", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant), and radiotherapy (if applicable). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "breast cancer", "raw_therapeutics": "Herceptin (trastuzumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 565, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10083, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:5", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "breast cancer", "raw_therapeutics": "Herceptin (trastuzumab) in combination with paclitaxel or docetaxel", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 566, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 110, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10084, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:5", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with paclitaxel or docetaxel for the treatment of adult patients with HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "breast cancer", "raw_therapeutics": "Herceptin (trastuzumab) in combination with paclitaxel or docetaxel", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 550, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 108, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10085, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin for the treatment of adult patients with HER2 positive early breast cancer (EBC). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:6", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin for the treatment of adult patients with HER2 positive early breast cancer (EBC). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "breast cancer", "raw_therapeutics": "Herceptin (trastuzumab) in combination with adjuvant chemotherapy containing docetaxel and carboplatin", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 568, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 112, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10086, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) whose tumors are locally advanced (including inflammatory) disease or > 2 cm in diameter. This indication is based on the multicenter randomized trial MO16432 which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:7", "indication": "Herceptin is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC) in combination with neoadjuvant chemotherapy followed by adjuvant Herceptin therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab for the treatment of adult patients with HER2 positive early breast cancer (EBC) whose tumors are locally advanced (including inflammatory) disease or > 2 cm in diameter. This indication is based on the multicenter randomized trial MO16432 which used doxorubicin in combination with paclitaxel for the neoadjuvant chemotherapy. The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "breast cancer", "raw_therapeutics": "Herceptin (trastuzumab) in combination with neoadjuvant chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 569, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 114, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10087, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:8", "indication": "Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "adenocracinoma of the stomach or gastroesophageal junction", "raw_therapeutics": "Herceptin (trastuzumab) in combination with capecitabine or 5-fluorouracil and cisplatin", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 570, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 81, "conceptType": "Disease", "name": "Esophagogastric Adenocarcinoma", "primaryCoding": {"id": "oncotree:EGC", "code": "EGC", "name": "Esophagogastric Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=EGC"]}, "mappings": []}, "objectTherapeutic": {"id": 115, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 38, "conceptType": "Drug", "name": "Capecitabine", "primaryCoding": {"id": "ncit:C1794", "code": "C1794", "name": "Capecitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10088, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:8", "indication": "Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "adenocracinoma of the stomach or gastroesophageal junction", "raw_therapeutics": "Herceptin (trastuzumab) in combination with capecitabine or 5-fluorouracil and cisplatin", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 571, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 81, "conceptType": "Disease", "name": "Esophagogastric Adenocarcinoma", "primaryCoding": {"id": "oncotree:EGC", "code": "EGC", "name": "Esophagogastric Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=EGC"]}, "mappings": []}, "objectTherapeutic": {"id": 116, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10089, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:8", "indication": "Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "adenocracinoma of the stomach or gastroesophageal junction", "raw_therapeutics": "Herceptin (trastuzumab) in combination with capecitabine or 5-fluorouracil and cisplatin", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 572, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 81, "conceptType": "Disease", "name": "Esophagogastric Adenocarcinoma", "primaryCoding": {"id": "oncotree:EGC", "code": "EGC", "name": "Esophagogastric Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=EGC"]}, "mappings": []}, "objectTherapeutic": {"id": 115, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 38, "conceptType": "Drug", "name": "Capecitabine", "primaryCoding": {"id": "ncit:C1794", "code": "C1794", "name": "Capecitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10090, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.herceptin:8", "indication": "Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.", "raw_biomarkers": null, "raw_cancer_type": "adenocracinoma of the stomach or gastroesophageal junction", "raw_therapeutics": "Herceptin (trastuzumab) in combination with capecitabine or 5-fluorouracil and cisplatin", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.herceptin", "type": "Document", "subtype": "Regulatory approval", "name": "Herceptin (trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.", "company": "", "drug_name_brand": "Herceptin", "drug_name_generic": "trastuzumab", "first_published": "2010-03-01", "access_date": null, "publication_date": "2023-03-17", "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 573, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 81, "conceptType": "Disease", "name": "Esophagogastric Adenocarcinoma", "primaryCoding": {"id": "oncotree:EGC", "code": "EGC", "name": "Esophagogastric Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=EGC"]}, "mappings": []}, "objectTherapeutic": {"id": 116, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10091, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.ibrance", "type": "Document", "subtype": "Regulatory approval", "name": "Ibrance (palbociclib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Ibrance", "drug_name_generic": "palbociclib", "first_published": "2016-11-25", "access_date": null, "publication_date": "2023-06-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.ibrance:0", "indication": "IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Ibrance (palbociclib) in combination with an aromatase inhibitor", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.ibrance", "type": "Document", "subtype": "Regulatory approval", "name": "Ibrance (palbociclib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Ibrance", "drug_name_generic": "palbociclib", "first_published": "2016-11-25", "access_date": null, "publication_date": "2023-06-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 311, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 49, "membership_operator": "AND", "therapies": [{"id": 31, "conceptType": "Drug", "name": "Palbociclib", "primaryCoding": {"id": "ncit:C49176", "code": "C49176", "name": "Palbociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10092, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.ibrance", "type": "Document", "subtype": "Regulatory approval", "name": "Ibrance (palbociclib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Ibrance", "drug_name_generic": "palbociclib", "first_published": "2016-11-25", "access_date": null, "publication_date": "2023-06-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.ibrance:0", "indication": "IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Ibrance (palbociclib) in combination with an aromatase inhibitor", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.ibrance", "type": "Document", "subtype": "Regulatory approval", "name": "Ibrance (palbociclib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Ibrance", "drug_name_generic": "palbociclib", "first_published": "2016-11-25", "access_date": null, "publication_date": "2023-06-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 312, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 49, "membership_operator": "AND", "therapies": [{"id": 31, "conceptType": "Drug", "name": "Palbociclib", "primaryCoding": {"id": "ncit:C49176", "code": "C49176", "name": "Palbociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10093, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.ibrance", "type": "Document", "subtype": "Regulatory approval", "name": "Ibrance (palbociclib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Ibrance", "drug_name_generic": "palbociclib", "first_published": "2016-11-25", "access_date": null, "publication_date": "2023-06-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.ibrance:0", "indication": "IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with an aromatase inhibitor for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This indication is based on a randomized phase 3 study, PALOMA-2, that evaluated letrozole in combination with either palbociclib or placebo. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Ibrance (palbociclib) in combination with an aromatase inhibitor", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.ibrance", "type": "Document", "subtype": "Regulatory approval", "name": "Ibrance (palbociclib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Ibrance", "drug_name_generic": "palbociclib", "first_published": "2016-11-25", "access_date": null, "publication_date": "2023-06-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 313, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 49, "membership_operator": "AND", "therapies": [{"id": 31, "conceptType": "Drug", "name": "Palbociclib", "primaryCoding": {"id": "ncit:C49176", "code": "C49176", "name": "Palbociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10097, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.ibrance", "type": "Document", "subtype": "Regulatory approval", "name": "Ibrance (palbociclib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Ibrance", "drug_name_generic": "palbociclib", "first_published": "2016-11-25", "access_date": null, "publication_date": "2023-06-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.ibrance:1", "indication": "IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Ibrance (palbociclib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.ibrance", "type": "Document", "subtype": "Regulatory approval", "name": "Ibrance (palbociclib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Ibrance", "drug_name_generic": "palbociclib", "first_published": "2016-11-25", "access_date": null, "publication_date": "2023-06-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 143, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 28, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 31, "conceptType": "Drug", "name": "Palbociclib", "primaryCoding": {"id": "ncit:C49176", "code": "C49176", "name": "Palbociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10098, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.ibrance", "type": "Document", "subtype": "Regulatory approval", "name": "Ibrance (palbociclib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Ibrance", "drug_name_generic": "palbociclib", "first_published": "2016-11-25", "access_date": null, "publication_date": "2023-06-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.ibrance:1", "indication": "IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Ibrance (palbociclib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.ibrance", "type": "Document", "subtype": "Regulatory approval", "name": "Ibrance (palbociclib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Ibrance", "drug_name_generic": "palbociclib", "first_published": "2016-11-25", "access_date": null, "publication_date": "2023-06-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 144, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 28, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 31, "conceptType": "Drug", "name": "Palbociclib", "primaryCoding": {"id": "ncit:C49176", "code": "C49176", "name": "Palbociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10099, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.ibrance", "type": "Document", "subtype": "Regulatory approval", "name": "Ibrance (palbociclib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Ibrance", "drug_name_generic": "palbociclib", "first_published": "2016-11-25", "access_date": null, "publication_date": "2023-06-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.ibrance:1", "indication": "IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized palbociclib in combination with fulvestrant for patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, who have also received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Ibrance (palbociclib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.ibrance", "type": "Document", "subtype": "Regulatory approval", "name": "Ibrance (palbociclib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Ibrance", "drug_name_generic": "palbociclib", "first_published": "2016-11-25", "access_date": null, "publication_date": "2023-06-06", "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 145, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 28, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 31, "conceptType": "Drug", "name": "Palbociclib", "primaryCoding": {"id": "ncit:C49176", "code": "C49176", "name": "Palbociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10103, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:0", "indication": "Glivec is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.", "raw_biomarkers": null, "raw_cancer_type": "Chronic Myeloid Leukemia", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 578, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10104, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:1", "indication": "Glivec is indicated for the treatment of adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.", "raw_biomarkers": null, "raw_cancer_type": "Chronic Myeloid Leukemia", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 578, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10105, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:2", "indication": "Glivec is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 579, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10106, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized imatinib as a monotherapy treatment for adult patients with relapased or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:3", "indication": "Glivec is indicated for the treatment of adult patients with relapsed or refractory Ph+ ALL as monotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib as a monotherapy treatment for adult patients with relapased or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).", "raw_biomarkers": null, "raw_cancer_type": "Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL)", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 579, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10107, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:4", "indication": "Glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.", "raw_biomarkers": null, "raw_cancer_type": "Myelodysplastic/myeloproliferative diseases (MDS/MPD)", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 161, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 28, "name": "PDGFRA rearrangements", "genes": [{"id": 39, "name": "PDGFRA", "primaryCoding": {"id": "hgnc:8803", "code": "HGNC:8803", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8803"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_006206.6", "code": "NM_006206.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_006206.6"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000134853", "code": "ENSG00000134853", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000134853"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5156", "code": "5156", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5156"]}}], "extensions": [{"name": "location", "value": "4q12"}, {"name": "location_sortable", "value": "04q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 43, "conceptType": "Disease", "name": "Myelodysplastic Syndromes", "primaryCoding": {"id": "oncotree:MDS", "code": "MDS", "name": "Myelodysplastic Syndromes", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10108, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:4", "indication": "Glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.", "raw_biomarkers": null, "raw_cancer_type": "Myelodysplastic/myeloproliferative diseases (MDS/MPD)", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 162, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 29, "name": "PDGFRB rearrangements", "genes": [{"id": 40, "name": "PDGFRB", "primaryCoding": {"id": "hgnc:8804", "code": "HGNC:8804", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8804"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000113721", "code": "ENSG00000113721", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000113721"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5159", "code": "5159", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5159"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_002609.4", "code": "NM_002609.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_002609.4"]}}], "extensions": [{"name": "location", "value": "5q32"}, {"name": "location_sortable", "value": "05q32"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 43, "conceptType": "Disease", "name": "Myelodysplastic Syndromes", "primaryCoding": {"id": "oncotree:MDS", "code": "MDS", "name": "Myelodysplastic Syndromes", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10109, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:4", "indication": "Glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.", "raw_biomarkers": null, "raw_cancer_type": "Myelodysplastic/myeloproliferative diseases (MDS/MPD)", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 580, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 28, "name": "PDGFRA rearrangements", "genes": [{"id": 39, "name": "PDGFRA", "primaryCoding": {"id": "hgnc:8803", "code": "HGNC:8803", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8803"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_006206.6", "code": "NM_006206.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_006206.6"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000134853", "code": "ENSG00000134853", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000134853"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5156", "code": "5156", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5156"]}}], "extensions": [{"name": "location", "value": "4q12"}, {"name": "location_sortable", "value": "04q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 45, "conceptType": "Disease", "name": "Myeloproliferative Neoplasm", "primaryCoding": {"id": "oncotree:MPN", "code": "MPN", "name": "Myeloproliferative Neoplasm", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MPN"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10110, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:4", "indication": "Glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.", "raw_biomarkers": null, "raw_cancer_type": "Myelodysplastic/myeloproliferative diseases (MDS/MPD)", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 581, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 29, "name": "PDGFRB rearrangements", "genes": [{"id": 40, "name": "PDGFRB", "primaryCoding": {"id": "hgnc:8804", "code": "HGNC:8804", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8804"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000113721", "code": "ENSG00000113721", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000113721"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5159", "code": "5159", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5159"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_002609.4", "code": "NM_002609.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_002609.4"]}}], "extensions": [{"name": "location", "value": "5q32"}, {"name": "location_sortable", "value": "05q32"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 45, "conceptType": "Disease", "name": "Myeloproliferative Neoplasm", "primaryCoding": {"id": "oncotree:MPN", "code": "MPN", "name": "Myeloproliferative Neoplasm", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MPN"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10111, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with a FIP1L1::PDGFRA rearrangement.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:5", "indication": "Glivec is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with a FIP1L1::PDGFRA rearrangement.", "raw_biomarkers": null, "raw_cancer_type": "Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL)", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 164, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 30, "name": "FIP1L1::PDGFRA", "genes": [{"id": 25, "name": "FIP1L1", "primaryCoding": {"id": "hgnc:19124", "code": "HGNC:19124", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19124"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_030917.4", "code": "NM_030917.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_030917.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000145216", "code": "ENSG00000145216", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000145216"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:81608", "code": "81608", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/81608"]}}], "extensions": [{"name": "location", "value": "4q12"}, {"name": "location_sortable", "value": "04q12"}]}, {"id": 39, "name": "PDGFRA", "primaryCoding": {"id": "hgnc:8803", "code": "HGNC:8803", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8803"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_006206.6", "code": "NM_006206.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_006206.6"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000134853", "code": "ENSG00000134853", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000134853"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5156", "code": "5156", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5156"]}}], "extensions": [{"name": "location", "value": "4q12"}, {"name": "location_sortable", "value": "04q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 12, "conceptType": "Disease", "name": "Chronic Eosinophilic Leukemia, NOS", "primaryCoding": {"id": "oncotree:CELNOS", "code": "CELNOS", "name": "Chronic Eosinophilic Leukemia, NOS", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CELNOS"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10112, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:6", "indication": "Glivec is indicated for the treatment of the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).", "raw_biomarkers": null, "raw_cancer_type": "Gastrointestinal Stromal Tumor (GIST)", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 165, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 31, "name": "CD117 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD117"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 22, "conceptType": "Disease", "name": "Gastrointestinal Stromal Tumor", "primaryCoding": {"id": "oncotree:GIST", "code": "GIST", "name": "Gastrointestinal Stromal Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GIST"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10113, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized imatinib for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD 117) positive gastrointestinal stromal tumors (GIST). Patients who have a low or very low risk of recurrence should not received adjuvant treatment.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:7", "indication": "Glivec is indicated for the treatment of the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD 117) positive gastrointestinal stromal tumors (GIST). Patients who have a low or very low risk of recurrence should not received adjuvant treatment.", "raw_biomarkers": null, "raw_cancer_type": "Gastrointestinal Stromal Tumor (GIST)", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 165, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 31, "name": "CD117 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD117"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 22, "conceptType": "Disease", "name": "Gastrointestinal Stromal Tumor", "primaryCoding": {"id": "oncotree:GIST", "code": "GIST", "name": "Gastrointestinal Stromal Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GIST"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10114, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the p.T315I variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.iclusig", "type": "Document", "subtype": "Regulatory approval", "name": "Iclusig (ponatinib) [product information]. EMA.", "citation": "Incyte Biosciences Distribution B.V. Iclusig (ponatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf. Revised October 2022. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Iclusig", "drug_name_generic": "ponatinib", "first_published": "2013-07-11", "access_date": null, "publication_date": "2022-10-21", "url": "https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.iclusig:0", "indication": "Iclusig is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the p.T315I variant.", "raw_biomarkers": null, "raw_cancer_type": "Chronic Myeloid Leukemia", "raw_therapeutics": "Iclusig (ponatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.iclusig", "type": "Document", "subtype": "Regulatory approval", "name": "Iclusig (ponatinib) [product information]. EMA.", "citation": "Incyte Biosciences Distribution B.V. Iclusig (ponatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf. Revised October 2022. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Iclusig", "drug_name_generic": "ponatinib", "first_published": "2013-07-11", "access_date": null, "publication_date": "2022-10-21", "url": "https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 363, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 32, "name": "ABL1 p.T315I", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "9"}, {"name": "start_position", "value": 133748283}, {"name": "end_position", "value": 133748283}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.944C>T"}, {"name": "protein_change", "value": "p.T315I"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "5"}, {"name": "rsid", "value": "rs121913459"}, {"name": "hgvsg", "value": "9:g.133748283C>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "conceptType": "Drug", "name": "Ponatinib", "primaryCoding": {"id": "ncit:C95777", "code": "C95777", "name": "Ponatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95777"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10115, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.iclusig", "type": "Document", "subtype": "Regulatory approval", "name": "Iclusig (ponatinib) [product information]. EMA.", "citation": "Incyte Biosciences Distribution B.V. Iclusig (ponatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf. Revised October 2022. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Iclusig", "drug_name_generic": "ponatinib", "first_published": "2013-07-11", "access_date": null, "publication_date": "2022-10-21", "url": "https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.iclusig:1", "indication": "Iclusig is indicated in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I variant.", "raw_biomarkers": null, "raw_cancer_type": "Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) ", "raw_therapeutics": "Iclusig (ponatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.iclusig", "type": "Document", "subtype": "Regulatory approval", "name": "Iclusig (ponatinib) [product information]. EMA.", "citation": "Incyte Biosciences Distribution B.V. Iclusig (ponatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf. Revised October 2022. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Iclusig", "drug_name_generic": "ponatinib", "first_published": "2013-07-11", "access_date": null, "publication_date": "2022-10-21", "url": "https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 582, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "conceptType": "Drug", "name": "Ponatinib", "primaryCoding": {"id": "ncit:C95777", "code": "C95777", "name": "Ponatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95777"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10116, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.iclusig", "type": "Document", "subtype": "Regulatory approval", "name": "Iclusig (ponatinib) [product information]. EMA.", "citation": "Incyte Biosciences Distribution B.V. Iclusig (ponatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf. Revised October 2022. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Iclusig", "drug_name_generic": "ponatinib", "first_published": "2013-07-11", "access_date": null, "publication_date": "2022-10-21", "url": "https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.iclusig:1", "indication": "Iclusig is indicated in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I variant.", "raw_biomarkers": null, "raw_cancer_type": "Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) ", "raw_therapeutics": "Iclusig (ponatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.iclusig", "type": "Document", "subtype": "Regulatory approval", "name": "Iclusig (ponatinib) [product information]. EMA.", "citation": "Incyte Biosciences Distribution B.V. Iclusig (ponatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf. Revised October 2022. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Iclusig", "drug_name_generic": "ponatinib", "first_published": "2013-07-11", "access_date": null, "publication_date": "2022-10-21", "url": "https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 583, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}, {"id": 32, "name": "ABL1 p.T315I", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "9"}, {"name": "start_position", "value": 133748283}, {"name": "end_position", "value": 133748283}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.944C>T"}, {"name": "protein_change", "value": "p.T315I"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "5"}, {"name": "rsid", "value": "rs121913459"}, {"name": "hgvsg", "value": "9:g.133748283C>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "conceptType": "Drug", "name": "Ponatinib", "primaryCoding": {"id": "ncit:C95777", "code": "C95777", "name": "Ponatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95777"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10117, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized durvalumab as a monotherapy for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumors express PD-L1 on >= 1% of tumor cells and whose disease has not progressed following platinum-based chemoradiation therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.imfinzi:0", "indication": "IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on >= 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized durvalumab as a monotherapy for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumors express PD-L1 on >= 1% of tumor cells and whose disease has not progressed following platinum-based chemoradiation therapy.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Imfinzi (durvalumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 584, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 33, "name": "PD-L1 >= 1%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.01"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10118, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) and no sensitizing EGFR mutations or ALK positive mutations. This indication is POSEIDON (NCT03164616), a randomized, multicenter, active-controlled, and open-label study where the specific chemotherapy regime used was based on the histology of the patient's NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.imfinzi:1", "indication": "IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) and no sensitizing EGFR mutations or ALK positive mutations. This indication is POSEIDON (NCT03164616), a randomized, multicenter, active-controlled, and open-label study where the specific chemotherapy regime used was based on the histology of the patient's NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Imfinzi (durvalumab) in combination with tremelimumab and platinum-based chemotherapy.", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 585, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 117, "membership_operator": "AND", "therapies": [{"id": 45, "conceptType": "Drug", "name": "Tremelimumab", "primaryCoding": {"id": "ncit:C49085", "code": "C49085", "name": "Tremelimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10119, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.imfinzi:2", "indication": "IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).", "initial_approval_date": "2024-08-19", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-1049-ws-2463-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).", "raw_biomarkers": "mismatch repair deficient (dMMR) or mismatch repair proficient (pMMR).", "raw_cancer_type": "Endometrial cancer", "raw_therapeutics": "Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi (durvalumab) as monotherapy for endometrial cancer that is mismatch repair deficient (dMMR) or Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi (durvalumab) in combination with olaparib for endometrial cancer that is mismatch repair proficient (pMMR).", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 109, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Mismatch Repair"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 18, "conceptType": "Disease", "name": "Endometrial Carcinoma", "primaryCoding": {"id": "oncotree:UCEC", "code": "UCEC", "name": "Endometrial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC"]}, "mappings": []}, "objectTherapeutic": {"id": 25, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10120, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.imfinzi:2", "indication": "IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).", "initial_approval_date": "2024-08-19", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-1049-ws-2463-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).", "raw_biomarkers": "mismatch repair deficient (dMMR) or mismatch repair proficient (pMMR).", "raw_cancer_type": "Endometrial cancer", "raw_therapeutics": "Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi (durvalumab) as monotherapy for endometrial cancer that is mismatch repair deficient (dMMR) or Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi (durvalumab) in combination with olaparib for endometrial cancer that is mismatch repair proficient (pMMR).", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 586, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 37, "name": "pMMR", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Mismatch Repair"}, {"name": "present", "value": true}, {"name": "status", "value": "Proficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 18, "conceptType": "Disease", "name": "Endometrial Carcinoma", "primaryCoding": {"id": "oncotree:UCEC", "code": "UCEC", "name": "Endometrial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC"]}, "mappings": []}, "objectTherapeutic": {"id": 118, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10121, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) and no sensitizing EGFR mutations or ALK positive mutations. This indication is POSEIDON (NCT03164616), a randomized, multicenter, active-controlled, and open-label study where the specific chemotherapy regime used was based on the histology of the patient's NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.imjudo", "type": "Document", "subtype": "Regulatory approval", "name": "Imjudo (tremelimumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imjudo (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf. Revised March 2024. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Imjudo", "drug_name_generic": "tremelimumab", "first_published": "2023-03-02", "access_date": null, "publication_date": "2024-03-13", "url": "https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.imjudo:0", "indication": "IMJUDO in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) and no sensitizing EGFR mutations or ALK positive mutations. This indication is POSEIDON (NCT03164616), a randomized, multicenter, active-controlled, and open-label study where the specific chemotherapy regime used was based on the histology of the patient's NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Imjudo (tremelimumab) in combination with durvalumab and platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.imjudo", "type": "Document", "subtype": "Regulatory approval", "name": "Imjudo (tremelimumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imjudo (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf. Revised March 2024. Accessed March 13, 2024.", "company": "", "drug_name_brand": "Imjudo", "drug_name_generic": "tremelimumab", "first_published": "2023-03-02", "access_date": null, "publication_date": "2024-03-13", "url": "https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 585, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 117, "membership_operator": "AND", "therapies": [{"id": 45, "conceptType": "Drug", "name": "Tremelimumab", "primaryCoding": {"id": "ncit:C49085", "code": "C49085", "name": "Tremelimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10122, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.jemperli", "type": "Document", "subtype": "Regulatory approval", "name": "Jemperli (dostarlimab) [product information]. EMA.", "citation": "GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Jemperli", "drug_name_generic": "dostarlimab", "first_published": "2021-05-03", "access_date": null, "publication_date": "2025-06-24", "url": "https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.jemperli:0", "indication": "JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Endometrial cancer (EC)", "raw_therapeutics": "Jemperli (dostarlimab) in combination with carboplatin and paclixtaxel", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.jemperli", "type": "Document", "subtype": "Regulatory approval", "name": "Jemperli (dostarlimab) [product information]. EMA.", "citation": "GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Jemperli", "drug_name_generic": "dostarlimab", "first_published": "2021-05-03", "access_date": null, "publication_date": "2025-06-24", "url": "https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 101, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 38, "name": "MSI-H", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Microsatellite Stability"}, {"name": "present", "value": true}, {"name": "status", "value": "Microsatellite instability-high (MSI-H)"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 18, "conceptType": "Disease", "name": "Endometrial Carcinoma", "primaryCoding": {"id": "oncotree:UCEC", "code": "UCEC", "name": "Endometrial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC"]}, "mappings": []}, "objectTherapeutic": {"id": 19, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 47, "conceptType": "Drug", "name": "Dostarlimab", "primaryCoding": {"id": "ncit:C126799", "code": "C126799", "name": "Dostarlimab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C126799"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10123, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.jemperli", "type": "Document", "subtype": "Regulatory approval", "name": "Jemperli (dostarlimab) [product information]. EMA.", "citation": "GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Jemperli", "drug_name_generic": "dostarlimab", "first_published": "2021-05-03", "access_date": null, "publication_date": "2025-06-24", "url": "https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.jemperli:0", "indication": "JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Endometrial cancer (EC)", "raw_therapeutics": "Jemperli (dostarlimab) in combination with carboplatin and paclixtaxel", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.jemperli", "type": "Document", "subtype": "Regulatory approval", "name": "Jemperli (dostarlimab) [product information]. EMA.", "citation": "GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Jemperli", "drug_name_generic": "dostarlimab", "first_published": "2021-05-03", "access_date": null, "publication_date": "2025-06-24", "url": "https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 100, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Mismatch Repair"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 18, "conceptType": "Disease", "name": "Endometrial Carcinoma", "primaryCoding": {"id": "oncotree:UCEC", "code": "UCEC", "name": "Endometrial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC"]}, "mappings": []}, "objectTherapeutic": {"id": 19, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 47, "conceptType": "Drug", "name": "Dostarlimab", "primaryCoding": {"id": "ncit:C126799", "code": "C126799", "name": "Dostarlimab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C126799"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10124, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.jemperli", "type": "Document", "subtype": "Regulatory approval", "name": "Jemperli (dostarlimab) [product information]. EMA.", "citation": "GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Jemperli", "drug_name_generic": "dostarlimab", "first_published": "2021-05-03", "access_date": null, "publication_date": "2025-06-24", "url": "https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.jemperli:1", "indication": "JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.", "raw_biomarkers": null, "raw_cancer_type": "Endometrial cancer (EC)", "raw_therapeutics": "Jemperli (dostarlimab) in combination with carboplatin and paclixtaxel", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.jemperli", "type": "Document", "subtype": "Regulatory approval", "name": "Jemperli (dostarlimab) [product information]. EMA.", "citation": "GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Jemperli", "drug_name_generic": "dostarlimab", "first_published": "2021-05-03", "access_date": null, "publication_date": "2025-06-24", "url": "https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 587, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 38, "name": "MSI-H", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Microsatellite Stability"}, {"name": "present", "value": true}, {"name": "status", "value": "Microsatellite instability-high (MSI-H)"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 18, "conceptType": "Disease", "name": "Endometrial Carcinoma", "primaryCoding": {"id": "oncotree:UCEC", "code": "UCEC", "name": "Endometrial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC"]}, "mappings": []}, "objectTherapeutic": {"id": 47, "conceptType": "Drug", "name": "Dostarlimab", "primaryCoding": {"id": "ncit:C126799", "code": "C126799", "name": "Dostarlimab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C126799"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10125, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.jemperli", "type": "Document", "subtype": "Regulatory approval", "name": "Jemperli (dostarlimab) [product information]. EMA.", "citation": "GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Jemperli", "drug_name_generic": "dostarlimab", "first_published": "2021-05-03", "access_date": null, "publication_date": "2025-06-24", "url": "https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.jemperli:1", "indication": "JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.", "raw_biomarkers": null, "raw_cancer_type": "Endometrial cancer (EC)", "raw_therapeutics": "Jemperli (dostarlimab) in combination with carboplatin and paclixtaxel", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.jemperli", "type": "Document", "subtype": "Regulatory approval", "name": "Jemperli (dostarlimab) [product information]. EMA.", "citation": "GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised June 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Jemperli", "drug_name_generic": "dostarlimab", "first_published": "2021-05-03", "access_date": null, "publication_date": "2025-06-24", "url": "https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 102, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Mismatch Repair"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 18, "conceptType": "Disease", "name": "Endometrial Carcinoma", "primaryCoding": {"id": "oncotree:UCEC", "code": "UCEC", "name": "Endometrial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC"]}, "mappings": []}, "objectTherapeutic": {"id": 47, "conceptType": "Drug", "name": "Dostarlimab", "primaryCoding": {"id": "ncit:C126799", "code": "C126799", "name": "Dostarlimab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C126799"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10126, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:0", "indication": "KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a >= 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations.", "raw_biomarkers": null, "raw_cancer_type": "non-small cell lung carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 588, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 39, "name": "PD-L1 >= 50%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.5"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10127, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:0", "indication": "KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a >= 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors express PD-L1 with a >= 50% tumor proportion score (TPS) with no EGFR or ALK positive tumor mutations.", "raw_biomarkers": null, "raw_cancer_type": "non-small cell lung carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 589, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 40, "name": "CD274 amplification", "genes": [{"id": 13, "name": "CD274", "primaryCoding": {"id": "hgnc:17635", "code": "HGNC:17635", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:17635"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_014143.4", "code": "NM_014143.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_014143.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000120217", "code": "ENSG00000120217", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000120217"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:29126", "code": "29126", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/29126"]}}], "extensions": [{"name": "location", "value": "9p24.1"}, {"name": "location_sortable", "value": "09p24.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10128, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:1", "indication": "KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "non-small cell lung carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 316, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 51, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10129, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:1", "indication": "KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "non-small cell lung carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 317, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 52, "membership_operator": "AND", "therapies": [{"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10130, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:1", "indication": "KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "non-small cell lung carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 592, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 119, "membership_operator": "AND", "therapies": [{"id": 50, "conceptType": "Drug", "name": "Gemcitabine", "primaryCoding": {"id": "ncit:C66876", "code": "C66876", "name": "Gemcitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antimetabolite"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10131, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:1", "indication": "KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "non-small cell lung carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 593, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 64, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 50, "conceptType": "Drug", "name": "Gemcitabine", "primaryCoding": {"id": "ncit:C66876", "code": "C66876", "name": "Gemcitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antimetabolite"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10132, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:1", "indication": "KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-small cell lung carcinoma in adult patients whose tumors have no EGFR or ALK positive mutations. This indication is based on results from KEYNOTE-024, where patients received pembrolizumab in combination with investigator's choice of platinum-containing chemotherapy, including: pemetrexed with carboplatin, pemetrexed with cisplatin, gemcitabine and cisplatin, gemcitabine and carboplatin, or paclitaxel and carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "non-small cell lung carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 594, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 59, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10133, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung carcinoma whose tumors express PD-L1 with a >= 1% tumor proportion score (TPS) and who have recieved at least one prior chemotherapy regime. Patients with EGFR or ALK positive tumor mutations should also have received targeted therapy before receiving pembrolizumab.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:2", "indication": "KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a >= 1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung carcinoma whose tumors express PD-L1 with a >= 1% tumor proportion score (TPS) and who have recieved at least one prior chemotherapy regime. Patients with EGFR or ALK positive tumor mutations should also have received targeted therapy before receiving pembrolizumab.", "raw_biomarkers": null, "raw_cancer_type": "non-small cell lung carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 319, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 33, "name": "PD-L1 >= 1%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.01"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10134, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 with a combined positive score (CPS) >= 10.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:3", "indication": "KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy and whose tumours express PD-L1 with a combined positive score (CPS) >= 10.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 with a combined positive score (CPS) >= 10.", "raw_biomarkers": null, "raw_cancer_type": "urothelial carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 595, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 41, "name": "PD-L1 (CPS) >= 10", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "10"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 8, "conceptType": "Disease", "name": "Bladder Urothelial Carcinoma", "primaryCoding": {"id": "oncotree:BLCA", "code": "BLCA", "name": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10135, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:4", "indication": "KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a CPS >= 1.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "raw_biomarkers": null, "raw_cancer_type": "head and neck squamous cell carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 320, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 42, "name": "PD-L1 (CPS) >= 1", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "1"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 25, "conceptType": "Disease", "name": "Head and Neck Squamous Cell Carcinoma", "primaryCoding": {"id": "oncotree:HNSC", "code": "HNSC", "name": "Head and Neck Squamous Cell Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HNSC"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10136, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:4", "indication": "KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a CPS >= 1.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "raw_biomarkers": null, "raw_cancer_type": "head and neck squamous cell carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 596, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 42, "name": "PD-L1 (CPS) >= 1", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "1"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 25, "conceptType": "Disease", "name": "Head and Neck Squamous Cell Carcinoma", "primaryCoding": {"id": "oncotree:HNSC", "code": "HNSC", "name": "Head and Neck Squamous Cell Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HNSC"]}, "mappings": []}, "objectTherapeutic": {"id": 120, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10137, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:4", "indication": "KEYTRUDA, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a CPS >= 1.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "raw_biomarkers": null, "raw_cancer_type": "head and neck squamous cell carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 597, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 42, "name": "PD-L1 (CPS) >= 1", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "1"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 25, "conceptType": "Disease", "name": "Head and Neck Squamous Cell Carcinoma", "primaryCoding": {"id": "oncotree:HNSC", "code": "HNSC", "name": "Head and Neck Squamous Cell Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HNSC"]}, "mappings": []}, "objectTherapeutic": {"id": 55, "membership_operator": "AND", "therapies": [{"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10138, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma whose tumors express PD-L1 with a tumor proportion score >= 50% and who have progressed on or after platinum-containing chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:5", "indication": "KEYTRUDA as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a >= 50% TPS and progressing on or after platinum -containing chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma whose tumors express PD-L1 with a tumor proportion score >= 50% and who have progressed on or after platinum-containing chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "head and neck squamous cell carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 598, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 39, "name": "PD-L1 >= 50%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.5"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 25, "conceptType": "Disease", "name": "Head and Neck Squamous Cell Carcinoma", "primaryCoding": {"id": "oncotree:HNSC", "code": "HNSC", "name": "Head and Neck Squamous Cell Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HNSC"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10139, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer as a first line-treatment for metastatic colorectal cancer or treatment of unresectable or metastatic colorectal cancer after previously fluoropryimidine-based combination therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:6", "indication": "KEYTRUDA as monotherapy is indicated for adults with MSI-H or dMMR colorectal cancer in the following settings: first-line treatment of metastatic colorectal cancer; treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine -based combination therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer as a first line-treatment for metastatic colorectal cancer or treatment of unresectable or metastatic colorectal cancer after previously fluoropryimidine-based combination therapy.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 324, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 38, "name": "MSI-H", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Microsatellite Stability"}, {"name": "present", "value": true}, {"name": "status", "value": "Microsatellite instability-high (MSI-H)"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10140, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer as a first line-treatment for metastatic colorectal cancer or treatment of unresectable or metastatic colorectal cancer after previously fluoropryimidine-based combination therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:6", "indication": "KEYTRUDA as monotherapy is indicated for adults with MSI-H or dMMR colorectal cancer in the following settings: first-line treatment of metastatic colorectal cancer; treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine -based combination therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) colorectal cancer as a first line-treatment for metastatic colorectal cancer or treatment of unresectable or metastatic colorectal cancer after previously fluoropryimidine-based combination therapy.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 323, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Mismatch Repair"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10141, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:7", "indication": "KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.", "raw_biomarkers": null, "raw_cancer_type": "Endometrial carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 343, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 38, "name": "MSI-H", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Microsatellite Stability"}, {"name": "present", "value": true}, {"name": "status", "value": "Microsatellite instability-high (MSI-H)"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 18, "conceptType": "Disease", "name": "Endometrial Carcinoma", "primaryCoding": {"id": "oncotree:UCEC", "code": "UCEC", "name": "Endometrial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10142, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:7", "indication": "KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.", "raw_biomarkers": null, "raw_cancer_type": "Endometrial carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 599, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Mismatch Repair"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 18, "conceptType": "Disease", "name": "Endometrial Carcinoma", "primaryCoding": {"id": "oncotree:UCEC", "code": "UCEC", "name": "Endometrial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10143, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:8", "indication": "KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "raw_biomarkers": null, "raw_cancer_type": "gastric, small intestine, or biliary cancer", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 600, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 38, "name": "MSI-H", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Microsatellite Stability"}, {"name": "present", "value": true}, {"name": "status", "value": "Microsatellite instability-high (MSI-H)"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 81, "conceptType": "Disease", "name": "Esophagogastric Adenocarcinoma", "primaryCoding": {"id": "oncotree:EGC", "code": "EGC", "name": "Esophagogastric Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=EGC"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10144, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:8", "indication": "KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "raw_biomarkers": null, "raw_cancer_type": "gastric, small intestine, or biliary cancer", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 601, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Mismatch Repair"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 81, "conceptType": "Disease", "name": "Esophagogastric Adenocarcinoma", "primaryCoding": {"id": "oncotree:EGC", "code": "EGC", "name": "Esophagogastric Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=EGC"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10145, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:8", "indication": "KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "raw_biomarkers": null, "raw_cancer_type": "gastric, small intestine, or biliary cancer", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 602, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 38, "name": "MSI-H", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Microsatellite Stability"}, {"name": "present", "value": true}, {"name": "status", "value": "Microsatellite instability-high (MSI-H)"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 22, "conceptType": "Disease", "name": "Gastrointestinal Stromal Tumor", "primaryCoding": {"id": "oncotree:GIST", "code": "GIST", "name": "Gastrointestinal Stromal Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GIST"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10146, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:8", "indication": "KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "raw_biomarkers": null, "raw_cancer_type": "gastric, small intestine, or biliary cancer", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 603, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Mismatch Repair"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 22, "conceptType": "Disease", "name": "Gastrointestinal Stromal Tumor", "primaryCoding": {"id": "oncotree:GIST", "code": "GIST", "name": "Gastrointestinal Stromal Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GIST"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10147, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:8", "indication": "KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "raw_biomarkers": null, "raw_cancer_type": "gastric, small intestine, or biliary cancer", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 604, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 38, "name": "MSI-H", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Microsatellite Stability"}, {"name": "present", "value": true}, {"name": "status", "value": "Microsatellite instability-high (MSI-H)"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 11, "conceptType": "Disease", "name": "Cholangiocarcinoma", "primaryCoding": {"id": "oncotree:CHOL", "code": "CHOL", "name": "Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10148, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:8", "indication": "KEYTRUDA as monotherapy is indicated for the treatment of the following MSI-H or dMMR tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab as a monotherapy for the treatment of adult patients with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR) unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.", "raw_biomarkers": null, "raw_cancer_type": "gastric, small intestine, or biliary cancer", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 605, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Mismatch Repair"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 11, "conceptType": "Disease", "name": "Cholangiocarcinoma", "primaryCoding": {"id": "oncotree:CHOL", "code": "CHOL", "name": "Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10149, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adult patients with locally advanced unresectable or metastatic esophageal carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 10.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:9", "indication": "KEYTRUDA, in combination with platinum and fluoropyrimidine -based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD-L1 with a CPS >= 10.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adult patients with locally advanced unresectable or metastatic esophageal carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 10.", "raw_biomarkers": null, "raw_cancer_type": "Oesophageal carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 606, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 41, "name": "PD-L1 (CPS) >= 10", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "10"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 74, "conceptType": "Disease", "name": "Esophageal Adenocarcinoma", "primaryCoding": {"id": "oncotree:ESCA", "code": "ESCA", "name": "Esophageal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCA"]}, "mappings": []}, "objectTherapeutic": {"id": 55, "membership_operator": "AND", "therapies": [{"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10150, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adult patients with locally advanced unresectable or metastatic esophageal carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 10.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:9", "indication": "KEYTRUDA, in combination with platinum and fluoropyrimidine -based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD-L1 with a CPS >= 10.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adult patients with locally advanced unresectable or metastatic esophageal carcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 10.", "raw_biomarkers": null, "raw_cancer_type": "Oesophageal carcinoma", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 607, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 41, "name": "PD-L1 (CPS) >= 10", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "10"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 74, "conceptType": "Disease", "name": "Esophageal Adenocarcinoma", "primaryCoding": {"id": "oncotree:ESCA", "code": "ESCA", "name": "Esophageal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCA"]}, "mappings": []}, "objectTherapeutic": {"id": 120, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10151, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then continued as a monotherapy for the adjuvant treatment after surgery, of adult patients with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:10", "indication": "KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then continued as a monotherapy for the adjuvant treatment after surgery, of adult patients with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence.", "raw_biomarkers": null, "raw_cancer_type": "Triple-negative breast cancer", "raw_therapeutics": "Keytruda (pembrolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 608, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 43, "name": "ER negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 44, "name": "PR negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10152, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:11", "indication": "KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS >= 10 and who have not received prior chemotherapy for metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.", "raw_biomarkers": null, "raw_cancer_type": "Triple-negative breast cancer", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 346, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 43, "name": "ER negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 44, "name": "PR negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 41, "name": "PD-L1 (CPS) >= 10", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "10"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 63, "membership_operator": "AND", "therapies": [{"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10153, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:11", "indication": "KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS >= 10 and who have not received prior chemotherapy for metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.", "raw_biomarkers": null, "raw_cancer_type": "Triple-negative breast cancer", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 609, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 43, "name": "ER negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 44, "name": "PR negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 41, "name": "PD-L1 (CPS) >= 10", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "10"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 121, "membership_operator": "AND", "therapies": [{"id": 51, "conceptType": "Drug", "name": "Nab-paclitaxel", "primaryCoding": {"id": "ncit:C2688", "code": "C2688", "name": "Nab-paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2688"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10154, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:11", "indication": "KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS >= 10 and who have not received prior chemotherapy for metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 10 and who have not received prior chemotherapy for metastatic disease. This indication is based on KEYNOTE-355, a phase 3, randomizewd, double-blind, multi-center, placebo-controlled study where the efficacy of pembrolizumab in combination with: (i) paclitaxel, (ii) nab-paclitaxel, or (iii) gemcitabine and carboplatin were investigated for the treatment of patients with TNBC who were previously untreated for metastatic disease.", "raw_biomarkers": null, "raw_cancer_type": "Triple-negative breast cancer", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 347, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 43, "name": "ER negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 44, "name": "PR negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 41, "name": "PD-L1 (CPS) >= 10", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "10"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 64, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 50, "conceptType": "Drug", "name": "Gemcitabine", "primaryCoding": {"id": "ncit:C66876", "code": "C66876", "name": "Gemcitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antimetabolite"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10155, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy and with or without bevacizumab for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1. This indication is based on KEYNOTE-826, a multicenter, randomized, double-blind, and placebo-controlled study that studied the efficacy of pembrolizumab in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab in 617 patients meeting this indication's clinical criteria.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:12", "indication": "KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy and with or without bevacizumab for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1. This indication is based on KEYNOTE-826, a multicenter, randomized, double-blind, and placebo-controlled study that studied the efficacy of pembrolizumab in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab in 617 patients meeting this indication's clinical criteria.", "raw_biomarkers": null, "raw_cancer_type": "Cervical cancer", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy with or without bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 335, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 42, "name": "PD-L1 (CPS) >= 1", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "1"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 72, "conceptType": "Disease", "name": "Cervical Adenocarcinoma", "primaryCoding": {"id": "oncotree:CEAD", "code": "CEAD", "name": "Cervical Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CEAD"]}, "mappings": []}, "objectTherapeutic": {"id": 59, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10156, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy and with or without bevacizumab for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1. This indication is based on KEYNOTE-826, a multicenter, randomized, double-blind, and placebo-controlled study that studied the efficacy of pembrolizumab in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab in 617 patients meeting this indication's clinical criteria.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:12", "indication": "KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with chemotherapy and with or without bevacizumab for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 with a combined positive score (CPS) >= 1. This indication is based on KEYNOTE-826, a multicenter, randomized, double-blind, and placebo-controlled study that studied the efficacy of pembrolizumab in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab in 617 patients meeting this indication's clinical criteria.", "raw_biomarkers": null, "raw_cancer_type": "Cervical cancer", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with chemotherapy with or without bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 337, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 42, "name": "PD-L1 (CPS) >= 1", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "1"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 72, "conceptType": "Disease", "name": "Cervical Adenocarcinoma", "primaryCoding": {"id": "oncotree:CEAD", "code": "CEAD", "name": "Cervical Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CEAD"]}, "mappings": []}, "objectTherapeutic": {"id": 60, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10157, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:13", "indication": "KEYTRUDA, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS >= 1.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "raw_biomarkers": null, "raw_cancer_type": "Gastric or gastro-esophagael junction (GEJ) adenocracinoma", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 325, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 42, "name": "PD-L1 (CPS) >= 1", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "1"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 2, "conceptType": "Disease", "name": "Adenocarcinoma of the Gastroesophageal Junction", "primaryCoding": {"id": "oncotree:GEJ", "code": "GEJ", "name": "Adenocarcinoma of the Gastroesophageal Junction", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ"]}, "mappings": []}, "objectTherapeutic": {"id": 53, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10158, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:13", "indication": "KEYTRUDA, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS >= 1.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "raw_biomarkers": null, "raw_cancer_type": "Gastric or gastro-esophagael junction (GEJ) adenocracinoma", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 610, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 42, "name": "PD-L1 (CPS) >= 1", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "1"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 2, "conceptType": "Disease", "name": "Adenocarcinoma of the Gastroesophageal Junction", "primaryCoding": {"id": "oncotree:GEJ", "code": "GEJ", "name": "Adenocarcinoma of the Gastroesophageal Junction", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ"]}, "mappings": []}, "objectTherapeutic": {"id": 122, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10159, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:14", "indication": "KEYTRUDA, in combination with fluoropyrimidine and platinum -containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS >= 1.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "raw_biomarkers": null, "raw_cancer_type": "Gastric or gastro-esophagael junction (GEJ) adenocracinoma", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with fluoropyrimidine and platinum-containing chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 611, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 42, "name": "PD-L1 (CPS) >= 1", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "1"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 2, "conceptType": "Disease", "name": "Adenocarcinoma of the Gastroesophageal Junction", "primaryCoding": {"id": "oncotree:GEJ", "code": "GEJ", "name": "Adenocarcinoma of the Gastroesophageal Junction", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ"]}, "mappings": []}, "objectTherapeutic": {"id": 55, "membership_operator": "AND", "therapies": [{"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10160, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.keytruda:14", "indication": "KEYTRUDA, in combination with fluoropyrimidine and platinum -containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro -oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS >= 1.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pembrolizumab in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 1.", "raw_biomarkers": null, "raw_cancer_type": "Gastric or gastro-esophagael junction (GEJ) adenocracinoma", "raw_therapeutics": "Keytruda (pembrolizumab) in combination with fluoropyrimidine and platinum-containing chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.keytruda", "type": "Document", "subtype": "Regulatory approval", "name": "Keytruda (pembrolizumab) [product information]. EMA.", "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.", "company": "", "drug_name_brand": "Keytruda", "drug_name_generic": "pembrolizumab", "first_published": "2015-07-30", "access_date": null, "publication_date": "2024-01-11", "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 612, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 42, "name": "PD-L1 (CPS) >= 1", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "1"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 2, "conceptType": "Disease", "name": "Adenocarcinoma of the Gastroesophageal Junction", "primaryCoding": {"id": "oncotree:GEJ", "code": "GEJ", "name": "Adenocarcinoma of the Gastroesophageal Junction", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ"]}, "mappings": []}, "objectTherapeutic": {"id": 120, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 48, "conceptType": "Drug", "name": "Pembrolizumab", "primaryCoding": {"id": "ncit:C106432", "code": "C106432", "name": "Pembrolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10161, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.kadcyla", "type": "Document", "subtype": "Regulatory approval", "name": "Kadcyla (trastuzumab emtansine) [product information]. EMA.", "citation": "Roche Registration GmbH. Kadcyla (trastuzumab emtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf. Revised March 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kadcyla", "drug_name_generic": "trastuzumab emtansine", "first_published": "2013-12-19", "access_date": null, "publication_date": "2023-03-22", "url": "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.kadcyla:0", "indication": "Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Kadcyla (trastuzumab emtansine)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.kadcyla", "type": "Document", "subtype": "Regulatory approval", "name": "Kadcyla (trastuzumab emtansine) [product information]. EMA.", "citation": "Roche Registration GmbH. Kadcyla (trastuzumab emtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf. Revised March 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kadcyla", "drug_name_generic": "trastuzumab emtansine", "first_published": "2013-12-19", "access_date": null, "publication_date": "2023-03-22", "url": "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 20, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 52, "conceptType": "Drug", "name": "Trastuzumab emtansine", "primaryCoding": {"id": "ncit:C82492", "code": "C82492", "name": "Trastuzumab Emtansine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82492"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10162, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.kadcyla", "type": "Document", "subtype": "Regulatory approval", "name": "Kadcyla (trastuzumab emtansine) [product information]. EMA.", "citation": "Roche Registration GmbH. Kadcyla (trastuzumab emtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf. Revised March 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kadcyla", "drug_name_generic": "trastuzumab emtansine", "first_published": "2013-12-19", "access_date": null, "publication_date": "2023-03-22", "url": "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.kadcyla:0", "indication": "Kadcyla, as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Kadcyla (trastuzumab emtansine)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.kadcyla", "type": "Document", "subtype": "Regulatory approval", "name": "Kadcyla (trastuzumab emtansine) [product information]. EMA.", "citation": "Roche Registration GmbH. Kadcyla (trastuzumab emtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf. Revised March 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kadcyla", "drug_name_generic": "trastuzumab emtansine", "first_published": "2013-12-19", "access_date": null, "publication_date": "2023-03-22", "url": "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 613, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 52, "conceptType": "Drug", "name": "Trastuzumab emtansine", "primaryCoding": {"id": "ncit:C82492", "code": "C82492", "name": "Trastuzumab Emtansine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82492"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10163, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.kadcyla", "type": "Document", "subtype": "Regulatory approval", "name": "Kadcyla (trastuzumab emtansine) [product information]. EMA.", "citation": "Roche Registration GmbH. Kadcyla (trastuzumab emtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf. Revised March 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kadcyla", "drug_name_generic": "trastuzumab emtansine", "first_published": "2013-12-19", "access_date": null, "publication_date": "2023-03-22", "url": "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.kadcyla:1", "indication": "Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Kadcyla (trastuzumab emtansine)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.kadcyla", "type": "Document", "subtype": "Regulatory approval", "name": "Kadcyla (trastuzumab emtansine) [product information]. EMA.", "citation": "Roche Registration GmbH. Kadcyla (trastuzumab emtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf. Revised March 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kadcyla", "drug_name_generic": "trastuzumab emtansine", "first_published": "2013-12-19", "access_date": null, "publication_date": "2023-03-22", "url": "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 20, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 52, "conceptType": "Drug", "name": "Trastuzumab emtansine", "primaryCoding": {"id": "ncit:C82492", "code": "C82492", "name": "Trastuzumab Emtansine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82492"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10164, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.kadcyla", "type": "Document", "subtype": "Regulatory approval", "name": "Kadcyla (trastuzumab emtansine) [product information]. EMA.", "citation": "Roche Registration GmbH. Kadcyla (trastuzumab emtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf. Revised March 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kadcyla", "drug_name_generic": "trastuzumab emtansine", "first_published": "2013-12-19", "access_date": null, "publication_date": "2023-03-22", "url": "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.kadcyla:1", "indication": "Kadcyla, as a single agent, is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trastuzumab emtansine for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in cobmination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Kadcyla (trastuzumab emtansine)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.kadcyla", "type": "Document", "subtype": "Regulatory approval", "name": "Kadcyla (trastuzumab emtansine) [product information]. EMA.", "citation": "Roche Registration GmbH. Kadcyla (trastuzumab emtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf. Revised March 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kadcyla", "drug_name_generic": "trastuzumab emtansine", "first_published": "2013-12-19", "access_date": null, "publication_date": "2023-03-22", "url": "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 613, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 52, "conceptType": "Drug", "name": "Trastuzumab emtansine", "primaryCoding": {"id": "ncit:C82492", "code": "C82492", "name": "Trastuzumab Emtansine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82492"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10167, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.kisqali", "type": "Document", "subtype": "Regulatory approval", "name": "Kisqali (ribociclib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kisqali", "drug_name_generic": "ribociclib", "first_published": "2017-08-31", "access_date": null, "publication_date": "2023-10-17", "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.kisqali:0", "indication": "Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Kisqali (ribociclib) in combination with an aromatase inhibitor or fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.kisqali", "type": "Document", "subtype": "Regulatory approval", "name": "Kisqali (ribociclib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kisqali", "drug_name_generic": "ribociclib", "first_published": "2017-08-31", "access_date": null, "publication_date": "2023-10-17", "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 375, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 78, "membership_operator": "AND", "therapies": [{"id": 53, "conceptType": "Drug", "name": "Ribociclib", "primaryCoding": {"id": "ncit:C95701", "code": "C95701", "name": "Ribociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10168, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.kisqali", "type": "Document", "subtype": "Regulatory approval", "name": "Kisqali (ribociclib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kisqali", "drug_name_generic": "ribociclib", "first_published": "2017-08-31", "access_date": null, "publication_date": "2023-10-17", "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.kisqali:0", "indication": "Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Kisqali (ribociclib) in combination with an aromatase inhibitor or fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.kisqali", "type": "Document", "subtype": "Regulatory approval", "name": "Kisqali (ribociclib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kisqali", "drug_name_generic": "ribociclib", "first_published": "2017-08-31", "access_date": null, "publication_date": "2023-10-17", "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 376, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 78, "membership_operator": "AND", "therapies": [{"id": 53, "conceptType": "Drug", "name": "Ribociclib", "primaryCoding": {"id": "ncit:C95701", "code": "C95701", "name": "Ribociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10169, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.kisqali", "type": "Document", "subtype": "Regulatory approval", "name": "Kisqali (ribociclib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kisqali", "drug_name_generic": "ribociclib", "first_published": "2017-08-31", "access_date": null, "publication_date": "2023-10-17", "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.kisqali:0", "indication": "Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Kisqali (ribociclib) in combination with an aromatase inhibitor or fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.kisqali", "type": "Document", "subtype": "Regulatory approval", "name": "Kisqali (ribociclib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kisqali", "drug_name_generic": "ribociclib", "first_published": "2017-08-31", "access_date": null, "publication_date": "2023-10-17", "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 377, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 78, "membership_operator": "AND", "therapies": [{"id": 53, "conceptType": "Drug", "name": "Ribociclib", "primaryCoding": {"id": "ncit:C95701", "code": "C95701", "name": "Ribociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10173, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.kisqali", "type": "Document", "subtype": "Regulatory approval", "name": "Kisqali (ribociclib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kisqali", "drug_name_generic": "ribociclib", "first_published": "2017-08-31", "access_date": null, "publication_date": "2023-10-17", "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.kisqali:0", "indication": "Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Kisqali (ribociclib) in combination with an aromatase inhibitor or fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.kisqali", "type": "Document", "subtype": "Regulatory approval", "name": "Kisqali (ribociclib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kisqali", "drug_name_generic": "ribociclib", "first_published": "2017-08-31", "access_date": null, "publication_date": "2023-10-17", "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 140, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 27, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 53, "conceptType": "Drug", "name": "Ribociclib", "primaryCoding": {"id": "ncit:C95701", "code": "C95701", "name": "Ribociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10174, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.kisqali", "type": "Document", "subtype": "Regulatory approval", "name": "Kisqali (ribociclib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kisqali", "drug_name_generic": "ribociclib", "first_published": "2017-08-31", "access_date": null, "publication_date": "2023-10-17", "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.kisqali:0", "indication": "Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Kisqali (ribociclib) in combination with an aromatase inhibitor or fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.kisqali", "type": "Document", "subtype": "Regulatory approval", "name": "Kisqali (ribociclib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kisqali", "drug_name_generic": "ribociclib", "first_published": "2017-08-31", "access_date": null, "publication_date": "2023-10-17", "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 141, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 27, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 53, "conceptType": "Drug", "name": "Ribociclib", "primaryCoding": {"id": "ncit:C95701", "code": "C95701", "name": "Ribociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10175, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.kisqali", "type": "Document", "subtype": "Regulatory approval", "name": "Kisqali (ribociclib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kisqali", "drug_name_generic": "ribociclib", "first_published": "2017-08-31", "access_date": null, "publication_date": "2023-10-17", "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.kisqali:0", "indication": "Kisqali is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ribociclib in combination with an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy for the treatment of patients who are women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. This indication is based on three clinical trials: MONALEESA-2, MONALEESA-3, and MONALEESA-7, and MONALEESA-2 evaluated ribociclib in combination with letrozole, an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Kisqali (ribociclib) in combination with an aromatase inhibitor or fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.kisqali", "type": "Document", "subtype": "Regulatory approval", "name": "Kisqali (ribociclib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Kisqali", "drug_name_generic": "ribociclib", "first_published": "2017-08-31", "access_date": null, "publication_date": "2023-10-17", "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 142, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 27, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 53, "conceptType": "Drug", "name": "Ribociclib", "primaryCoding": {"id": "ncit:C95701", "code": "C95701", "name": "Ribociclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10179, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized adagrasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and disease progression after at least one prior systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.krazati", "type": "Document", "subtype": "Regulatory approval", "name": "Krazati (adagrasib) [product information]. EMA.", "citation": "Mirati Therapeutics B.V. Krazati (adagrasib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Krazati", "drug_name_generic": "adagrasib", "first_published": "2024-03-13", "access_date": null, "publication_date": "2024-03-13", "url": "https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.krazati:0", "indication": "KRAZATI as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized adagrasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and disease progression after at least one prior systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Krazati (adagrasib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.krazati", "type": "Document", "subtype": "Regulatory approval", "name": "Krazati (adagrasib) [product information]. EMA.", "citation": "Mirati Therapeutics B.V. Krazati (adagrasib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Krazati", "drug_name_generic": "adagrasib", "first_published": "2024-03-13", "access_date": null, "publication_date": "2024-03-13", "url": "https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 19, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 45, "name": "KRAS p.G12C", "genes": [{"id": 31, "name": "KRAS", "primaryCoding": {"id": "hgnc:6407", "code": "HGNC:6407", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_004985.5", "code": "NM_004985.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000133703", "code": "ENSG00000133703", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000133703"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3845", "code": "3845", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3845"]}}], "extensions": [{"name": "location", "value": "12p12.1"}, {"name": "location_sortable", "value": "12p12.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "12"}, {"name": "start_position", "value": 25398285}, {"name": "end_position", "value": 25398285}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "A"}, {"name": "cdna_change", "value": "c.34G>T"}, {"name": "protein_change", "value": "p.G12C"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "2"}, {"name": "rsid", "value": "rs121913530"}, {"name": "hgvsg", "value": "12:g.25398285C>A"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 54, "conceptType": "Drug", "name": "Adagrasib", "primaryCoding": {"id": "ncit:C157493", "code": "C157493", "name": "Adagrasib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C157493"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["RAS inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10180, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized cemiplimab as a monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in >= 50% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.libtayo", "type": "Document", "subtype": "Regulatory approval", "name": "Libtayo (cemiplimab) [product information]. EMA.", "citation": "Regeneron Ireland Designated Activity Company (DAC). Libtayo (cemiplimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Libtayo", "drug_name_generic": "cemiplimab", "first_published": "2019-07-05", "access_date": null, "publication_date": "2024-01-12", "url": "https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.libtayo:0", "indication": "LIBTAYO as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in >= 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized cemiplimab as a monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in >= 50% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Libtayo (cemiplimab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.libtayo", "type": "Document", "subtype": "Regulatory approval", "name": "Libtayo (cemiplimab) [product information]. EMA.", "citation": "Regeneron Ireland Designated Activity Company (DAC). Libtayo (cemiplimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Libtayo", "drug_name_generic": "cemiplimab", "first_published": "2019-07-05", "access_date": null, "publication_date": "2024-01-12", "url": "https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 618, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 39, "name": "PD-L1 >= 50%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.5"}]}, {"id": 46, "name": "Wild type ROS1", "genes": [{"id": 50, "name": "ROS1", "primaryCoding": {"id": "hgnc:10261", "code": "HGNC:10261", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000047936", "code": "ENSG00000047936", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000047936"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:6098", "code": "6098", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/6098"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_001378902.1", "code": "NM_001378902.1", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1"]}}], "extensions": [{"name": "location", "value": "6q22.1"}, {"name": "location_sortable", "value": "06q22.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 55, "conceptType": "Drug", "name": "Cemiplimab", "primaryCoding": {"id": "ncit:C121540", "code": "C121540", "name": "Cemiplimab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121540"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10181, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with NSCLC expressing PD-L1 (in >= 1% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC. This indication is based on Study 16113, a randomized, multi-center, double-blind, active-controlled trial. The chemotherapy used in this study consisted of either carboplatin or cisplatin in combination with paclitaxel or pemetrexed.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.libtayo", "type": "Document", "subtype": "Regulatory approval", "name": "Libtayo (cemiplimab) [product information]. EMA.", "citation": "Regeneron Ireland Designated Activity Company (DAC). Libtayo (cemiplimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Libtayo", "drug_name_generic": "cemiplimab", "first_published": "2019-07-05", "access_date": null, "publication_date": "2024-01-12", "url": "https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.libtayo:1", "indication": "LIBTAYO in combination with platinum_based chemotherapy is indicated for the first_line treatment of adult patients with NSCLC expressing PD-L1 (in >= 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with NSCLC expressing PD-L1 (in >= 1% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC. This indication is based on Study 16113, a randomized, multi-center, double-blind, active-controlled trial. The chemotherapy used in this study consisted of either carboplatin or cisplatin in combination with paclitaxel or pemetrexed.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Libtayo (cemiplimab) in combination with platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.libtayo", "type": "Document", "subtype": "Regulatory approval", "name": "Libtayo (cemiplimab) [product information]. EMA.", "citation": "Regeneron Ireland Designated Activity Company (DAC). Libtayo (cemiplimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Libtayo", "drug_name_generic": "cemiplimab", "first_published": "2019-07-05", "access_date": null, "publication_date": "2024-01-12", "url": "https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 619, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 33, "name": "PD-L1 >= 1%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.01"}]}, {"id": 46, "name": "Wild type ROS1", "genes": [{"id": 50, "name": "ROS1", "primaryCoding": {"id": "hgnc:10261", "code": "HGNC:10261", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000047936", "code": "ENSG00000047936", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000047936"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:6098", "code": "6098", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/6098"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_001378902.1", "code": "NM_001378902.1", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1"]}}], "extensions": [{"name": "location", "value": "6q22.1"}, {"name": "location_sortable", "value": "06q22.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 13, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 55, "conceptType": "Drug", "name": "Cemiplimab", "primaryCoding": {"id": "ncit:C121540", "code": "C121540", "name": "Cemiplimab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121540"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10182, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized lorlatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lorviqua", "type": "Document", "subtype": "Regulatory approval", "name": "Lorviqua (lorlatinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Lorviqua (lorlatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Lorviqua", "drug_name_generic": "lorlatinib", "first_published": "2019-06-17", "access_date": null, "publication_date": "2024-01-12", "url": "https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lorviqua:0", "indication": "Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized lorlatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Lorviqua (lorlatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lorviqua", "type": "Document", "subtype": "Regulatory approval", "name": "Lorviqua (lorlatinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Lorviqua (lorlatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Lorviqua", "drug_name_generic": "lorlatinib", "first_published": "2019-06-17", "access_date": null, "publication_date": "2024-01-12", "url": "https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 203, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 56, "conceptType": "Drug", "name": "Lorlatinib", "primaryCoding": {"id": "ncit:C113655", "code": "C113655", "name": "Lorlatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C113655"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10183, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized lorlatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lorviqua", "type": "Document", "subtype": "Regulatory approval", "name": "Lorviqua (lorlatinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Lorviqua (lorlatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Lorviqua", "drug_name_generic": "lorlatinib", "first_published": "2019-06-17", "access_date": null, "publication_date": "2024-01-12", "url": "https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lorviqua:1", "indication": "Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized lorlatinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or crizotinib and at least one other ALK TKI.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Lorviqua (lorlatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lorviqua", "type": "Document", "subtype": "Regulatory approval", "name": "Lorviqua (lorlatinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Lorviqua (lorlatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Lorviqua", "drug_name_generic": "lorlatinib", "first_published": "2019-06-17", "access_date": null, "publication_date": "2024-01-12", "url": "https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 203, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 56, "conceptType": "Drug", "name": "Lorlatinib", "primaryCoding": {"id": "ncit:C113655", "code": "C113655", "name": "Lorlatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C113655"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10184, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized sotorasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and who have progressed after at least one prior line of systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lumykras", "type": "Document", "subtype": "Regulatory approval", "name": "Lumykras (sotorasib) [product information]. EMA.", "citation": "Amgen Europe BV. Lumykras (sotorasib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf. Revised February 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Lumykras", "drug_name_generic": "sotorasib", "first_published": "2022-03-31", "access_date": null, "publication_date": "2024-02-27", "url": "https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lumykras:0", "indication": "LUMYKRAS as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized sotorasib as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the KRAS p.G12C variant and who have progressed after at least one prior line of systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Lumykras (sotorasib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lumykras", "type": "Document", "subtype": "Regulatory approval", "name": "Lumykras (sotorasib) [product information]. EMA.", "citation": "Amgen Europe BV. Lumykras (sotorasib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf. Revised February 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Lumykras", "drug_name_generic": "sotorasib", "first_published": "2022-03-31", "access_date": null, "publication_date": "2024-02-27", "url": "https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 411, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 45, "name": "KRAS p.G12C", "genes": [{"id": 31, "name": "KRAS", "primaryCoding": {"id": "hgnc:6407", "code": "HGNC:6407", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_004985.5", "code": "NM_004985.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000133703", "code": "ENSG00000133703", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000133703"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3845", "code": "3845", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3845"]}}], "extensions": [{"name": "location", "value": "12p12.1"}, {"name": "location_sortable", "value": "12p12.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "12"}, {"name": "start_position", "value": 25398285}, {"name": "end_position", "value": 25398285}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "A"}, {"name": "cdna_change", "value": "c.34G>T"}, {"name": "protein_change", "value": "p.G12C"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "2"}, {"name": "rsid", "value": "rs121913530"}, {"name": "hgvsg", "value": "12:g.25398285C>A"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 57, "conceptType": "Drug", "name": "Sotorasib", "primaryCoding": {"id": "ncit:C154287", "code": "C154287", "name": "Sotorasib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C154287"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["RAS inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10185, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:0", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 231, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 47, "name": "BRCA1 oncogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 51, "conceptType": "Disease", "name": "Ovarian Epithelial Tumor", "primaryCoding": {"id": "oncotree:OVT", "code": "OVT", "name": "Ovarian Epithelial Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10186, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:0", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 235, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 47, "name": "BRCA1 oncogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 27, "conceptType": "Disease", "name": "High-Grade Serous Fallopian Tube Cancer", "primaryCoding": {"id": "oncotree:HGSFT", "code": "HGSFT", "name": "High-Grade Serous Fallopian Tube Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10187, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:0", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 239, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 47, "name": "BRCA1 oncogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 54, "conceptType": "Disease", "name": "Peritoneal Serous Carcinoma", "primaryCoding": {"id": "oncotree:PSEC", "code": "PSEC", "name": "Peritoneal Serous Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10188, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:0", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 232, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 48, "name": "BRCA1 pathogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 51, "conceptType": "Disease", "name": "Ovarian Epithelial Tumor", "primaryCoding": {"id": "oncotree:OVT", "code": "OVT", "name": "Ovarian Epithelial Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10189, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:0", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 236, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 48, "name": "BRCA1 pathogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 27, "conceptType": "Disease", "name": "High-Grade Serous Fallopian Tube Cancer", "primaryCoding": {"id": "oncotree:HGSFT", "code": "HGSFT", "name": "High-Grade Serous Fallopian Tube Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10190, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:0", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 240, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 48, "name": "BRCA1 pathogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 54, "conceptType": "Disease", "name": "Peritoneal Serous Carcinoma", "primaryCoding": {"id": "oncotree:PSEC", "code": "PSEC", "name": "Peritoneal Serous Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10191, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:0", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 233, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 49, "name": "BRCA2 oncogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 51, "conceptType": "Disease", "name": "Ovarian Epithelial Tumor", "primaryCoding": {"id": "oncotree:OVT", "code": "OVT", "name": "Ovarian Epithelial Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10192, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:0", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 237, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 49, "name": "BRCA2 oncogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 27, "conceptType": "Disease", "name": "High-Grade Serous Fallopian Tube Cancer", "primaryCoding": {"id": "oncotree:HGSFT", "code": "HGSFT", "name": "High-Grade Serous Fallopian Tube Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10193, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:0", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 241, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 49, "name": "BRCA2 oncogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 54, "conceptType": "Disease", "name": "Peritoneal Serous Carcinoma", "primaryCoding": {"id": "oncotree:PSEC", "code": "PSEC", "name": "Peritoneal Serous Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10194, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:0", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 234, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 50, "name": "BRCA2 pathogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 51, "conceptType": "Disease", "name": "Ovarian Epithelial Tumor", "primaryCoding": {"id": "oncotree:OVT", "code": "OVT", "name": "Ovarian Epithelial Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10195, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:0", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 238, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 50, "name": "BRCA2 pathogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 27, "conceptType": "Disease", "name": "High-Grade Serous Fallopian Tube Cancer", "primaryCoding": {"id": "oncotree:HGSFT", "code": "HGSFT", "name": "High-Grade Serous Fallopian Tube Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10196, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:0", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 242, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 50, "name": "BRCA2 pathogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 54, "conceptType": "Disease", "name": "Peritoneal Serous Carcinoma", "primaryCoding": {"id": "oncotree:PSEC", "code": "PSEC", "name": "Peritoneal Serous Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10197, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 243, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 47, "name": "BRCA1 oncogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 51, "conceptType": "Disease", "name": "Ovarian Epithelial Tumor", "primaryCoding": {"id": "oncotree:OVT", "code": "OVT", "name": "Ovarian Epithelial Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10198, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 248, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 47, "name": "BRCA1 oncogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 27, "conceptType": "Disease", "name": "High-Grade Serous Fallopian Tube Cancer", "primaryCoding": {"id": "oncotree:HGSFT", "code": "HGSFT", "name": "High-Grade Serous Fallopian Tube Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10199, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 253, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 47, "name": "BRCA1 oncogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 54, "conceptType": "Disease", "name": "Peritoneal Serous Carcinoma", "primaryCoding": {"id": "oncotree:PSEC", "code": "PSEC", "name": "Peritoneal Serous Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10200, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 244, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 48, "name": "BRCA1 pathogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 51, "conceptType": "Disease", "name": "Ovarian Epithelial Tumor", "primaryCoding": {"id": "oncotree:OVT", "code": "OVT", "name": "Ovarian Epithelial Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10201, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 249, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 48, "name": "BRCA1 pathogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 27, "conceptType": "Disease", "name": "High-Grade Serous Fallopian Tube Cancer", "primaryCoding": {"id": "oncotree:HGSFT", "code": "HGSFT", "name": "High-Grade Serous Fallopian Tube Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10202, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 254, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 48, "name": "BRCA1 pathogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 54, "conceptType": "Disease", "name": "Peritoneal Serous Carcinoma", "primaryCoding": {"id": "oncotree:PSEC", "code": "PSEC", "name": "Peritoneal Serous Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10203, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 245, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 49, "name": "BRCA2 oncogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 51, "conceptType": "Disease", "name": "Ovarian Epithelial Tumor", "primaryCoding": {"id": "oncotree:OVT", "code": "OVT", "name": "Ovarian Epithelial Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10204, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 250, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 49, "name": "BRCA2 oncogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 27, "conceptType": "Disease", "name": "High-Grade Serous Fallopian Tube Cancer", "primaryCoding": {"id": "oncotree:HGSFT", "code": "HGSFT", "name": "High-Grade Serous Fallopian Tube Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10205, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 255, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 49, "name": "BRCA2 oncogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 54, "conceptType": "Disease", "name": "Peritoneal Serous Carcinoma", "primaryCoding": {"id": "oncotree:PSEC", "code": "PSEC", "name": "Peritoneal Serous Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10206, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 246, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 50, "name": "BRCA2 pathogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 51, "conceptType": "Disease", "name": "Ovarian Epithelial Tumor", "primaryCoding": {"id": "oncotree:OVT", "code": "OVT", "name": "Ovarian Epithelial Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10207, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 251, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 50, "name": "BRCA2 pathogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 27, "conceptType": "Disease", "name": "High-Grade Serous Fallopian Tube Cancer", "primaryCoding": {"id": "oncotree:HGSFT", "code": "HGSFT", "name": "High-Grade Serous Fallopian Tube Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10208, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 256, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 50, "name": "BRCA2 pathogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 54, "conceptType": "Disease", "name": "Peritoneal Serous Carcinoma", "primaryCoding": {"id": "oncotree:PSEC", "code": "PSEC", "name": "Peritoneal Serous Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10209, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 247, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 51, "name": "HRD", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Homologous Recombination"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 51, "conceptType": "Disease", "name": "Ovarian Epithelial Tumor", "primaryCoding": {"id": "oncotree:OVT", "code": "OVT", "name": "Ovarian Epithelial Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10210, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 252, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 51, "name": "HRD", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Homologous Recombination"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 27, "conceptType": "Disease", "name": "High-Grade Serous Fallopian Tube Cancer", "primaryCoding": {"id": "oncotree:HGSFT", "code": "HGSFT", "name": "High-Grade Serous Fallopian Tube Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10211, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:1", "indication": "Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.", "raw_biomarkers": null, "raw_cancer_type": "epithelial ovarian, fallopian tube, or primary peritoneal cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with bevacizumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 257, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 51, "name": "HRD", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Homologous Recombination"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 54, "conceptType": "Disease", "name": "Peritoneal Serous Carcinoma", "primaryCoding": {"id": "oncotree:PSEC", "code": "PSEC", "name": "Peritoneal Serous Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC"]}, "mappings": []}, "objectTherapeutic": {"id": 43, "membership_operator": "AND", "therapies": [{"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10212, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:2", "indication": "Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 258, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 48, "name": "BRCA1 pathogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10214, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as both a monotherapy and in combination with endocrine for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Lynparza's product information cites the OlympiA trial, where olaparib was compared against placebo for the treatment of patients with germline BRCA1/2 mutated and HER2-negative high risk early breast cancer.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:3", "indication": "Lynparza is indicated as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as both a monotherapy and in combination with endocrine for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Lynparza's product information cites the OlympiA trial, where olaparib was compared against placebo for the treatment of patients with germline BRCA1/2 mutated and HER2-negative high risk early breast cancer.", "raw_biomarkers": null, "raw_cancer_type": "early breast cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 258, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 48, "name": "BRCA1 pathogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10215, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:2", "indication": "Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered sunsuitable for endocrine therapy.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 259, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 50, "name": "BRCA2 pathogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10217, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as both a monotherapy and in combination with endocrine for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Lynparza's product information cites the OlympiA trial, where olaparib was compared against placebo for the treatment of patients with germline BRCA1/2 mutated and HER2-negative high risk early breast cancer.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:3", "indication": "Lynparza is indicated as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as both a monotherapy and in combination with endocrine for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Lynparza's product information cites the OlympiA trial, where olaparib was compared against placebo for the treatment of patients with germline BRCA1/2 mutated and HER2-negative high risk early breast cancer.", "raw_biomarkers": null, "raw_cancer_type": "early breast cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 259, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 50, "name": "BRCA2 pathogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10218, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:4", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.", "raw_biomarkers": null, "raw_cancer_type": "Adenocarcinoma of the pancreas", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 260, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 48, "name": "BRCA1 pathogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 52, "conceptType": "Disease", "name": "Pancreatic Adenocarcinoma", "primaryCoding": {"id": "oncotree:PAAD", "code": "PAAD", "name": "Pancreatic Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PAAD"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10219, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:4", "indication": "Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.", "raw_biomarkers": null, "raw_cancer_type": "Adenocarcinoma of the pancreas", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 261, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 50, "name": "BRCA2 pathogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 52, "conceptType": "Disease", "name": "Pancreatic Adenocarcinoma", "primaryCoding": {"id": "oncotree:PAAD", "code": "PAAD", "name": "Pancreatic Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PAAD"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10220, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:5", "indication": "Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.", "raw_biomarkers": null, "raw_cancer_type": "Prostate cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 263, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 47, "name": "BRCA1 oncogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 55, "conceptType": "Disease", "name": "Prostate Adenocarcinoma", "primaryCoding": {"id": "oncotree:PRAD", "code": "PRAD", "name": "Prostate Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10221, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:5", "indication": "Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.", "raw_biomarkers": null, "raw_cancer_type": "Prostate cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 265, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 49, "name": "BRCA2 oncogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 55, "conceptType": "Disease", "name": "Prostate Adenocarcinoma", "primaryCoding": {"id": "oncotree:PRAD", "code": "PRAD", "name": "Prostate Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10222, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:5", "indication": "Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.", "raw_biomarkers": null, "raw_cancer_type": "Prostate cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 264, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 48, "name": "BRCA1 pathogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 55, "conceptType": "Disease", "name": "Prostate Adenocarcinoma", "primaryCoding": {"id": "oncotree:PRAD", "code": "PRAD", "name": "Prostate Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10223, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:5", "indication": "Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.", "raw_biomarkers": null, "raw_cancer_type": "Prostate cancer", "raw_therapeutics": "Lynparza (olaparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 266, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 50, "name": "BRCA2 pathogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 55, "conceptType": "Disease", "name": "Prostate Adenocarcinoma", "primaryCoding": {"id": "oncotree:PRAD", "code": "PRAD", "name": "Prostate Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD"]}, "mappings": []}, "objectTherapeutic": {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10224, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with durvalumab for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lynparza:6", "indication": "Lynparza in combination with durvalumab is indicated for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized olaparib in combination with durvalumab for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.", "raw_biomarkers": null, "raw_cancer_type": "Endometrial cancer", "raw_therapeutics": "Lynparza (olaparib) in combination with durvalumab for maintence treatment, after not progressing on first-line treatment with durvalumab in combination with carboplatin and paclitaxel", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lynparza", "type": "Document", "subtype": "Regulatory approval", "name": "Lynparza (olaparib) [product information]. EMA.", "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Lynparza", "drug_name_generic": "olaparib", "first_published": "2015-01-09", "access_date": null, "publication_date": "2024-08-20", "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 620, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 37, "name": "pMMR", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Mismatch Repair"}, {"name": "present", "value": true}, {"name": "status", "value": "Proficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 18, "conceptType": "Disease", "name": "Endometrial Carcinoma", "primaryCoding": {"id": "oncotree:UCEC", "code": "UCEC", "name": "Endometrial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC"]}, "mappings": []}, "objectTherapeutic": {"id": 123, "membership_operator": "AND", "therapies": [{"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 46, "conceptType": "Drug", "name": "Olaparib", "primaryCoding": {"id": "ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10225, "type": "Statement", "description": "The European Medicines Agency (EMA) has given futibatinib conditional market authorization as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement that have progressed after at least one line of prior systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lytgobi", "type": "Document", "subtype": "Regulatory approval", "name": "Lytgobi (futibatinib) [product information]. EMA.", "citation": "Taiho Pharma Netherlands B.V. Lytgobi (futibatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Lytgobi", "drug_name_generic": "futibatinib", "first_published": "2023-07-18", "access_date": null, "publication_date": "2023-10-19", "url": "https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lytgobi:0", "indication": "Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has given futibatinib conditional market authorization as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement that have progressed after at least one line of prior systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Cholangiocarcinoma", "raw_therapeutics": "Lytgobi (futibatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lytgobi", "type": "Document", "subtype": "Regulatory approval", "name": "Lytgobi (futibatinib) [product information]. EMA.", "citation": "Taiho Pharma Netherlands B.V. Lytgobi (futibatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Lytgobi", "drug_name_generic": "futibatinib", "first_published": "2023-07-18", "access_date": null, "publication_date": "2023-10-19", "url": "https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 146, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 52, "name": "FGFR2::v", "genes": [{"id": 23, "name": "FGFR2", "primaryCoding": {"id": "hgnc:3689", "code": "HGNC:3689", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_000141.5", "code": "NM_000141.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000141.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000066468", "code": "ENSG00000066468", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000066468"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2263", "code": "2263", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2263"]}}], "extensions": [{"name": "location", "value": "10q26.13"}, {"name": "location_sortable", "value": "10q26.13"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 29, "conceptType": "Disease", "name": "Intrahepatic Cholangiocarcinoma", "primaryCoding": {"id": "oncotree:IHCH", "code": "IHCH", "name": "Intrahepatic Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=IHCH"]}, "mappings": []}, "objectTherapeutic": {"id": 58, "conceptType": "Drug", "name": "Futibatinib", "primaryCoding": {"id": "ncit:C114283", "code": "C114283", "name": "Futibatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114283"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10226, "type": "Statement", "description": "The European Medicines Agency (EMA) has given futibatinib conditional market authorization as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement that have progressed after at least one line of prior systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.lytgobi", "type": "Document", "subtype": "Regulatory approval", "name": "Lytgobi (futibatinib) [product information]. EMA.", "citation": "Taiho Pharma Netherlands B.V. Lytgobi (futibatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Lytgobi", "drug_name_generic": "futibatinib", "first_published": "2023-07-18", "access_date": null, "publication_date": "2023-10-19", "url": "https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.lytgobi:0", "indication": "Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has given futibatinib conditional market authorization as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement that have progressed after at least one line of prior systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Cholangiocarcinoma", "raw_therapeutics": "Lytgobi (futibatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.lytgobi", "type": "Document", "subtype": "Regulatory approval", "name": "Lytgobi (futibatinib) [product information]. EMA.", "citation": "Taiho Pharma Netherlands B.V. Lytgobi (futibatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Lytgobi", "drug_name_generic": "futibatinib", "first_published": "2023-07-18", "access_date": null, "publication_date": "2023-10-19", "url": "https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 621, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 53, "name": "FGFR2 rearrangements", "genes": [{"id": 23, "name": "FGFR2", "primaryCoding": {"id": "hgnc:3689", "code": "HGNC:3689", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_000141.5", "code": "NM_000141.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000141.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000066468", "code": "ENSG00000066468", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000066468"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2263", "code": "2263", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2263"]}}], "extensions": [{"name": "location", "value": "10q26.13"}, {"name": "location_sortable", "value": "10q26.13"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 29, "conceptType": "Disease", "name": "Intrahepatic Cholangiocarcinoma", "primaryCoding": {"id": "oncotree:IHCH", "code": "IHCH", "name": "Intrahepatic Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=IHCH"]}, "mappings": []}, "objectTherapeutic": {"id": 58, "conceptType": "Drug", "name": "Futibatinib", "primaryCoding": {"id": "ncit:C114283", "code": "C114283", "name": "Futibatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114283"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10227, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mabthera", "type": "Document", "subtype": "Regulatory approval", "name": "MabThera (rituximab) [product information]. EMA.", "citation": "Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "MabThera", "drug_name_generic": "rituximab", "first_published": "2009-10-30", "access_date": null, "publication_date": "2023-11-29", "url": "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mabthera:0", "indication": "MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine,prednisolone) chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.", "raw_biomarkers": null, "raw_cancer_type": "diffuse large B cell non-Hodgkin's lymphoma", "raw_therapeutics": "MabThera (rituximab) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mabthera", "type": "Document", "subtype": "Regulatory approval", "name": "MabThera (rituximab) [product information]. EMA.", "citation": "Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "MabThera", "drug_name_generic": "rituximab", "first_published": "2009-10-30", "access_date": null, "publication_date": "2023-11-29", "url": "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 622, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 54, "name": "CD20 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD20"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 77, "conceptType": "Disease", "name": "Diffuse Large B-Cell Lymphoma", "primaryCoding": {"id": "oncotree:DLBCLNOS", "code": "DLBCLNOS", "name": "Diffuse Large B-Cell Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=DLBCLNOS"]}, "mappings": []}, "objectTherapeutic": {"id": 124, "membership_operator": "AND", "therapies": [{"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 8, "conceptType": "Drug", "name": "Prednisolone", "primaryCoding": {"id": "ncit:C769", "code": "C769", "name": "Prednisolone", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Corticosteroid"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 61, "conceptType": "Drug", "name": "Vincristine", "primaryCoding": {"id": "ncit:C933", "code": "C933", "name": "Vincristine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Vinca alkaloid chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 60, "conceptType": "Drug", "name": "Rituximab", "primaryCoding": {"id": "ncit:C1702", "code": "C1702", "name": "Rituximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD20 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10228, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mabthera", "type": "Document", "subtype": "Regulatory approval", "name": "MabThera (rituximab) [product information]. EMA.", "citation": "Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "MabThera", "drug_name_generic": "rituximab", "first_published": "2009-10-30", "access_date": null, "publication_date": "2023-11-29", "url": "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mabthera:0", "indication": "MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine,prednisolone) chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma.", "raw_biomarkers": null, "raw_cancer_type": "diffuse large B cell non-Hodgkin's lymphoma", "raw_therapeutics": "MabThera (rituximab) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mabthera", "type": "Document", "subtype": "Regulatory approval", "name": "MabThera (rituximab) [product information]. EMA.", "citation": "Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "MabThera", "drug_name_generic": "rituximab", "first_published": "2009-10-30", "access_date": null, "publication_date": "2023-11-29", "url": "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 380, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 54, "name": "CD20 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD20"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 76, "conceptType": "Disease", "name": "Non-Hodgkin Lymphoma", "primaryCoding": {"id": "oncotree:NHL", "code": "NHL", "name": "Non-Hodgkin Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NHL"]}, "mappings": []}, "objectTherapeutic": {"id": 124, "membership_operator": "AND", "therapies": [{"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 8, "conceptType": "Drug", "name": "Prednisolone", "primaryCoding": {"id": "ncit:C769", "code": "C769", "name": "Prednisolone", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Corticosteroid"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 61, "conceptType": "Drug", "name": "Vincristine", "primaryCoding": {"id": "ncit:C933", "code": "C933", "name": "Vincristine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Vinca alkaloid chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 60, "conceptType": "Drug", "name": "Rituximab", "primaryCoding": {"id": "ncit:C1702", "code": "C1702", "name": "Rituximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD20 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10229, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mabthera", "type": "Document", "subtype": "Regulatory approval", "name": "MabThera (rituximab) [product information]. EMA.", "citation": "Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "MabThera", "drug_name_generic": "rituximab", "first_published": "2009-10-30", "access_date": null, "publication_date": "2023-11-29", "url": "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mabthera:1", "indication": "MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.", "raw_biomarkers": "CD20 positive", "raw_cancer_type": "diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL)", "raw_therapeutics": "MabThera (rituximab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mabthera", "type": "Document", "subtype": "Regulatory approval", "name": "MabThera (rituximab) [product information]. EMA.", "citation": "Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "MabThera", "drug_name_generic": "rituximab", "first_published": "2009-10-30", "access_date": null, "publication_date": "2023-11-29", "url": "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 624, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 54, "name": "CD20 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD20"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 77, "conceptType": "Disease", "name": "Diffuse Large B-Cell Lymphoma", "primaryCoding": {"id": "oncotree:DLBCLNOS", "code": "DLBCLNOS", "name": "Diffuse Large B-Cell Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=DLBCLNOS"]}, "mappings": []}, "objectTherapeutic": {"id": 125, "membership_operator": "AND", "therapies": [{"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 61, "conceptType": "Drug", "name": "Vincristine", "primaryCoding": {"id": "ncit:C933", "code": "C933", "name": "Vincristine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Vinca alkaloid chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 65, "conceptType": "Drug", "name": "Methotrexate", "primaryCoding": {"id": "ncit:C642", "code": "C642", "name": "Methotrexate", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C642"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 60, "conceptType": "Drug", "name": "Rituximab", "primaryCoding": {"id": "ncit:C1702", "code": "C1702", "name": "Rituximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD20 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 62, "conceptType": "Drug", "name": "Corticosteroid", "primaryCoding": {"id": "ncit:C2322", "code": "C2322", "name": "Corticosteroid", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2322"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Anti-inflammatory"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 64, "conceptType": "Drug", "name": "Etoposide", "primaryCoding": {"id": "ncit:C491", "code": "C491", "name": "Etoposide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C491"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 63, "conceptType": "Drug", "name": "Cytarabine", "primaryCoding": {"id": "ncit:C408", "code": "C408", "name": "Cytarabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["DNA Polymerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10230, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mabthera", "type": "Document", "subtype": "Regulatory approval", "name": "MabThera (rituximab) [product information]. EMA.", "citation": "Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "MabThera", "drug_name_generic": "rituximab", "first_published": "2009-10-30", "access_date": null, "publication_date": "2023-11-29", "url": "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mabthera:1", "indication": "MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.", "raw_biomarkers": "CD20 positive", "raw_cancer_type": "diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL)", "raw_therapeutics": "MabThera (rituximab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mabthera", "type": "Document", "subtype": "Regulatory approval", "name": "MabThera (rituximab) [product information]. EMA.", "citation": "Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "MabThera", "drug_name_generic": "rituximab", "first_published": "2009-10-30", "access_date": null, "publication_date": "2023-11-29", "url": "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 625, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 54, "name": "CD20 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD20"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 76, "conceptType": "Disease", "name": "Non-Hodgkin Lymphoma", "primaryCoding": {"id": "oncotree:NHL", "code": "NHL", "name": "Non-Hodgkin Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NHL"]}, "mappings": []}, "objectTherapeutic": {"id": 125, "membership_operator": "AND", "therapies": [{"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 61, "conceptType": "Drug", "name": "Vincristine", "primaryCoding": {"id": "ncit:C933", "code": "C933", "name": "Vincristine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Vinca alkaloid chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 65, "conceptType": "Drug", "name": "Methotrexate", "primaryCoding": {"id": "ncit:C642", "code": "C642", "name": "Methotrexate", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C642"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 60, "conceptType": "Drug", "name": "Rituximab", "primaryCoding": {"id": "ncit:C1702", "code": "C1702", "name": "Rituximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD20 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 62, "conceptType": "Drug", "name": "Corticosteroid", "primaryCoding": {"id": "ncit:C2322", "code": "C2322", "name": "Corticosteroid", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2322"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Anti-inflammatory"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 64, "conceptType": "Drug", "name": "Etoposide", "primaryCoding": {"id": "ncit:C491", "code": "C491", "name": "Etoposide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C491"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 63, "conceptType": "Drug", "name": "Cytarabine", "primaryCoding": {"id": "ncit:C408", "code": "C408", "name": "Cytarabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["DNA Polymerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10231, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mabthera", "type": "Document", "subtype": "Regulatory approval", "name": "MabThera (rituximab) [product information]. EMA.", "citation": "Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "MabThera", "drug_name_generic": "rituximab", "first_published": "2009-10-30", "access_date": null, "publication_date": "2023-11-29", "url": "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mabthera:1", "indication": "MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.", "raw_biomarkers": "CD20 positive", "raw_cancer_type": "diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL)", "raw_therapeutics": "MabThera (rituximab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mabthera", "type": "Document", "subtype": "Regulatory approval", "name": "MabThera (rituximab) [product information]. EMA.", "citation": "Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.", "company": "", "drug_name_brand": "MabThera", "drug_name_generic": "rituximab", "first_published": "2009-10-30", "access_date": null, "publication_date": "2023-11-29", "url": "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 626, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 54, "name": "CD20 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD20"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 78, "conceptType": "Disease", "name": "Burkitt Lymphoma", "primaryCoding": {"id": "oncotree:BL", "code": "BL", "name": "Burkitt Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BL"]}, "mappings": []}, "objectTherapeutic": {"id": 125, "membership_operator": "AND", "therapies": [{"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 61, "conceptType": "Drug", "name": "Vincristine", "primaryCoding": {"id": "ncit:C933", "code": "C933", "name": "Vincristine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Vinca alkaloid chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 65, "conceptType": "Drug", "name": "Methotrexate", "primaryCoding": {"id": "ncit:C642", "code": "C642", "name": "Methotrexate", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C642"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 60, "conceptType": "Drug", "name": "Rituximab", "primaryCoding": {"id": "ncit:C1702", "code": "C1702", "name": "Rituximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD20 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 62, "conceptType": "Drug", "name": "Corticosteroid", "primaryCoding": {"id": "ncit:C2322", "code": "C2322", "name": "Corticosteroid", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2322"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Anti-inflammatory"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 64, "conceptType": "Drug", "name": "Etoposide", "primaryCoding": {"id": "ncit:C491", "code": "C491", "name": "Etoposide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C491"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 63, "conceptType": "Drug", "name": "Cytarabine", "primaryCoding": {"id": "ncit:C408", "code": "C408", "name": "Cytarabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["DNA Polymerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10232, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mekinist:0", "indication": "Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "trametinib as a monotherapy or in combination with dabrafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 416, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10233, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mekinist:0", "indication": "Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "trametinib as a monotherapy or in combination with dabrafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 417, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 17, "name": "BRAF p.V600K", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453137}, {"name": "reference_allele", "value": "AC"}, {"name": "alternate_allele", "value": "TT"}, {"name": "cdna_change", "value": "c.1798_1799GT>AA"}, {"name": "protein_change", "value": "p.V600K"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs121913227"}, {"name": "hgvsg", "value": "7:g.140453136_140453137delinsTT"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10234, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mekinist:0", "indication": "Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "trametinib as a monotherapy or in combination with dabrafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 89, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10235, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 variant, following complete resection.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mekinist:1", "indication": "Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 variant, following complete resection.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 89, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10236, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mekinist:0", "indication": "Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant. Trametinib's product information further states that trametinib as a monotherapy has not demonstrated clinical activity in patients who have progressed on prior BRAF inhibitor therapy.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "trametinib as a monotherapy or in combination with dabrafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 90, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 17, "name": "BRAF p.V600K", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453137}, {"name": "reference_allele", "value": "AC"}, {"name": "alternate_allele", "value": "TT"}, {"name": "cdna_change", "value": "c.1798_1799GT>AA"}, {"name": "protein_change", "value": "p.V600K"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs121913227"}, {"name": "hgvsg", "value": "7:g.140453136_140453137delinsTT"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10237, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 variant, following complete resection.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mekinist:1", "indication": "Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trametinib as a monotherapy or in combination with dabrafenib for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 variant, following complete resection.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 90, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 17, "name": "BRAF p.V600K", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453137}, {"name": "reference_allele", "value": "AC"}, {"name": "alternate_allele", "value": "TT"}, {"name": "cdna_change", "value": "c.1798_1799GT>AA"}, {"name": "protein_change", "value": "p.V600K"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs121913227"}, {"name": "hgvsg", "value": "7:g.140453136_140453137delinsTT"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10238, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mekinist:2", "indication": "Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 91, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10239, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mekinist:2", "indication": "Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Mekinist (trametinib) in combination with dabrafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mekinist", "type": "Document", "subtype": "Regulatory approval", "name": "Mekinist (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.", "company": "", "drug_name_brand": "Mekinist", "drug_name_generic": "trametinib", "first_published": "2014-07-09", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 627, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 17, "name": "BRAF p.V600K", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453137}, {"name": "reference_allele", "value": "AC"}, {"name": "alternate_allele", "value": "TT"}, {"name": "cdna_change", "value": "c.1798_1799GT>AA"}, {"name": "protein_change", "value": "p.V600K"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs121913227"}, {"name": "hgvsg", "value": "7:g.140453136_140453137delinsTT"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10240, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mektovi", "type": "Document", "subtype": "Regulatory approval", "name": "Mektovi (binimetinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Mektovi (binimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Mektovi", "drug_name_generic": "binimetinib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mektovi:0", "indication": "Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Mektovi (binimetinib) in combination with encorafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mektovi", "type": "Document", "subtype": "Regulatory approval", "name": "Mektovi (binimetinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Mektovi (binimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Mektovi", "drug_name_generic": "binimetinib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 41, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 10, "membership_operator": "AND", "therapies": [{"id": 17, "conceptType": "Drug", "name": "Binimetinib", "primaryCoding": {"id": "ncit:C84865", "code": "C84865", "name": "Binimetinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 18, "conceptType": "Drug", "name": "Encorafenib", "primaryCoding": {"id": "ncit:C98283", "code": "C98283", "name": "Encorafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10241, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mektovi", "type": "Document", "subtype": "Regulatory approval", "name": "Mektovi (binimetinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Mektovi (binimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Mektovi", "drug_name_generic": "binimetinib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mektovi:0", "indication": "Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Mektovi (binimetinib) in combination with encorafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mektovi", "type": "Document", "subtype": "Regulatory approval", "name": "Mektovi (binimetinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Mektovi (binimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Mektovi", "drug_name_generic": "binimetinib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 42, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 17, "name": "BRAF p.V600K", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453137}, {"name": "reference_allele", "value": "AC"}, {"name": "alternate_allele", "value": "TT"}, {"name": "cdna_change", "value": "c.1798_1799GT>AA"}, {"name": "protein_change", "value": "p.V600K"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs121913227"}, {"name": "hgvsg", "value": "7:g.140453136_140453137delinsTT"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 10, "membership_operator": "AND", "therapies": [{"id": 17, "conceptType": "Drug", "name": "Binimetinib", "primaryCoding": {"id": "ncit:C84865", "code": "C84865", "name": "Binimetinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 18, "conceptType": "Drug", "name": "Encorafenib", "primaryCoding": {"id": "ncit:C98283", "code": "C98283", "name": "Encorafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10242, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mektovi", "type": "Document", "subtype": "Regulatory approval", "name": "Mektovi (binimetinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Mektovi (binimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Mektovi", "drug_name_generic": "binimetinib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mektovi:1", "indication": "Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized binimetinib in combination with encorafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Mektovi (binimetinib) in combination with encorafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mektovi", "type": "Document", "subtype": "Regulatory approval", "name": "Mektovi (binimetinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Mektovi (binimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Mektovi", "drug_name_generic": "binimetinib", "first_published": "2018-10-12", "access_date": null, "publication_date": "2024-09-05", "url": "https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 43, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 10, "membership_operator": "AND", "therapies": [{"id": 17, "conceptType": "Drug", "name": "Binimetinib", "primaryCoding": {"id": "ncit:C84865", "code": "C84865", "name": "Binimetinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 18, "conceptType": "Drug", "name": "Encorafenib", "primaryCoding": {"id": "ncit:C98283", "code": "C98283", "name": "Encorafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10243, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized gemtuzumab ozogamicin in combination with cytarabine and daunorubicin for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukaemia (APL).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.mylotarg", "type": "Document", "subtype": "Regulatory approval", "name": "Mylotarg (gemtuzumab ozogamicin) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Mylotarg (gemtuzumab ozogamicin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf. Revised November 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Mylotarg", "drug_name_generic": "gemtuzumab ozogamicin", "first_published": "2018-05-04", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.mylotarg:0", "indication": "MYLOTARG is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized gemtuzumab ozogamicin in combination with cytarabine and daunorubicin for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukaemia (APL).", "raw_biomarkers": null, "raw_cancer_type": "Acute myeloid leukaemia", "raw_therapeutics": "Mylotarg (gemtuzumab ozogamicin) in combination with daunorubicin (DNR) and cytarabine (AraC)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.mylotarg", "type": "Document", "subtype": "Regulatory approval", "name": "Mylotarg (gemtuzumab ozogamicin) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Mylotarg (gemtuzumab ozogamicin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf. Revised November 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Mylotarg", "drug_name_generic": "gemtuzumab ozogamicin", "first_published": "2018-05-04", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 628, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 55, "name": "CD33 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD33"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 1, "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "primaryCoding": {"id": "oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML"]}, "mappings": []}, "objectTherapeutic": {"id": 126, "membership_operator": "AND", "therapies": [{"id": 68, "conceptType": "Drug", "name": "Daunorubicin", "primaryCoding": {"id": "ncit:C62091", "code": "C62091", "name": "Daunorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["DNA Polymerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 63, "conceptType": "Drug", "name": "Cytarabine", "primaryCoding": {"id": "ncit:C408", "code": "C408", "name": "Cytarabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["DNA Polymerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 69, "conceptType": "Drug", "name": "Gemtuzumab ozogamicin", "primaryCoding": {"id": "ncit:C1806", "code": "C1806", "name": "Gemtuzumab Ozogamicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1806"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD33 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10244, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.nerlynx", "type": "Document", "subtype": "Regulatory approval", "name": "Nerlynx (neratinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Nerlynx", "drug_name_generic": "neratinib", "first_published": "2018-09-12", "access_date": null, "publication_date": "2023-06-15", "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.nerlynx:0", "indication": "Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Nerlynx (neratinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.nerlynx", "type": "Document", "subtype": "Regulatory approval", "name": "Nerlynx (neratinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Nerlynx", "drug_name_generic": "neratinib", "first_published": "2018-09-12", "access_date": null, "publication_date": "2023-06-15", "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 629, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 70, "conceptType": "Drug", "name": "Neratinib", "primaryCoding": {"id": "ncit:C49094", "code": "C49094", "name": "Neratinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49094"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10245, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.nerlynx", "type": "Document", "subtype": "Regulatory approval", "name": "Nerlynx (neratinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Nerlynx", "drug_name_generic": "neratinib", "first_published": "2018-09-12", "access_date": null, "publication_date": "2023-06-15", "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.nerlynx:0", "indication": "Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Nerlynx (neratinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.nerlynx", "type": "Document", "subtype": "Regulatory approval", "name": "Nerlynx (neratinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Nerlynx", "drug_name_generic": "neratinib", "first_published": "2018-09-12", "access_date": null, "publication_date": "2023-06-15", "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 630, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 70, "conceptType": "Drug", "name": "Neratinib", "primaryCoding": {"id": "ncit:C49094", "code": "C49094", "name": "Neratinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49094"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10246, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.nerlynx", "type": "Document", "subtype": "Regulatory approval", "name": "Nerlynx (neratinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Nerlynx", "drug_name_generic": "neratinib", "first_published": "2018-09-12", "access_date": null, "publication_date": "2023-06-15", "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.nerlynx:0", "indication": "Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Nerlynx (neratinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.nerlynx", "type": "Document", "subtype": "Regulatory approval", "name": "Nerlynx (neratinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Nerlynx", "drug_name_generic": "neratinib", "first_published": "2018-09-12", "access_date": null, "publication_date": "2023-06-15", "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 631, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 70, "conceptType": "Drug", "name": "Neratinib", "primaryCoding": {"id": "ncit:C49094", "code": "C49094", "name": "Neratinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49094"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10247, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.nerlynx", "type": "Document", "subtype": "Regulatory approval", "name": "Nerlynx (neratinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Nerlynx", "drug_name_generic": "neratinib", "first_published": "2018-09-12", "access_date": null, "publication_date": "2023-06-15", "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.nerlynx:0", "indication": "Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Nerlynx (neratinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.nerlynx", "type": "Document", "subtype": "Regulatory approval", "name": "Nerlynx (neratinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Nerlynx", "drug_name_generic": "neratinib", "first_published": "2018-09-12", "access_date": null, "publication_date": "2023-06-15", "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 632, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 70, "conceptType": "Drug", "name": "Neratinib", "primaryCoding": {"id": "ncit:C49094", "code": "C49094", "name": "Neratinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49094"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10248, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.nerlynx", "type": "Document", "subtype": "Regulatory approval", "name": "Nerlynx (neratinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Nerlynx", "drug_name_generic": "neratinib", "first_published": "2018-09-12", "access_date": null, "publication_date": "2023-06-15", "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.nerlynx:0", "indication": "Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Nerlynx (neratinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.nerlynx", "type": "Document", "subtype": "Regulatory approval", "name": "Nerlynx (neratinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Nerlynx", "drug_name_generic": "neratinib", "first_published": "2018-09-12", "access_date": null, "publication_date": "2023-06-15", "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 633, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 70, "conceptType": "Drug", "name": "Neratinib", "primaryCoding": {"id": "ncit:C49094", "code": "C49094", "name": "Neratinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49094"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10249, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.nerlynx", "type": "Document", "subtype": "Regulatory approval", "name": "Nerlynx (neratinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Nerlynx", "drug_name_generic": "neratinib", "first_published": "2018-09-12", "access_date": null, "publication_date": "2023-06-15", "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.nerlynx:0", "indication": "Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized neratinib for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Nerlynx (neratinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.nerlynx", "type": "Document", "subtype": "Regulatory approval", "name": "Nerlynx (neratinib) [product information]. EMA.", "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.", "company": "", "drug_name_brand": "Nerlynx", "drug_name_generic": "neratinib", "first_published": "2018-09-12", "access_date": null, "publication_date": "2023-06-15", "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 634, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 70, "conceptType": "Drug", "name": "Neratinib", "primaryCoding": {"id": "ncit:C49094", "code": "C49094", "name": "Neratinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49094"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10250, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:0", "indication": "OPDIVO in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab and 2 cycles of platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 172, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 30, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": {"id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10251, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:0", "indication": "OPDIVO in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab and 2 cycles of platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 173, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 31, "membership_operator": "AND", "therapies": [{"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": {"id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10252, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:0", "indication": "OPDIVO in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab and 2 cycles of platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 174, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 32, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": {"id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10253, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:1", "indication": "OPDIVO in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Opdivo (nivolumab) in combination with platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 638, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 33, "name": "PD-L1 >= 1%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.01"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 42, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10254, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:1", "indication": "OPDIVO in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Opdivo (nivolumab) in combination with platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 639, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 33, "name": "PD-L1 >= 1%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.01"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 127, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10255, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:1", "indication": "OPDIVO in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors haev PD-L1 expression >= 1%. This indication is based on CA209816, a randomized, open-label, phase 3 study where the selection of platinum-based chemotherapy was investigator's choice of paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Opdivo (nivolumab) in combination with platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 640, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 33, "name": "PD-L1 >= 1%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.01"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 94, "membership_operator": "AND", "therapies": [{"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 50, "conceptType": "Drug", "name": "Gemcitabine", "primaryCoding": {"id": "ncit:C66876", "code": "C66876", "name": "Gemcitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antimetabolite"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10256, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab as a monotherapy for the adjuvant treatment of adult patients with muscle invasive urothelial carcinoma (MIUC) with tumor cell PD-L1 expression >= 1%, who are at high risk of recurrence after undergoing radical resection of MIUC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:2", "indication": "OPDIVO as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression >= 1%, who are at high risk of recurrence after undergoing radical resection of MIUC.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab as a monotherapy for the adjuvant treatment of adult patients with muscle invasive urothelial carcinoma (MIUC) with tumor cell PD-L1 expression >= 1%, who are at high risk of recurrence after undergoing radical resection of MIUC.", "raw_biomarkers": null, "raw_cancer_type": "Urothelial carcinoma", "raw_therapeutics": "Opdivo (nivolumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 641, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 33, "name": "PD-L1 >= 1%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.01"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 8, "conceptType": "Disease", "name": "Bladder Urothelial Carcinoma", "primaryCoding": {"id": "oncotree:BLCA", "code": "BLCA", "name": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"]}, "mappings": []}, "objectTherapeutic": {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10257, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:3", "indication": "OPDIVO in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 169, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 38, "name": "MSI-H", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Microsatellite Stability"}, {"name": "present", "value": true}, {"name": "status", "value": "Microsatellite instability-high (MSI-H)"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 29, "membership_operator": "AND", "therapies": [{"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": {"id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10258, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:3", "indication": "OPDIVO in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 507, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Mismatch Repair"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 29, "membership_operator": "AND", "therapies": [{"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": {"id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10259, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:4", "indication": "OPDIVO in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.", "raw_biomarkers": null, "raw_cancer_type": "Oesophageal squamous cell carcinoma", "raw_therapeutics": "Opdivo (nivolumab) in combination with ipilimumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 642, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 33, "name": "PD-L1 >= 1%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.01"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 82, "conceptType": "Disease", "name": "Esophageal Squamous Cell Carcinoma", "primaryCoding": {"id": "oncotree:ESCC", "code": "ESCC", "name": "Esophageal Squamous Cell Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCC"]}, "mappings": []}, "objectTherapeutic": {"id": 29, "membership_operator": "AND", "therapies": [{"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": {"id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10260, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable, advanced, or recurrent metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%. This indication is based on CA209648, a randomized, active-controlled, and open-label study where the choice of chemotherapy was fluorouracil and cisplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:5", "indication": "OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable, advanced, or recurrent metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%. This indication is based on CA209648, a randomized, active-controlled, and open-label study where the choice of chemotherapy was fluorouracil and cisplatin.", "raw_biomarkers": null, "raw_cancer_type": "Oesophageal squamous cell carcinoma", "raw_therapeutics": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 643, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 33, "name": "PD-L1 >= 1%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.01"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 82, "conceptType": "Disease", "name": "Esophageal Squamous Cell Carcinoma", "primaryCoding": {"id": "oncotree:ESCC", "code": "ESCC", "name": "Esophageal Squamous Cell Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCC"]}, "mappings": []}, "objectTherapeutic": {"id": 128, "membership_operator": "AND", "therapies": [{"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10261, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:6", "indication": "OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).", "raw_biomarkers": null, "raw_cancer_type": "gastric, gastro-oesophageal junction or oesophageal adenocarcinoma", "raw_therapeutics": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 644, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 56, "name": "PD-L1 (CPS) >= 5", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "5"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 74, "conceptType": "Disease", "name": "Esophageal Adenocarcinoma", "primaryCoding": {"id": "oncotree:ESCA", "code": "ESCA", "name": "Esophageal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCA"]}, "mappings": []}, "objectTherapeutic": {"id": 129, "membership_operator": "AND", "therapies": [{"id": 28, "conceptType": "Drug", "name": "Oxaliplatin", "primaryCoding": {"id": "ncit:C1181", "code": "C1181", "name": "Oxaliplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10262, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:6", "indication": "OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).", "raw_biomarkers": null, "raw_cancer_type": "gastric, gastro-oesophageal junction or oesophageal adenocarcinoma", "raw_therapeutics": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 645, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 56, "name": "PD-L1 (CPS) >= 5", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "5"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 74, "conceptType": "Disease", "name": "Esophageal Adenocarcinoma", "primaryCoding": {"id": "oncotree:ESCA", "code": "ESCA", "name": "Esophageal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCA"]}, "mappings": []}, "objectTherapeutic": {"id": 130, "membership_operator": "AND", "therapies": [{"id": 28, "conceptType": "Drug", "name": "Oxaliplatin", "primaryCoding": {"id": "ncit:C1181", "code": "C1181", "name": "Oxaliplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10263, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:6", "indication": "OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).", "raw_biomarkers": null, "raw_cancer_type": "gastric, gastro-oesophageal junction or oesophageal adenocarcinoma", "raw_therapeutics": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 646, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 56, "name": "PD-L1 (CPS) >= 5", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "5"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 81, "conceptType": "Disease", "name": "Esophagogastric Adenocarcinoma", "primaryCoding": {"id": "oncotree:EGC", "code": "EGC", "name": "Esophagogastric Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=EGC"]}, "mappings": []}, "objectTherapeutic": {"id": 129, "membership_operator": "AND", "therapies": [{"id": 28, "conceptType": "Drug", "name": "Oxaliplatin", "primaryCoding": {"id": "ncit:C1181", "code": "C1181", "name": "Oxaliplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10264, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:6", "indication": "OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).", "raw_biomarkers": null, "raw_cancer_type": "gastric, gastro-oesophageal junction or oesophageal adenocarcinoma", "raw_therapeutics": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 647, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 56, "name": "PD-L1 (CPS) >= 5", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "5"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 81, "conceptType": "Disease", "name": "Esophagogastric Adenocarcinoma", "primaryCoding": {"id": "oncotree:EGC", "code": "EGC", "name": "Esophagogastric Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=EGC"]}, "mappings": []}, "objectTherapeutic": {"id": 130, "membership_operator": "AND", "therapies": [{"id": 28, "conceptType": "Drug", "name": "Oxaliplatin", "primaryCoding": {"id": "ncit:C1181", "code": "C1181", "name": "Oxaliplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10265, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:6", "indication": "OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).", "raw_biomarkers": null, "raw_cancer_type": "gastric, gastro-oesophageal junction or oesophageal adenocarcinoma", "raw_therapeutics": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 648, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 56, "name": "PD-L1 (CPS) >= 5", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "5"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 2, "conceptType": "Disease", "name": "Adenocarcinoma of the Gastroesophageal Junction", "primaryCoding": {"id": "oncotree:GEJ", "code": "GEJ", "name": "Adenocarcinoma of the Gastroesophageal Junction", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ"]}, "mappings": []}, "objectTherapeutic": {"id": 129, "membership_operator": "AND", "therapies": [{"id": 28, "conceptType": "Drug", "name": "Oxaliplatin", "primaryCoding": {"id": "ncit:C1181", "code": "C1181", "name": "Oxaliplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10266, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdivo:6", "indication": "OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) >= 5.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (oxaliplatin).", "raw_biomarkers": null, "raw_cancer_type": "gastric, gastro-oesophageal junction or oesophageal adenocarcinoma", "raw_therapeutics": "Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdivo", "type": "Document", "subtype": "Regulatory approval", "name": "Opdivo (nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdivo", "drug_name_generic": "nivolumab", "first_published": "2015-07-16", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 649, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 56, "name": "PD-L1 (CPS) >= 5", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Combined Positive Score (CPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "5"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 2, "conceptType": "Disease", "name": "Adenocarcinoma of the Gastroesophageal Junction", "primaryCoding": {"id": "oncotree:GEJ", "code": "GEJ", "name": "Adenocarcinoma of the Gastroesophageal Junction", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ"]}, "mappings": []}, "objectTherapeutic": {"id": 130, "membership_operator": "AND", "therapies": [{"id": 28, "conceptType": "Drug", "name": "Oxaliplatin", "primaryCoding": {"id": "ncit:C1181", "code": "C1181", "name": "Oxaliplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10267, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Opdualag (relatlimab / nivolumab) for the first-line treatment of adults and adolescents 12 years of age and older with advanced (unresectable or metastatic) melanoma with tumor cell PD-L1 expression < 1%.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.opdualag", "type": "Document", "subtype": "Regulatory approval", "name": "Opdualag (relatlimab / nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdualag (relatlimab / nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf. Revised February 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdualag", "drug_name_generic": "relatlimab / nivolumab", "first_published": "2022-09-20", "access_date": null, "publication_date": "2024-02-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.opdualag:0", "indication": "Opdualag is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Opdualag (relatlimab / nivolumab) for the first-line treatment of adults and adolescents 12 years of age and older with advanced (unresectable or metastatic) melanoma with tumor cell PD-L1 expression < 1%.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Opdualag (relatlimab / nivolumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.opdualag", "type": "Document", "subtype": "Regulatory approval", "name": "Opdualag (relatlimab / nivolumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Opdualag (relatlimab / nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf. Revised February 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Opdualag", "drug_name_generic": "relatlimab / nivolumab", "first_published": "2022-09-20", "access_date": null, "publication_date": "2024-02-21", "url": "https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 650, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 57, "name": "PD-L1 < 1%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": "<"}, {"name": "value", "value": "0.01"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 131, "membership_operator": "AND", "therapies": [{"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 73, "conceptType": "Drug", "name": "Relatlimab", "primaryCoding": {"id": "ncit:C111999", "code": "C111999", "name": "Relatlimab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C111999"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["LAG-3 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10268, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized elacestrant for the treatment of postmenopausal women and men with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.orserdu", "type": "Document", "subtype": "Regulatory approval", "name": "Orserdu (elacestrant) [product information]. EMA.", "citation": "Stemline Therapeutics B.V. Orserdu (elacestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf. Revised February 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Orserdu", "drug_name_generic": "elacestrant", "first_published": "2023-11-27", "access_date": null, "publication_date": "2024-02-14", "url": "https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.orserdu:0", "indication": "ORSERDU monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized elacestrant for the treatment of postmenopausal women and men with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Orserdu (elacestrant)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.orserdu", "type": "Document", "subtype": "Regulatory approval", "name": "Orserdu (elacestrant) [product information]. EMA.", "citation": "Stemline Therapeutics B.V. Orserdu (elacestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf. Revised February 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Orserdu", "drug_name_generic": "elacestrant", "first_published": "2023-11-27", "access_date": null, "publication_date": "2024-02-14", "url": "https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 110, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 58, "name": "ESR1 oncogenic variants", "genes": [{"id": 19, "name": "ESR1", "primaryCoding": {"id": "hgnc:3467", "code": "HGNC:3467", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3467"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_000125.4", "code": "NM_000125.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000125.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000091831", "code": "ENSG00000091831", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000091831"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2099", "code": "2099", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2099"]}}], "extensions": [{"name": "location", "value": "6q25.1-q25.2"}, {"name": "location_sortable", "value": "06q25.1-q25.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "6"}, {"name": "requires_oncogenic", "value": true}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 74, "conceptType": "Drug", "name": "Elacestrant", "primaryCoding": {"id": "ncit:C120211", "code": "C120211", "name": "Elacestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C120211"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ER signaling inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10270, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.pemazyre", "type": "Document", "subtype": "Regulatory approval", "name": "Pemazyre (pemigatinib) [product information]. EMA.", "citation": "Incyte Biosciences Distribution B.V. Pemazyre (pemigatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf. Revised September 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Pemazyre", "drug_name_generic": "pemigatinib", "first_published": "2021-05-04", "access_date": null, "publication_date": "2023-09-12", "url": "https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.pemazyre:0", "indication": "Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Cholangiocarcinoma", "raw_therapeutics": "Orserdu (elacestrant)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.pemazyre", "type": "Document", "subtype": "Regulatory approval", "name": "Pemazyre (pemigatinib) [product information]. EMA.", "citation": "Incyte Biosciences Distribution B.V. Pemazyre (pemigatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf. Revised September 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Pemazyre", "drug_name_generic": "pemigatinib", "first_published": "2021-05-04", "access_date": null, "publication_date": "2023-09-12", "url": "https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 651, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 52, "name": "FGFR2::v", "genes": [{"id": 23, "name": "FGFR2", "primaryCoding": {"id": "hgnc:3689", "code": "HGNC:3689", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_000141.5", "code": "NM_000141.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000141.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000066468", "code": "ENSG00000066468", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000066468"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2263", "code": "2263", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2263"]}}], "extensions": [{"name": "location", "value": "10q26.13"}, {"name": "location_sortable", "value": "10q26.13"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 29, "conceptType": "Disease", "name": "Intrahepatic Cholangiocarcinoma", "primaryCoding": {"id": "oncotree:IHCH", "code": "IHCH", "name": "Intrahepatic Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=IHCH"]}, "mappings": []}, "objectTherapeutic": {"id": 74, "conceptType": "Drug", "name": "Elacestrant", "primaryCoding": {"id": "ncit:C120211", "code": "C120211", "name": "Elacestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C120211"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ER signaling inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10271, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.pemazyre", "type": "Document", "subtype": "Regulatory approval", "name": "Pemazyre (pemigatinib) [product information]. EMA.", "citation": "Incyte Biosciences Distribution B.V. Pemazyre (pemigatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf. Revised September 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Pemazyre", "drug_name_generic": "pemigatinib", "first_published": "2021-05-04", "access_date": null, "publication_date": "2023-09-12", "url": "https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.pemazyre:0", "indication": "Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized pemigatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Cholangiocarcinoma", "raw_therapeutics": "Orserdu (elacestrant)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.pemazyre", "type": "Document", "subtype": "Regulatory approval", "name": "Pemazyre (pemigatinib) [product information]. EMA.", "citation": "Incyte Biosciences Distribution B.V. Pemazyre (pemigatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf. Revised September 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Pemazyre", "drug_name_generic": "pemigatinib", "first_published": "2021-05-04", "access_date": null, "publication_date": "2023-09-12", "url": "https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 652, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 53, "name": "FGFR2 rearrangements", "genes": [{"id": 23, "name": "FGFR2", "primaryCoding": {"id": "hgnc:3689", "code": "HGNC:3689", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_000141.5", "code": "NM_000141.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000141.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000066468", "code": "ENSG00000066468", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000066468"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2263", "code": "2263", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2263"]}}], "extensions": [{"name": "location", "value": "10q26.13"}, {"name": "location_sortable", "value": "10q26.13"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 29, "conceptType": "Disease", "name": "Intrahepatic Cholangiocarcinoma", "primaryCoding": {"id": "oncotree:IHCH", "code": "IHCH", "name": "Intrahepatic Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=IHCH"]}, "mappings": []}, "objectTherapeutic": {"id": 74, "conceptType": "Drug", "name": "Elacestrant", "primaryCoding": {"id": "ncit:C120211", "code": "C120211", "name": "Elacestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C120211"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ER signaling inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10272, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.perjeta:0", "indication": "Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 352, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 66, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10273, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.perjeta:0", "indication": "Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 351, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 65, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10274, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.perjeta:1", "indication": "Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 355, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 69, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10275, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.perjeta:1", "indication": "Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 356, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 70, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10276, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.perjeta:1", "indication": "Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 357, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 71, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 76, "conceptType": "Drug", "name": "Epirubicin", "primaryCoding": {"id": "ncit:C62028", "code": "C62028", "name": "Epirubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10277, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.perjeta:1", "indication": "Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 358, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 72, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 76, "conceptType": "Drug", "name": "Epirubicin", "primaryCoding": {"id": "ncit:C62028", "code": "C62028", "name": "Epirubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10278, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.perjeta:1", "indication": "Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Investigators selected one of the following chemotherapy regimes: (i) 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; (ii) 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or (iii) 6 cycles of docetaxel in combination with carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 360, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 74, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10279, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.perjeta:2", "indication": "Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized pertuzumab in combination with trastuzumab and docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Perjeta (pertuzumab) in combination with trastuzumab and docetaxel", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.perjeta", "type": "Document", "subtype": "Regulatory approval", "name": "Perjeta (pertuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Perjeta", "drug_name_generic": "pertuzumab", "first_published": "2013-04-02", "access_date": null, "publication_date": "2024-04-05", "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 351, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 65, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10280, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.phesgo:0", "indication": "Phesgo is indicated for use in combination with chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 352, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 66, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10281, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.phesgo:0", "indication": "Phesgo is indicated for use in combination with chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. This indication is based on BERENICE (WO29217), a nonrandomized, open-label, multicenter, multinational, phase 2 clinical study where the treatment regimes were either (i) doxoruicin and cyclophosphamide followed by pertuzumab in combination with trastuzumab and paclitaxel or (ii) pertuzumab in combination with trastuzumab and docetaxel.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 351, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 65, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10282, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.phesgo:1", "indication": "Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 353, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 67, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 76, "conceptType": "Drug", "name": "Epirubicin", "primaryCoding": {"id": "ncit:C62028", "code": "C62028", "name": "Epirubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10283, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.phesgo:1", "indication": "Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 354, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 68, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 76, "conceptType": "Drug", "name": "Epirubicin", "primaryCoding": {"id": "ncit:C62028", "code": "C62028", "name": "Epirubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10284, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.phesgo:1", "indication": "Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 355, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 69, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10285, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.phesgo:1", "indication": "Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 356, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 70, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 2, "conceptType": "Drug", "name": "Doxorubicin", "primaryCoding": {"id": "ncit:C456", "code": "C456", "name": "Doxorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10286, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.phesgo:1", "indication": "Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 357, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 71, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 76, "conceptType": "Drug", "name": "Epirubicin", "primaryCoding": {"id": "ncit:C62028", "code": "C62028", "name": "Epirubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10287, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.phesgo:1", "indication": "Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 358, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 72, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 76, "conceptType": "Drug", "name": "Epirubicin", "primaryCoding": {"id": "ncit:C62028", "code": "C62028", "name": "Epirubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 59, "conceptType": "Drug", "name": "Cyclophosphamide", "primaryCoding": {"id": "ncit:C405", "code": "C405", "name": "Cyclophosphamide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Alkylating chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10288, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.phesgo:1", "indication": "Phesgo is indicated for use in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on APHINITY (BO25126), a multicenter, randomized, double-blind, and placebo-cotrolled phase 3 trial conducted in 4804 patients with HER2-positive early breast cancer. Within this trial, investigators had the choice of one of the following chemotherapy regimens: 3 or 4 cycles of FEC or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxell; 4 cycles of AC or epirubicin and cyclophosphamide (EC), followed by 3 or 4 cycles of docetaxel or 12 cycles of weekly paclitaxel; or 6 cycles of docetaxel in combination with carboplatin.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 360, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 74, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10289, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.phesgo:2", "indication": "Phesgo is indicated for use in combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized Phesgo (pertuzumab / trastuzumab) in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Phesgo (pertuzumab / trastuzumab) in combination with docetaxel", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.phesgo", "type": "Document", "subtype": "Regulatory approval", "name": "Phesgo (pertuzumab / trastuzumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Phesgo", "drug_name_generic": "pertuzumab / trastuzumab", "first_published": "2021-01-13", "access_date": null, "publication_date": "2022-03-02", "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 351, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 65, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 24, "conceptType": "Drug", "name": "Docetaxel", "primaryCoding": {"id": "ncit:C1526", "code": "C1526", "name": "Docetaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 75, "conceptType": "Drug", "name": "Pertuzumab", "primaryCoding": {"id": "ncit:C38692", "code": "C38692", "name": "Pertuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10290, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.piqray", "type": "Document", "subtype": "Regulatory approval", "name": "Piqray (alpelisib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Piqray (alpelisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf. Revised October 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Piqray", "drug_name_generic": "alpelisib", "first_published": "2020-07-30", "access_date": null, "publication_date": "2023-10-26", "url": "https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.piqray:0", "indication": "Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Piqray (alpelisib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.piqray", "type": "Document", "subtype": "Regulatory approval", "name": "Piqray (alpelisib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Piqray (alpelisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf. Revised October 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Piqray", "drug_name_generic": "alpelisib", "first_published": "2020-07-30", "access_date": null, "publication_date": "2023-10-26", "url": "https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 653, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 87, "name": "PIK3CA somatic variants", "genes": [{"id": 41, "name": "PIK3CA", "primaryCoding": {"id": "hgnc:8975", "code": "HGNC:8975", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_006218.4", "code": "NM_006218.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000121879", "code": "ENSG00000121879", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000121879"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5290", "code": "5290", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5290"]}}], "extensions": [{"name": "location", "value": "3q26.32"}, {"name": "location_sortable", "value": "03q26.32"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 5, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 77, "conceptType": "Drug", "name": "Alpelisib", "primaryCoding": {"id": "ncit:C94214", "code": "C94214", "name": "Alpelisib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C94214"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10291, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.piqray", "type": "Document", "subtype": "Regulatory approval", "name": "Piqray (alpelisib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Piqray (alpelisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf. Revised October 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Piqray", "drug_name_generic": "alpelisib", "first_published": "2020-07-30", "access_date": null, "publication_date": "2023-10-26", "url": "https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.piqray:0", "indication": "Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Piqray (alpelisib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.piqray", "type": "Document", "subtype": "Regulatory approval", "name": "Piqray (alpelisib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Piqray (alpelisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf. Revised October 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Piqray", "drug_name_generic": "alpelisib", "first_published": "2020-07-30", "access_date": null, "publication_date": "2023-10-26", "url": "https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 654, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 87, "name": "PIK3CA somatic variants", "genes": [{"id": 41, "name": "PIK3CA", "primaryCoding": {"id": "hgnc:8975", "code": "HGNC:8975", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_006218.4", "code": "NM_006218.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000121879", "code": "ENSG00000121879", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000121879"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5290", "code": "5290", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5290"]}}], "extensions": [{"name": "location", "value": "3q26.32"}, {"name": "location_sortable", "value": "03q26.32"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 5, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 77, "conceptType": "Drug", "name": "Alpelisib", "primaryCoding": {"id": "ncit:C94214", "code": "C94214", "name": "Alpelisib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C94214"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10292, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.piqray", "type": "Document", "subtype": "Regulatory approval", "name": "Piqray (alpelisib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Piqray (alpelisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf. Revised October 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Piqray", "drug_name_generic": "alpelisib", "first_published": "2020-07-30", "access_date": null, "publication_date": "2023-10-26", "url": "https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.piqray:0", "indication": "Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized alpelisib in combination with fulvestrant for the treatment of patients who are either postmenopausal women or men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as a monotherapy. This indication is based on C2301, a phase 3, randomized, double-blind, and placebo-controlled study that evaluated alpelisib in combination with fulvestrant based on the presence or absence of a PIK3CA. No survival benefit was shown in the group without PIK3CA variants and PIK3CA variants observed were: p.C420R, p.E542K, p.E545A, p.E545D (1635G>T), p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, and p.H1047Y.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Piqray (alpelisib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.piqray", "type": "Document", "subtype": "Regulatory approval", "name": "Piqray (alpelisib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Piqray (alpelisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf. Revised October 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Piqray", "drug_name_generic": "alpelisib", "first_published": "2020-07-30", "access_date": null, "publication_date": "2023-10-26", "url": "https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 655, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 87, "name": "PIK3CA somatic variants", "genes": [{"id": 41, "name": "PIK3CA", "primaryCoding": {"id": "hgnc:8975", "code": "HGNC:8975", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_006218.4", "code": "NM_006218.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000121879", "code": "ENSG00000121879", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000121879"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5290", "code": "5290", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5290"]}}], "extensions": [{"name": "location", "value": "3q26.32"}, {"name": "location_sortable", "value": "03q26.32"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 5, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 77, "conceptType": "Drug", "name": "Alpelisib", "primaryCoding": {"id": "ncit:C94214", "code": "C94214", "name": "Alpelisib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C94214"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10296, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive non-small cell lung cancer not previously treated with a RET inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.retsevmo", "type": "Document", "subtype": "Regulatory approval", "name": "Retsevmo (selpercatinib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Retsevmo (selpercatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Retsevmo", "drug_name_generic": "selpercatinib", "first_published": "2021-04-23", "access_date": null, "publication_date": "2024-05-28", "url": "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.retsevmo:0", "indication": "Retsevmo as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive non-small cell lung cancer not previously treated with a RET inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Retsevmo (selpercatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.retsevmo", "type": "Document", "subtype": "Regulatory approval", "name": "Retsevmo (selpercatinib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Retsevmo (selpercatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Retsevmo", "drug_name_generic": "selpercatinib", "first_published": "2021-04-23", "access_date": null, "publication_date": "2024-05-28", "url": "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 407, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 18, "name": "v::RET", "genes": [{"id": 49, "name": "RET", "primaryCoding": {"id": "hgnc:9967", "code": "HGNC:9967", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_020975.6", "code": "NM_020975.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000165731", "code": "ENSG00000165731", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000165731"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5979", "code": "5979", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5979"]}}], "extensions": [{"name": "location", "value": "10q11.21"}, {"name": "location_sortable", "value": "10q11.21"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 78, "conceptType": "Drug", "name": "Selpercatinib", "primaryCoding": {"id": "ncit:C134987", "code": "C134987", "name": "Selpercatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C134987"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["RET inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10297, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.retsevmo", "type": "Document", "subtype": "Regulatory approval", "name": "Retsevmo (selpercatinib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Retsevmo (selpercatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Retsevmo", "drug_name_generic": "selpercatinib", "first_published": "2021-04-23", "access_date": null, "publication_date": "2024-05-28", "url": "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.retsevmo:1", "indication": "Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).", "raw_biomarkers": null, "raw_cancer_type": "Thyroid cancer", "raw_therapeutics": "Retsevmo (selpercatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.retsevmo", "type": "Document", "subtype": "Regulatory approval", "name": "Retsevmo (selpercatinib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Retsevmo (selpercatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Retsevmo", "drug_name_generic": "selpercatinib", "first_published": "2021-04-23", "access_date": null, "publication_date": "2024-05-28", "url": "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 656, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 18, "name": "v::RET", "genes": [{"id": 49, "name": "RET", "primaryCoding": {"id": "hgnc:9967", "code": "HGNC:9967", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_020975.6", "code": "NM_020975.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000165731", "code": "ENSG00000165731", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000165731"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5979", "code": "5979", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5979"]}}], "extensions": [{"name": "location", "value": "10q11.21"}, {"name": "location_sortable", "value": "10q11.21"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 75, "conceptType": "Disease", "name": "Papillary Thyroid Cancer", "primaryCoding": {"id": "oncotree:THPA", "code": "THPA", "name": "Papillary Thyroid Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THPA"]}, "mappings": []}, "objectTherapeutic": {"id": 78, "conceptType": "Drug", "name": "Selpercatinib", "primaryCoding": {"id": "ncit:C134987", "code": "C134987", "name": "Selpercatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C134987"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["RET inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10298, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET-mutant medullary thyroid cancer. This indication is based on LIBRETTO-001 (a phase 1/2, multicenter, open-label, single-arm clinical study), where the most common variant was p.M918T, followed by extracelluar cysteine mutations.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.retsevmo", "type": "Document", "subtype": "Regulatory approval", "name": "Retsevmo (selpercatinib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Retsevmo (selpercatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Retsevmo", "drug_name_generic": "selpercatinib", "first_published": "2021-04-23", "access_date": null, "publication_date": "2024-05-28", "url": "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.retsevmo:2", "indication": "Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult and adolescent (12 years and older) patients with advanced RET-mutant medullary thyroid cancer. This indication is based on LIBRETTO-001 (a phase 1/2, multicenter, open-label, single-arm clinical study), where the most common variant was p.M918T, followed by extracelluar cysteine mutations.", "raw_biomarkers": null, "raw_cancer_type": "Medullary thyroid cancer", "raw_therapeutics": "Retsevmo (selpercatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.retsevmo", "type": "Document", "subtype": "Regulatory approval", "name": "Retsevmo (selpercatinib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Retsevmo (selpercatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Retsevmo", "drug_name_generic": "selpercatinib", "first_published": "2021-04-23", "access_date": null, "publication_date": "2024-05-28", "url": "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 657, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 60, "name": "RET p.M918T", "genes": [{"id": 49, "name": "RET", "primaryCoding": {"id": "hgnc:9967", "code": "HGNC:9967", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_020975.6", "code": "NM_020975.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000165731", "code": "ENSG00000165731", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000165731"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5979", "code": "5979", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5979"]}}], "extensions": [{"name": "location", "value": "10q11.21"}, {"name": "location_sortable", "value": "10q11.21"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "10"}, {"name": "start_position", "value": 43617416}, {"name": "end_position", "value": 43617416}, {"name": "reference_allele", "value": "T"}, {"name": "alternate_allele", "value": "C"}, {"name": "cdna_change", "value": "c.2753T>C"}, {"name": "protein_change", "value": "p.M918T"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "16"}, {"name": "rsid", "value": "rs74799832"}, {"name": "hgvsg", "value": "10:g.43617416T>C"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 38, "conceptType": "Disease", "name": "Medullary Thyroid Cancer", "primaryCoding": {"id": "oncotree:THME", "code": "THME", "name": "Medullary Thyroid Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THME"]}, "mappings": []}, "objectTherapeutic": {"id": 78, "conceptType": "Drug", "name": "Selpercatinib", "primaryCoding": {"id": "ncit:C134987", "code": "C134987", "name": "Selpercatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C134987"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["RET inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10299, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.retsevmo", "type": "Document", "subtype": "Regulatory approval", "name": "Retsevmo (selpercatinib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Retsevmo (selpercatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Retsevmo", "drug_name_generic": "selpercatinib", "first_published": "2021-04-23", "access_date": null, "publication_date": "2024-05-28", "url": "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.retsevmo:3", "indication": "Retsevmo as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.", "raw_biomarkers": null, "raw_cancer_type": "Any solid tumor", "raw_therapeutics": "Retsevmo (selpercatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.retsevmo", "type": "Document", "subtype": "Regulatory approval", "name": "Retsevmo (selpercatinib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Retsevmo (selpercatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Retsevmo", "drug_name_generic": "selpercatinib", "first_published": "2021-04-23", "access_date": null, "publication_date": "2024-05-28", "url": "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 410, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 18, "name": "v::RET", "genes": [{"id": 49, "name": "RET", "primaryCoding": {"id": "hgnc:9967", "code": "HGNC:9967", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_020975.6", "code": "NM_020975.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000165731", "code": "ENSG00000165731", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000165731"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5979", "code": "5979", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5979"]}}], "extensions": [{"name": "location", "value": "10q11.21"}, {"name": "location_sortable", "value": "10q11.21"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 5, "conceptType": "Disease", "name": "Any solid tumor", "primaryCoding": {"id": "ncit:C132146", "code": "C132146", "name": "Malignant Solid Neoplasm", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146"]}, "mappings": []}, "objectTherapeutic": {"id": 78, "conceptType": "Drug", "name": "Selpercatinib", "primaryCoding": {"id": "ncit:C134987", "code": "C134987", "name": "Selpercatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C134987"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["RET inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10300, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized lenalidomide for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermdeiate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.revlimid", "type": "Document", "subtype": "Regulatory approval", "name": "Revlimid (lenalidomide) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Revlimid (lenalidomide) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf. Revised January 2024. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Revlimid", "drug_name_generic": "lenalidomide", "first_published": "2009-10-29", "access_date": null, "publication_date": "2024-01-08", "url": "https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.revlimid:0", "indication": "Revlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized lenalidomide for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermdeiate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.", "raw_biomarkers": null, "raw_cancer_type": "myelodysplastic syndromes", "raw_therapeutics": "Revlimid (lenalidomide)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.revlimid", "type": "Document", "subtype": "Regulatory approval", "name": "Revlimid (lenalidomide) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Revlimid (lenalidomide) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf. Revised January 2024. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Revlimid", "drug_name_generic": "lenalidomide", "first_published": "2009-10-29", "access_date": null, "publication_date": "2024-01-08", "url": "https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 658, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 61, "name": "5q deletion", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number (arm level)"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "5"}, {"name": "direction", "value": "Deletion"}, {"name": "arm", "value": "q"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 45, "conceptType": "Disease", "name": "Myeloproliferative Neoplasm", "primaryCoding": {"id": "oncotree:MPN", "code": "MPN", "name": "Myeloproliferative Neoplasm", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MPN"]}, "mappings": []}, "objectTherapeutic": {"id": 79, "conceptType": "Drug", "name": "Lenalidomide", "primaryCoding": {"id": "ncit:C2668", "code": "C2668", "name": "Lenalidomide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2668"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Angiogenesis inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10301, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.rozlytrek", "type": "Document", "subtype": "Regulatory approval", "name": "Rozlytrek (entrectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Rozlytrek (entrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Rozlytrek", "drug_name_generic": "entrectinib", "first_published": "2020-09-11", "access_date": null, "publication_date": "2024-07-03", "url": "https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.rozlytrek:0", "indication": "Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Rozlytrek (entrectinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.rozlytrek", "type": "Document", "subtype": "Regulatory approval", "name": "Rozlytrek (entrectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Rozlytrek (entrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Rozlytrek", "drug_name_generic": "entrectinib", "first_published": "2020-09-11", "access_date": null, "publication_date": "2024-07-03", "url": "https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 120, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 62, "name": "v::ROS1", "genes": [{"id": 50, "name": "ROS1", "primaryCoding": {"id": "hgnc:10261", "code": "HGNC:10261", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000047936", "code": "ENSG00000047936", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000047936"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:6098", "code": "6098", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/6098"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_001378902.1", "code": "NM_001378902.1", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1"]}}], "extensions": [{"name": "location", "value": "6q22.1"}, {"name": "location_sortable", "value": "06q22.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 80, "conceptType": "Drug", "name": "Entrectinib", "primaryCoding": {"id": "ncit:C114984", "code": "C114984", "name": "Entrectinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition", "ROS1 inhibition", "NTRK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10302, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.rozlytrek", "type": "Document", "subtype": "Regulatory approval", "name": "Rozlytrek (entrectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Rozlytrek (entrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Rozlytrek", "drug_name_generic": "entrectinib", "first_published": "2020-09-11", "access_date": null, "publication_date": "2024-07-03", "url": "https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.rozlytrek:1", "indication": "Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients older than one month with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, (iii) who have no satisfactory treatment options.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.", "raw_biomarkers": null, "raw_cancer_type": "Any solid tumor", "raw_therapeutics": "Rozlytrek (entrectinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.rozlytrek", "type": "Document", "subtype": "Regulatory approval", "name": "Rozlytrek (entrectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Rozlytrek (entrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Rozlytrek", "drug_name_generic": "entrectinib", "first_published": "2020-09-11", "access_date": null, "publication_date": "2024-07-03", "url": "https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 121, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 63, "name": "v::NTRK1", "genes": [{"id": 35, "name": "NTRK1", "primaryCoding": {"id": "hgnc:8031", "code": "HGNC:8031", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8031"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_002529.4", "code": "NM_002529.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_002529.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000198400", "code": "ENSG00000198400", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000198400"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4914", "code": "4914", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4914"]}}], "extensions": [{"name": "location", "value": "1q23.1"}, {"name": "location_sortable", "value": "01q23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 5, "conceptType": "Disease", "name": "Any solid tumor", "primaryCoding": {"id": "ncit:C132146", "code": "C132146", "name": "Malignant Solid Neoplasm", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146"]}, "mappings": []}, "objectTherapeutic": {"id": 80, "conceptType": "Drug", "name": "Entrectinib", "primaryCoding": {"id": "ncit:C114984", "code": "C114984", "name": "Entrectinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition", "ROS1 inhibition", "NTRK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10303, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.rozlytrek", "type": "Document", "subtype": "Regulatory approval", "name": "Rozlytrek (entrectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Rozlytrek (entrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Rozlytrek", "drug_name_generic": "entrectinib", "first_published": "2020-09-11", "access_date": null, "publication_date": "2024-07-03", "url": "https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.rozlytrek:1", "indication": "Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients older than one month with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, (iii) who have no satisfactory treatment options.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.", "raw_biomarkers": null, "raw_cancer_type": "Any solid tumor", "raw_therapeutics": "Rozlytrek (entrectinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.rozlytrek", "type": "Document", "subtype": "Regulatory approval", "name": "Rozlytrek (entrectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Rozlytrek (entrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Rozlytrek", "drug_name_generic": "entrectinib", "first_published": "2020-09-11", "access_date": null, "publication_date": "2024-07-03", "url": "https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 122, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 64, "name": "v::NTRK2", "genes": [{"id": 36, "name": "NTRK2", "primaryCoding": {"id": "hgnc:8032", "code": "HGNC:8032", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8032"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000148053", "code": "ENSG00000148053", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000148053"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4915", "code": "4915", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4915"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_006180.6", "code": "NM_006180.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_006180.6"]}}], "extensions": [{"name": "location", "value": "9q21.33"}, {"name": "location_sortable", "value": "09q21.33"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 5, "conceptType": "Disease", "name": "Any solid tumor", "primaryCoding": {"id": "ncit:C132146", "code": "C132146", "name": "Malignant Solid Neoplasm", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146"]}, "mappings": []}, "objectTherapeutic": {"id": 80, "conceptType": "Drug", "name": "Entrectinib", "primaryCoding": {"id": "ncit:C114984", "code": "C114984", "name": "Entrectinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition", "ROS1 inhibition", "NTRK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10304, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.rozlytrek", "type": "Document", "subtype": "Regulatory approval", "name": "Rozlytrek (entrectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Rozlytrek (entrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Rozlytrek", "drug_name_generic": "entrectinib", "first_published": "2020-09-11", "access_date": null, "publication_date": "2024-07-03", "url": "https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.rozlytrek:1", "indication": "Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients older than one month with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion (i) who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and (ii) who have not received a prior NTRK inhibitor, (iii) who have no satisfactory treatment options.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neuotrophic tyrosine receptor kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.", "raw_biomarkers": null, "raw_cancer_type": "Any solid tumor", "raw_therapeutics": "Rozlytrek (entrectinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.rozlytrek", "type": "Document", "subtype": "Regulatory approval", "name": "Rozlytrek (entrectinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Rozlytrek (entrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Rozlytrek", "drug_name_generic": "entrectinib", "first_published": "2020-09-11", "access_date": null, "publication_date": "2024-07-03", "url": "https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 123, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 65, "name": "v::NTRK3", "genes": [{"id": 37, "name": "NTRK3", "primaryCoding": {"id": "hgnc:8033", "code": "HGNC:8033", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8033"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_001012338.3", "code": "NM_001012338.3", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_001012338.3"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000140538", "code": "ENSG00000140538", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000140538"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4916", "code": "4916", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4916"]}}], "extensions": [{"name": "location", "value": "15q25.3"}, {"name": "location_sortable", "value": "15q25.3"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 5, "conceptType": "Disease", "name": "Any solid tumor", "primaryCoding": {"id": "ncit:C132146", "code": "C132146", "name": "Malignant Solid Neoplasm", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146"]}, "mappings": []}, "objectTherapeutic": {"id": 80, "conceptType": "Drug", "name": "Entrectinib", "primaryCoding": {"id": "ncit:C114984", "code": "C114984", "name": "Entrectinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition", "ROS1 inhibition", "NTRK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10305, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized midostaurin in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintence therapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive. Midostaurin's product information further states that AML patients must have confirmation of the FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.rydapt", "type": "Document", "subtype": "Regulatory approval", "name": "Rydapt (midostaurin) [product information]. EMA.", "citation": "Novartis Europharm Ltd. Rydapt (midostaurin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Rydapt", "drug_name_generic": "midostaurin", "first_published": "2017-10-25", "access_date": null, "publication_date": "2023-07-26", "url": "https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.rydapt:0", "indication": "Rydapt is indicated in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation-positive.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized midostaurin in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintence therapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive. Midostaurin's product information further states that AML patients must have confirmation of the FLT3 mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test.", "raw_biomarkers": null, "raw_cancer_type": "Acute myeloid leukaemia", "raw_therapeutics": "Rydapt (midostaurin)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.rydapt", "type": "Document", "subtype": "Regulatory approval", "name": "Rydapt (midostaurin) [product information]. EMA.", "citation": "Novartis Europharm Ltd. Rydapt (midostaurin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Rydapt", "drug_name_generic": "midostaurin", "first_published": "2017-10-25", "access_date": null, "publication_date": "2023-07-26", "url": "https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 208, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 66, "name": "FLT3-ITD", "genes": [{"id": 26, "name": "FLT3", "primaryCoding": {"id": "hgnc:3765", "code": "HGNC:3765", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000122025", "code": "ENSG00000122025", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000122025"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2322", "code": "2322", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2322"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004119.3", "code": "NM_004119.3", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3"]}}], "extensions": [{"name": "location", "value": "13q12.2"}, {"name": "location_sortable", "value": "13q12.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "variant_annotation", "value": "Internal Tandem Duplication (ITD)"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 1, "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "primaryCoding": {"id": "oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML"]}, "mappings": []}, "objectTherapeutic": {"id": 40, "membership_operator": "AND", "therapies": [{"id": 82, "conceptType": "Drug", "name": "Midostaurin", "primaryCoding": {"id": "ncit:C1872", "code": "C1872", "name": "Midostaurin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FLT3 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 68, "conceptType": "Drug", "name": "Daunorubicin", "primaryCoding": {"id": "ncit:C62091", "code": "C62091", "name": "Daunorubicin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["DNA Polymerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 63, "conceptType": "Drug", "name": "Cytarabine", "primaryCoding": {"id": "ncit:C408", "code": "C408", "name": "Cytarabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["DNA Polymerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10306, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.scemblix", "type": "Document", "subtype": "Regulatory approval", "name": "Scemblix (asciminib) [product information]. EMA.", "citation": "Novartis Europharm Ltd. Scemblix (asciminib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/scemblix-epar-product-information_en.pdf. Revised January 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Scemblix", "drug_name_generic": "asciminib", "first_published": "2022-09-07", "access_date": null, "publication_date": "2024-01-12", "url": "https://www.ema.europa.eu/en/documents/product-information/scemblix-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.scemblix:0", "indication": "Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized asciminib for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.", "raw_biomarkers": null, "raw_cancer_type": "Chronic Myeloid Leukemia", "raw_therapeutics": "Scemblix (asciminib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.scemblix", "type": "Document", "subtype": "Regulatory approval", "name": "Scemblix (asciminib) [product information]. EMA.", "citation": "Novartis Europharm Ltd. Scemblix (asciminib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/scemblix-epar-product-information_en.pdf. Revised January 2024. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Scemblix", "drug_name_generic": "asciminib", "first_published": "2022-09-07", "access_date": null, "publication_date": "2024-01-12", "url": "https://www.ema.europa.eu/en/documents/product-information/scemblix-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 659, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 83, "conceptType": "Drug", "name": "Asciminib", "primaryCoding": {"id": "ncit:C114494", "code": "C114494", "name": "Asciminib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114494"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10307, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF p.V600E variant who require systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.spexotras", "type": "Document", "subtype": "Regulatory approval", "name": "Spexotras (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Spexotras (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf. Revised January 2024. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Spexotras", "drug_name_generic": "trametinib", "first_published": "2024-01-17", "access_date": null, "publication_date": "2024-01-17", "url": "https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.spexotras:0", "indication": "Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF p.V600E variant who require systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "low-grade glioma", "raw_therapeutics": "Spexotras (trametinib) in combination with dabrafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.spexotras", "type": "Document", "subtype": "Regulatory approval", "name": "Spexotras (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Spexotras (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf. Revised January 2024. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Spexotras", "drug_name_generic": "trametinib", "first_published": "2024-01-17", "access_date": null, "publication_date": "2024-01-17", "url": "https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 94, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 35, "conceptType": "Disease", "name": "Low-Grade Glioma, NOS", "primaryCoding": {"id": "oncotree:LGGNOS", "code": "LGGNOS", "name": "Low-Grade Glioma, NOS", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=LGGNOS"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10308, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF p.V600E variant who have received at least one prior radiation and/or chemotherapy treatment.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.spexotras", "type": "Document", "subtype": "Regulatory approval", "name": "Spexotras (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Spexotras (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf. Revised January 2024. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Spexotras", "drug_name_generic": "trametinib", "first_published": "2024-01-17", "access_date": null, "publication_date": "2024-01-17", "url": "https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.spexotras:1", "indication": "Spexotras in combination with dabrafenib is indicated for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of pediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF p.V600E variant who have received at least one prior radiation and/or chemotherapy treatment.", "raw_biomarkers": null, "raw_cancer_type": "high-grade glioma", "raw_therapeutics": "Spexotras (trametinib) in combination with dabrafenib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.spexotras", "type": "Document", "subtype": "Regulatory approval", "name": "Spexotras (trametinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Spexotras (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf. Revised January 2024. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Spexotras", "drug_name_generic": "trametinib", "first_published": "2024-01-17", "access_date": null, "publication_date": "2024-01-17", "url": "https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 660, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 83, "conceptType": "Disease", "name": "High-Grade Glioma, NOS", "primaryCoding": {"id": "oncotree:HGGNOS", "code": "HGGNOS", "name": "High-Grade Glioma, NOS", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGGNOS"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10309, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.sprycel", "type": "Document", "subtype": "Regulatory approval", "name": "Sprycel (dasatinib [anhydrous]) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Sprycel", "drug_name_generic": "dasatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2022-06-17", "url": "https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.sprycel:0", "indication": "SPRYCEL is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase.", "raw_biomarkers": null, "raw_cancer_type": "Chronic Myelogenous Leukemia", "raw_therapeutics": "Sprycel (dasatinib [anhydrous])", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.sprycel", "type": "Document", "subtype": "Regulatory approval", "name": "Sprycel (dasatinib [anhydrous]) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Sprycel", "drug_name_generic": "dasatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2022-06-17", "url": "https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 661, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 84, "conceptType": "Drug", "name": "Dasatinib", "primaryCoding": {"id": "ncit:C38713", "code": "C38713", "name": "Dasatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10310, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.sprycel", "type": "Document", "subtype": "Regulatory approval", "name": "Sprycel (dasatinib [anhydrous]) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Sprycel", "drug_name_generic": "dasatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2022-06-17", "url": "https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.sprycel:1", "indication": "SPRYCEL is indicated for the treatment of adult patients with Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.", "raw_biomarkers": null, "raw_cancer_type": "Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML)", "raw_therapeutics": "Sprycel (dasatinib [anhydrous])", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.sprycel", "type": "Document", "subtype": "Regulatory approval", "name": "Sprycel (dasatinib [anhydrous]) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Sprycel", "drug_name_generic": "dasatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2022-06-17", "url": "https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 662, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 84, "conceptType": "Drug", "name": "Dasatinib", "primaryCoding": {"id": "ncit:C38713", "code": "C38713", "name": "Dasatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10311, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.sprycel", "type": "Document", "subtype": "Regulatory approval", "name": "Sprycel (dasatinib [anhydrous]) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Sprycel", "drug_name_generic": "dasatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2022-06-17", "url": "https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.sprycel:1", "indication": "SPRYCEL is indicated for the treatment of adult patients with Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.", "raw_biomarkers": null, "raw_cancer_type": "Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML)", "raw_therapeutics": "Sprycel (dasatinib [anhydrous])", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.sprycel", "type": "Document", "subtype": "Regulatory approval", "name": "Sprycel (dasatinib [anhydrous]) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Sprycel", "drug_name_generic": "dasatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2022-06-17", "url": "https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 661, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 84, "conceptType": "Drug", "name": "Dasatinib", "primaryCoding": {"id": "ncit:C38713", "code": "C38713", "name": "Dasatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10312, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase (Ph+ CML-CP) or Ph+CML-CP with resistant or intolerant to prior therapy including imatinib.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.sprycel", "type": "Document", "subtype": "Regulatory approval", "name": "Sprycel (dasatinib [anhydrous]) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Sprycel", "drug_name_generic": "dasatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2022-06-17", "url": "https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.sprycel:2", "indication": "SPRYCEL is indicated for the treatment of paediatric patients with newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) in the chronic phase (Ph+ CML-CP) or Ph+CML-CP with resistant or intolerant to prior therapy including imatinib.", "raw_biomarkers": null, "raw_cancer_type": "Chronic Myelogenous Leukemia", "raw_therapeutics": "Sprycel (dasatinib [anhydrous])", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.sprycel", "type": "Document", "subtype": "Regulatory approval", "name": "Sprycel (dasatinib [anhydrous]) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Sprycel", "drug_name_generic": "dasatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2022-06-17", "url": "https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 661, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 84, "conceptType": "Drug", "name": "Dasatinib", "primaryCoding": {"id": "ncit:C38713", "code": "C38713", "name": "Dasatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10313, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia acute lymphoblastic leukemia (ALL) in combination with chemotherapy. The product information for this indication further states that his indication is based on a multicenter, historically-controlled phase 2 study that followed the chemotherapy regime detailed in another clinical trial, AIEOP-BFM ALL 2000 (chemotherapeutic standard multi-agent chemotherapy protocol).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.sprycel", "type": "Document", "subtype": "Regulatory approval", "name": "Sprycel (dasatinib [anhydrous]) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Sprycel", "drug_name_generic": "dasatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2022-06-17", "url": "https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.sprycel:3", "indication": "SPRYCEL is indicated for the treatment of paediatric patients with newly diagnosed Ph+ ALL in combination with chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia acute lymphoblastic leukemia (ALL) in combination with chemotherapy. The product information for this indication further states that his indication is based on a multicenter, historically-controlled phase 2 study that followed the chemotherapy regime detailed in another clinical trial, AIEOP-BFM ALL 2000 (chemotherapeutic standard multi-agent chemotherapy protocol).", "raw_biomarkers": null, "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)", "raw_therapeutics": "Sprycel (dasatinib [anhydrous]) in combination with chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.sprycel", "type": "Document", "subtype": "Regulatory approval", "name": "Sprycel (dasatinib [anhydrous]) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.", "company": "", "drug_name_brand": "Sprycel", "drug_name_generic": "dasatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2022-06-17", "url": "https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 662, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 84, "conceptType": "Drug", "name": "Dasatinib", "primaryCoding": {"id": "ncit:C38713", "code": "C38713", "name": "Dasatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10314, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tabrecta", "type": "Document", "subtype": "Regulatory approval", "name": "Tabrecta (capmatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tabrecta (capmatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf. Revised January 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tabrecta", "drug_name_generic": "capmatinib", "first_published": "2022-09-21", "access_date": null, "publication_date": "2023-01-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tabrecta:0", "indication": "Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tabrecta (capmatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tabrecta", "type": "Document", "subtype": "Regulatory approval", "name": "Tabrecta (capmatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tabrecta (capmatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf. Revised January 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tabrecta", "drug_name_generic": "capmatinib", "first_published": "2022-09-21", "access_date": null, "publication_date": "2023-01-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 73, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 67, "name": "MET Exon 14 (Splice Site)", "genes": [{"id": 32, "name": "MET", "primaryCoding": {"id": "hgnc:7029", "code": "HGNC:7029", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000105976", "code": "ENSG00000105976", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000105976"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4233", "code": "4233", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4233"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000245.4", "code": "NM_000245.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000245.4"]}}], "extensions": [{"name": "location", "value": "7q31.2"}, {"name": "location_sortable", "value": "07q31.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "variant_annotation", "value": "Splice Site"}, {"name": "exon", "value": "14"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 85, "conceptType": "Drug", "name": "Capmatinib", "primaryCoding": {"id": "ncit:C90564", "code": "C90564", "name": "Capmatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C90564"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MET inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10315, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tabrecta", "type": "Document", "subtype": "Regulatory approval", "name": "Tabrecta (capmatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tabrecta (capmatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf. Revised January 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tabrecta", "drug_name_generic": "capmatinib", "first_published": "2022-09-21", "access_date": null, "publication_date": "2023-01-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tabrecta:0", "indication": "Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized capmatinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tabrecta (capmatinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tabrecta", "type": "Document", "subtype": "Regulatory approval", "name": "Tabrecta (capmatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tabrecta (capmatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf. Revised January 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tabrecta", "drug_name_generic": "capmatinib", "first_published": "2022-09-21", "access_date": null, "publication_date": "2023-01-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 74, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 68, "name": "MET Exon 14 (Deletion)", "genes": [{"id": 32, "name": "MET", "primaryCoding": {"id": "hgnc:7029", "code": "HGNC:7029", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000105976", "code": "ENSG00000105976", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000105976"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4233", "code": "4233", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4233"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000245.4", "code": "NM_000245.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000245.4"]}}], "extensions": [{"name": "location", "value": "7q31.2"}, {"name": "location_sortable", "value": "07q31.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "variant_annotation", "value": "Deletion"}, {"name": "exon", "value": "14"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 85, "conceptType": "Drug", "name": "Capmatinib", "primaryCoding": {"id": "ncit:C90564", "code": "C90564", "name": "Capmatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C90564"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MET inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10316, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tafinlar:0", "indication": "Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Tafinlar (dabrafenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 88, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10317, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tafinlar:0", "indication": "Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Tafinlar (dabrafenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 663, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 17, "name": "BRAF p.V600K", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453137}, {"name": "reference_allele", "value": "AC"}, {"name": "alternate_allele", "value": "TT"}, {"name": "cdna_change", "value": "c.1798_1799GT>AA"}, {"name": "protein_change", "value": "p.V600K"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs121913227"}, {"name": "hgvsg", "value": "7:g.140453136_140453137delinsTT"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10318, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tafinlar:0", "indication": "Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Tafinlar (dabrafenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 89, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10319, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tafinlar:0", "indication": "Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dabrafenib as a monotherapy or in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 variant.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Tafinlar (dabrafenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 90, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 17, "name": "BRAF p.V600K", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453137}, {"name": "reference_allele", "value": "AC"}, {"name": "alternate_allele", "value": "TT"}, {"name": "cdna_change", "value": "c.1798_1799GT>AA"}, {"name": "protein_change", "value": "p.V600K"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs121913227"}, {"name": "hgvsg", "value": "7:g.140453136_140453137delinsTT"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10320, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult patients with stage 3 melanoma with a BRAF V600 variant, following complete resection.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tafinlar:1", "indication": "Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult patients with stage 3 melanoma with a BRAF V600 variant, following complete resection.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Tafinlar (dabrafenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 89, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10321, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult patients with stage 3 melanoma with a BRAF V600 variant, following complete resection.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tafinlar:1", "indication": "Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult patients with stage 3 melanoma with a BRAF V600 variant, following complete resection.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Tafinlar (dabrafenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 90, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 17, "name": "BRAF p.V600K", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453137}, {"name": "reference_allele", "value": "AC"}, {"name": "alternate_allele", "value": "TT"}, {"name": "cdna_change", "value": "c.1798_1799GT>AA"}, {"name": "protein_change", "value": "p.V600K"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs121913227"}, {"name": "hgvsg", "value": "7:g.140453136_140453137delinsTT"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10322, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tafinlar:2", "indication": "Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tafinlar (dabrafenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 91, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10323, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tafinlar:2", "indication": "Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tafinlar (dabrafenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tafinlar", "type": "Document", "subtype": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tafinlar", "drug_name_generic": "dabrafenib", "first_published": "2013-09-18", "access_date": null, "publication_date": "2024-03-07", "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 627, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 17, "name": "BRAF p.V600K", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453137}, {"name": "reference_allele", "value": "AC"}, {"name": "alternate_allele", "value": "TT"}, {"name": "cdna_change", "value": "c.1798_1799GT>AA"}, {"name": "protein_change", "value": "p.V600K"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs121913227"}, {"name": "hgvsg", "value": "7:g.140453136_140453137delinsTT"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 18, "membership_operator": "AND", "therapies": [{"id": 66, "conceptType": "Drug", "name": "Trametinib", "primaryCoding": {"id": "ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MEK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 67, "conceptType": "Drug", "name": "Dabrafenib", "primaryCoding": {"id": "ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10324, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized osimertinib for the adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution variants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tagrisso:0", "indication": "TAGRISSO as monotherapy is indicated for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized osimertinib for the adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution variants.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tagrisso (osimertinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 304, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 10, "name": "EGFR Exon 19 (Deletion)", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "variant_annotation", "value": "Deletion"}, {"name": "exon", "value": "19"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 86, "conceptType": "Drug", "name": "Osimertinib", "primaryCoding": {"id": "ncit:C116377", "code": "C116377", "name": "Osimertinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10325, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized osimertinib for the adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution variants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tagrisso:0", "indication": "TAGRISSO as monotherapy is indicated for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized osimertinib for the adjuvant treatment after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor (EGFR) exon 19 deletions or exon 21 (L858R) substitution variants.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tagrisso (osimertinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 305, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 9, "name": "EGFR p.L858R", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 55259515}, {"name": "end_position", "value": 55259515}, {"name": "reference_allele", "value": "T"}, {"name": "alternate_allele", "value": "G"}, {"name": "cdna_change", "value": "c.2573T>G"}, {"name": "protein_change", "value": "p.L858R"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "21"}, {"name": "rsid", "value": "rs121434568"}, {"name": "hgvsg", "value": "7:g.55259515T>G"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 86, "conceptType": "Drug", "name": "Osimertinib", "primaryCoding": {"id": "ncit:C116377", "code": "C116377", "name": "Osimertinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10326, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized osimertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR variants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tagrisso:1", "indication": "TAGRISSO as monotherapy is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized osimertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR variants.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tagrisso (osimertinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 664, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 19, "name": "EGFR oncogenic variants", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 86, "conceptType": "Drug", "name": "Osimertinib", "primaryCoding": {"id": "ncit:C116377", "code": "C116377", "name": "Osimertinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10327, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized osimertinib for treatment of adult patients with locally advanced or metastatic EGFR p.T790M mutation-positive non-small cell lung cancer.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tagrisso:2", "indication": "TAGRISSO as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized osimertinib for treatment of adult patients with locally advanced or metastatic EGFR p.T790M mutation-positive non-small cell lung cancer.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tagrisso (osimertinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 310, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 70, "name": "EGFR p.T790M", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 55249071}, {"name": "end_position", "value": 55249071}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.2369C>T"}, {"name": "protein_change", "value": "p.T790M"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "20"}, {"name": "rsid", "value": "rs121434569"}, {"name": "hgvsg", "value": "7:g.55249071C>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 86, "conceptType": "Drug", "name": "Osimertinib", "primaryCoding": {"id": "ncit:C116377", "code": "C116377", "name": "Osimertinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10328, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tagrisso:3", "indication": "TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 665, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 10, "name": "EGFR Exon 19 (Deletion)", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "variant_annotation", "value": "Deletion"}, {"name": "exon", "value": "19"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 132, "membership_operator": "AND", "therapies": [{"id": 86, "conceptType": "Drug", "name": "Osimertinib", "primaryCoding": {"id": "ncit:C116377", "code": "C116377", "name": "Osimertinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10329, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tagrisso:3", "indication": "TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 666, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 10, "name": "EGFR Exon 19 (Deletion)", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "variant_annotation", "value": "Deletion"}, {"name": "exon", "value": "19"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 133, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 86, "conceptType": "Drug", "name": "Osimertinib", "primaryCoding": {"id": "ncit:C116377", "code": "C116377", "name": "Osimertinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10330, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tagrisso:3", "indication": "TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 667, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 9, "name": "EGFR p.L858R", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 55259515}, {"name": "end_position", "value": 55259515}, {"name": "reference_allele", "value": "T"}, {"name": "alternate_allele", "value": "G"}, {"name": "cdna_change", "value": "c.2573T>G"}, {"name": "protein_change", "value": "p.L858R"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "21"}, {"name": "rsid", "value": "rs121434568"}, {"name": "hgvsg", "value": "7:g.55259515T>G"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 132, "membership_operator": "AND", "therapies": [{"id": 86, "conceptType": "Drug", "name": "Osimertinib", "primaryCoding": {"id": "ncit:C116377", "code": "C116377", "name": "Osimertinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10331, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tagrisso:3", "indication": "TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tagrisso", "type": "Document", "subtype": "Regulatory approval", "name": "Tagrisso (osimertinib) [product information]. EMA.", "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tagrisso", "drug_name_generic": "osimertinib", "first_published": "2016-02-17", "access_date": null, "publication_date": "2024-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 668, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 9, "name": "EGFR p.L858R", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 55259515}, {"name": "end_position", "value": 55259515}, {"name": "reference_allele", "value": "T"}, {"name": "alternate_allele", "value": "G"}, {"name": "cdna_change", "value": "c.2573T>G"}, {"name": "protein_change", "value": "p.L858R"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "21"}, {"name": "rsid", "value": "rs121434568"}, {"name": "hgvsg", "value": "7:g.55259515T>G"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 133, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 86, "conceptType": "Drug", "name": "Osimertinib", "primaryCoding": {"id": "ncit:C116377", "code": "C116377", "name": "Osimertinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10332, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.talzenna", "type": "Document", "subtype": "Regulatory approval", "name": "Talzenna (talazoparib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Talzenna (talazoparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Talzenna", "drug_name_generic": "talazoparib", "first_published": "2019-07-08", "access_date": null, "publication_date": "2024-01-16", "url": "https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.talzenna:0", "indication": "Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Talzenna (talazoparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.talzenna", "type": "Document", "subtype": "Regulatory approval", "name": "Talzenna (talazoparib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Talzenna (talazoparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Talzenna", "drug_name_generic": "talazoparib", "first_published": "2019-07-08", "access_date": null, "publication_date": "2024-01-16", "url": "https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 412, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 48, "name": "BRCA1 pathogenic variants", "genes": [{"id": 9, "name": "BRCA1", "primaryCoding": {"id": "hgnc:1100", "code": "HGNC:1100", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_007294.4", "code": "NM_007294.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000012048", "code": "ENSG00000012048", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000012048"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:672", "code": "672", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/672"]}}], "extensions": [{"name": "location", "value": "17q21.31"}, {"name": "location_sortable", "value": "17q21.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 87, "conceptType": "Drug", "name": "Talazoparib", "primaryCoding": {"id": "ncit:C95733", "code": "C95733", "name": "Talazoparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10333, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.talzenna", "type": "Document", "subtype": "Regulatory approval", "name": "Talzenna (talazoparib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Talzenna (talazoparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Talzenna", "drug_name_generic": "talazoparib", "first_published": "2019-07-08", "access_date": null, "publication_date": "2024-01-16", "url": "https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.talzenna:0", "indication": "Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized talazoparib for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endrocrine-based therapy, or be considered unsuitable for endocrine-based therapy.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Talzenna (talazoparib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.talzenna", "type": "Document", "subtype": "Regulatory approval", "name": "Talzenna (talazoparib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Talzenna (talazoparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Talzenna", "drug_name_generic": "talazoparib", "first_published": "2019-07-08", "access_date": null, "publication_date": "2024-01-16", "url": "https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 413, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 50, "name": "BRCA2 pathogenic variants", "genes": [{"id": 10, "name": "BRCA2", "primaryCoding": {"id": "hgnc:1101", "code": "HGNC:1101", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000139618", "code": "ENSG00000139618", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000139618"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:675", "code": "675", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/675"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000059.4", "code": "NM_000059.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4"]}}], "extensions": [{"name": "location", "value": "13q13.1"}, {"name": "location_sortable", "value": "13q13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Germline Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "requires_pathogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 87, "conceptType": "Drug", "name": "Talazoparib", "primaryCoding": {"id": "ncit:C95733", "code": "C95733", "name": "Talazoparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PARP inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10336, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized erlotinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating variants. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tarceva", "type": "Document", "subtype": "Regulatory approval", "name": "Tarceva (erlotinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Tarceva (erlotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf. Revised May 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tarceva", "drug_name_generic": "erlotinib", "first_published": "2009-07-14", "access_date": null, "publication_date": "2023-05-16", "url": "https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tarceva:0", "indication": "Tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized erlotinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating variants. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tarceva (erlotinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tarceva", "type": "Document", "subtype": "Regulatory approval", "name": "Tarceva (erlotinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Tarceva (erlotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf. Revised May 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tarceva", "drug_name_generic": "erlotinib", "first_published": "2009-07-14", "access_date": null, "publication_date": "2023-05-16", "url": "https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 669, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 19, "name": "EGFR oncogenic variants", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 12, "conceptType": "Drug", "name": "Erlotinib", "primaryCoding": {"id": "ncit:C65530", "code": "C65530", "name": "Erlotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C65530"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10337, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized erlotinib for switch maintenance treatemnt of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating variants and stable disease after first-line chemotherapy. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tarceva", "type": "Document", "subtype": "Regulatory approval", "name": "Tarceva (erlotinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Tarceva (erlotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf. Revised May 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tarceva", "drug_name_generic": "erlotinib", "first_published": "2009-07-14", "access_date": null, "publication_date": "2023-05-16", "url": "https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tarceva:1", "indication": "Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized erlotinib for switch maintenance treatemnt of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating variants and stable disease after first-line chemotherapy. Erlotinib's production information further states that factors associated with prolonged survival should be taken into account when prescribing erlotinib. It further states that no survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumors.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tarceva (erlotinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tarceva", "type": "Document", "subtype": "Regulatory approval", "name": "Tarceva (erlotinib) [product information]. EMA.", "citation": "Roche Registration GmbH. Tarceva (erlotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf. Revised May 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tarceva", "drug_name_generic": "erlotinib", "first_published": "2009-07-14", "access_date": null, "publication_date": "2023-05-16", "url": "https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 669, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 19, "name": "EGFR oncogenic variants", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 12, "conceptType": "Drug", "name": "Erlotinib", "primaryCoding": {"id": "ncit:C65530", "code": "C65530", "name": "Erlotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C65530"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10338, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia (CML) in the chronic phase.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tasigna", "type": "Document", "subtype": "Regulatory approval", "name": "Tasigna (nilotinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tasigna (nilotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tasigna", "drug_name_generic": "nilotinib", "first_published": "2009-09-29", "access_date": null, "publication_date": "2023-11-27", "url": "https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tasigna:0", "indication": "Tasigna is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia (CML) in the chronic phase.", "raw_biomarkers": null, "raw_cancer_type": "Chronic Myelogenous Leukemia", "raw_therapeutics": "Tasigna (nilotinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tasigna", "type": "Document", "subtype": "Regulatory approval", "name": "Tasigna (nilotinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tasigna (nilotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tasigna", "drug_name_generic": "nilotinib", "first_published": "2009-09-29", "access_date": null, "publication_date": "2023-11-27", "url": "https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 670, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 88, "conceptType": "Drug", "name": "Nilotinib", "primaryCoding": {"id": "ncit:C48375", "code": "C48375", "name": "Nilotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48375"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10339, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy including imatinib. Nilotinib's product information further states that efficacy data in patients with CML in blast crisis are not available.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tasigna", "type": "Document", "subtype": "Regulatory approval", "name": "Tasigna (nilotinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tasigna (nilotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tasigna", "drug_name_generic": "nilotinib", "first_published": "2009-09-29", "access_date": null, "publication_date": "2023-11-27", "url": "https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tasigna:1", "indication": "Tasigna is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy including imatinib. Nilotinib's product information further states that efficacy data in patients with CML in blast crisis are not available.", "raw_biomarkers": null, "raw_cancer_type": "Chronic Myelogenous Leukemia", "raw_therapeutics": "Tasigna (nilotinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tasigna", "type": "Document", "subtype": "Regulatory approval", "name": "Tasigna (nilotinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tasigna (nilotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tasigna", "drug_name_generic": "nilotinib", "first_published": "2009-09-29", "access_date": null, "publication_date": "2023-11-27", "url": "https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 670, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 88, "conceptType": "Drug", "name": "Nilotinib", "primaryCoding": {"id": "ncit:C48375", "code": "C48375", "name": "Nilotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48375"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10340, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of pediatric patients with chronic phase Phildelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tasigna", "type": "Document", "subtype": "Regulatory approval", "name": "Tasigna (nilotinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tasigna (nilotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tasigna", "drug_name_generic": "nilotinib", "first_published": "2009-09-29", "access_date": null, "publication_date": "2023-11-27", "url": "https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tasigna:2", "indication": "Tasigna is indicated for the treatment of paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized nilotinib for the treatment of pediatric patients with chronic phase Phildelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.", "raw_biomarkers": null, "raw_cancer_type": "Chronic Myelogenous Leukemia", "raw_therapeutics": "Tasigna (nilotinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tasigna", "type": "Document", "subtype": "Regulatory approval", "name": "Tasigna (nilotinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tasigna (nilotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tasigna", "drug_name_generic": "nilotinib", "first_published": "2009-09-29", "access_date": null, "publication_date": "2023-11-27", "url": "https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 670, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 88, "conceptType": "Drug", "name": "Nilotinib", "primaryCoding": {"id": "ncit:C48375", "code": "C48375", "name": "Nilotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48375"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10341, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are considered cisplatin ineligible, and whose tumors have PD-L1 expression >= 5%.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tecentriq:0", "indication": "Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic UC (i) after prior platinum-containing chemotherapy, or (ii) who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression >= 5%.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are considered cisplatin ineligible, and whose tumors have PD-L1 expression >= 5%.", "raw_biomarkers": null, "raw_cancer_type": "urothelial carcinoma", "raw_therapeutics": "Tecentriq (atezolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 671, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 71, "name": "PD-L1 >= 5%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.05"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 8, "conceptType": "Disease", "name": "Bladder Urothelial Carcinoma", "primaryCoding": {"id": "oncotree:BLCA", "code": "BLCA", "name": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"]}, "mappings": []}, "objectTherapeutic": {"id": 89, "conceptType": "Drug", "name": "Atezolizumab", "primaryCoding": {"id": "ncit:C106250", "code": "C106250", "name": "Atezolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10342, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the adjuvant treatment following complete resection and platinum-based chemotherapy of adult patients with non-small cell lung cancer with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tecentriq:1", "indication": "Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on >= 50% of tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the adjuvant treatment following complete resection and platinum-based chemotherapy of adult patients with non-small cell lung cancer with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tecentriq (atezolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 672, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 39, "name": "PD-L1 >= 50%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.5"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 89, "conceptType": "Drug", "name": "Atezolizumab", "primaryCoding": {"id": "ncit:C106250", "code": "C106250", "name": "Atezolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10343, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tecentriq:2", "indication": "Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel, and carboplatin", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 673, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 72, "name": "EGFR somatic variants", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 134, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 89, "conceptType": "Drug", "name": "Atezolizumab", "primaryCoding": {"id": "ncit:C106250", "code": "C106250", "name": "Atezolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10344, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tecentriq:2", "indication": "Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated only after failure of appropriate targeted therapies.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel, and carboplatin", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 674, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 134, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 11, "conceptType": "Drug", "name": "Bevacizumab", "primaryCoding": {"id": "ncit:C2039", "code": "C2039", "name": "Bevacizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["VEGF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 89, "conceptType": "Drug", "name": "Atezolizumab", "primaryCoding": {"id": "ncit:C106250", "code": "C106250", "name": "Atezolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10345, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tecentriq:3", "indication": "Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tecentriq (atezolizumab) in combination with nab-paclitaxel and carboplatin", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 675, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 135, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 51, "conceptType": "Drug", "name": "Nab-paclitaxel", "primaryCoding": {"id": "ncit:C2688", "code": "C2688", "name": "Nab-paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2688"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 89, "conceptType": "Drug", "name": "Atezolizumab", "primaryCoding": {"id": "ncit:C106250", "code": "C106250", "name": "Atezolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10346, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tecentriq:3", "indication": "Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tecentriq (atezolizumab) in combination with nab-paclitaxel and carboplatin", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 676, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 135, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 51, "conceptType": "Drug", "name": "Nab-paclitaxel", "primaryCoding": {"id": "ncit:C2688", "code": "C2688", "name": "Nab-paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2688"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 89, "conceptType": "Drug", "name": "Atezolizumab", "primaryCoding": {"id": "ncit:C106250", "code": "C106250", "name": "Atezolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10347, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tecentriq:3", "indication": "Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tecentriq (atezolizumab) in combination with nab-paclitaxel and carboplatin", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 677, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 135, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 51, "conceptType": "Drug", "name": "Nab-paclitaxel", "primaryCoding": {"id": "ncit:C2688", "code": "C2688", "name": "Nab-paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2688"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 89, "conceptType": "Drug", "name": "Atezolizumab", "primaryCoding": {"id": "ncit:C106250", "code": "C106250", "name": "Atezolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10348, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells or >= 10% tumor-infiltrating immune cells (IC) and who do not hvae EGFR mutant or ALK-positive NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tecentriq:4", "indication": "Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression >= 50% TC or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells or >= 10% tumor-infiltrating immune cells (IC) and who do not hvae EGFR mutant or ALK-positive NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tecentriq (atezolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 672, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 39, "name": "PD-L1 >= 50%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.5"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 89, "conceptType": "Drug", "name": "Atezolizumab", "primaryCoding": {"id": "ncit:C106250", "code": "C106250", "name": "Atezolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10349, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells or >= 10% tumor-infiltrating immune cells (IC) and who do not hvae EGFR mutant or ALK-positive NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tecentriq:4", "indication": "Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression >= 50% TC or >= 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells or >= 10% tumor-infiltrating immune cells (IC) and who do not hvae EGFR mutant or ALK-positive NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tecentriq (atezolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 678, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 73, "name": "PD-L1 >= 10% TIIC", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor-infiltrating immune cells (TIIC)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.1"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 89, "conceptType": "Drug", "name": "Atezolizumab", "primaryCoding": {"id": "ncit:C106250", "code": "C106250", "name": "Atezolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10350, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tecentriq:5", "indication": "Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tecentriq (atezolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 36, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 72, "name": "EGFR somatic variants", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 89, "conceptType": "Drug", "name": "Atezolizumab", "primaryCoding": {"id": "ncit:C106250", "code": "C106250", "name": "Atezolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10351, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tecentriq:5", "indication": "Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving atezolizumab.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tecentriq (atezolizumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 37, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 89, "conceptType": "Drug", "name": "Atezolizumab", "primaryCoding": {"id": "ncit:C106250", "code": "C106250", "name": "Atezolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10352, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tecentriq:6", "indication": "Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.", "raw_biomarkers": null, "raw_cancer_type": "Triple-negative breast cancer", "raw_therapeutics": "Tecentriq (atezolizumab) in combination with nab-paclitaxel", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tecentriq", "type": "Document", "subtype": "Regulatory approval", "name": "Tecentriq (atezolizumab) [product information]. EMA.", "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tecentriq", "drug_name_generic": "atezolizumab", "first_published": "2017-09-29", "access_date": null, "publication_date": "2024-03-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 679, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 43, "name": "ER negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 44, "name": "PR negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 33, "name": "PD-L1 >= 1%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.01"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 136, "membership_operator": "AND", "therapies": [{"id": 51, "conceptType": "Drug", "name": "Nab-paclitaxel", "primaryCoding": {"id": "ncit:C2688", "code": "C2688", "name": "Nab-paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2688"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 89, "conceptType": "Drug", "name": "Atezolizumab", "primaryCoding": {"id": "ncit:C106250", "code": "C106250", "name": "Atezolizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10353, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tepmetko", "type": "Document", "subtype": "Regulatory approval", "name": "Tepmetko (tepotinib) [product information]. EMA.", "citation": "Merck Europe B.V. Tepmetko (tepotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tepmetko", "drug_name_generic": "tepotinib", "first_published": "2022-05-05", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tepmetko:0", "indication": "TEPMETKO as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tepmetko (tepotinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tepmetko", "type": "Document", "subtype": "Regulatory approval", "name": "Tepmetko (tepotinib) [product information]. EMA.", "citation": "Merck Europe B.V. Tepmetko (tepotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tepmetko", "drug_name_generic": "tepotinib", "first_published": "2022-05-05", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 414, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 67, "name": "MET Exon 14 (Splice Site)", "genes": [{"id": 32, "name": "MET", "primaryCoding": {"id": "hgnc:7029", "code": "HGNC:7029", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000105976", "code": "ENSG00000105976", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000105976"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4233", "code": "4233", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4233"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000245.4", "code": "NM_000245.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000245.4"]}}], "extensions": [{"name": "location", "value": "7q31.2"}, {"name": "location_sortable", "value": "07q31.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "variant_annotation", "value": "Splice Site"}, {"name": "exon", "value": "14"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 90, "conceptType": "Drug", "name": "Tepotinib", "primaryCoding": {"id": "ncit:C88314", "code": "C88314", "name": "Tepotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C88314"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MET inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10354, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tepmetko", "type": "Document", "subtype": "Regulatory approval", "name": "Tepmetko (tepotinib) [product information]. EMA.", "citation": "Merck Europe B.V. Tepmetko (tepotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tepmetko", "drug_name_generic": "tepotinib", "first_published": "2022-05-05", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tepmetko:0", "indication": "TEPMETKO as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (MET exon 14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tepmetko (tepotinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tepmetko", "type": "Document", "subtype": "Regulatory approval", "name": "Tepmetko (tepotinib) [product information]. EMA.", "citation": "Merck Europe B.V. Tepmetko (tepotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tepmetko", "drug_name_generic": "tepotinib", "first_published": "2022-05-05", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 415, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 68, "name": "MET Exon 14 (Deletion)", "genes": [{"id": 32, "name": "MET", "primaryCoding": {"id": "hgnc:7029", "code": "HGNC:7029", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000105976", "code": "ENSG00000105976", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000105976"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4233", "code": "4233", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4233"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000245.4", "code": "NM_000245.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000245.4"]}}], "extensions": [{"name": "location", "value": "7q31.2"}, {"name": "location_sortable", "value": "07q31.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "variant_annotation", "value": "Deletion"}, {"name": "exon", "value": "14"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 90, "conceptType": "Drug", "name": "Tepotinib", "primaryCoding": {"id": "ncit:C88314", "code": "C88314", "name": "Tepotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C88314"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["MET inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10355, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tibsovo:0", "indication": "Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Acute myeloid leukaemia", "raw_therapeutics": "Tibsovo (ivosidenib) in combination with azacitidine", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 180, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 74, "name": "IDH1 p.R132C", "genes": [{"id": 28, "name": "IDH1", "primaryCoding": {"id": "hgnc:5382", "code": "HGNC:5382", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000138413", "code": "ENSG00000138413", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000138413"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3417", "code": "3417", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3417"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005896.4", "code": "NM_005896.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4"]}}], "extensions": [{"name": "location", "value": "2q34"}, {"name": "location_sortable", "value": "02q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "2"}, {"name": "start_position", "value": 209113113}, {"name": "end_position", "value": 209113113}, {"name": "reference_allele", "value": "G"}, {"name": "alternate_allele", "value": "A"}, {"name": "cdna_change", "value": "c.394C>T"}, {"name": "protein_change", "value": "p.R132C"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "4"}, {"name": "rsid", "value": "rs121913499"}, {"name": "hgvsg", "value": "2:g.209113113G>A"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 1, "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "primaryCoding": {"id": "oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML"]}, "mappings": []}, "objectTherapeutic": {"id": 33, "membership_operator": "AND", "therapies": [{"id": 92, "conceptType": "Drug", "name": "Ivosidenib", "primaryCoding": {"id": "ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["IDH1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 91, "conceptType": "Drug", "name": "Azacitidine", "primaryCoding": {"id": "ncit:C288", "code": "C288", "name": "Azacitidine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Hypomethylating agent chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10356, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tibsovo:0", "indication": "Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Acute myeloid leukaemia", "raw_therapeutics": "Tibsovo (ivosidenib) in combination with azacitidine", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 181, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 75, "name": "IDH1 p.R132G", "genes": [{"id": 28, "name": "IDH1", "primaryCoding": {"id": "hgnc:5382", "code": "HGNC:5382", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000138413", "code": "ENSG00000138413", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000138413"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3417", "code": "3417", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3417"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005896.4", "code": "NM_005896.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4"]}}], "extensions": [{"name": "location", "value": "2q34"}, {"name": "location_sortable", "value": "02q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "2"}, {"name": "start_position", "value": 209113113}, {"name": "end_position", "value": 209113113}, {"name": "reference_allele", "value": "G"}, {"name": "alternate_allele", "value": "C"}, {"name": "cdna_change", "value": "c.394C>G"}, {"name": "protein_change", "value": "p.R132G"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "4"}, {"name": "rsid", "value": "rs121913499"}, {"name": "hgvsg", "value": "2:g.209113113G>C"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 1, "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "primaryCoding": {"id": "oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML"]}, "mappings": []}, "objectTherapeutic": {"id": 33, "membership_operator": "AND", "therapies": [{"id": 92, "conceptType": "Drug", "name": "Ivosidenib", "primaryCoding": {"id": "ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["IDH1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 91, "conceptType": "Drug", "name": "Azacitidine", "primaryCoding": {"id": "ncit:C288", "code": "C288", "name": "Azacitidine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Hypomethylating agent chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10357, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tibsovo:0", "indication": "Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Acute myeloid leukaemia", "raw_therapeutics": "Tibsovo (ivosidenib) in combination with azacitidine", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 182, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 76, "name": "IDH1 p.R132H", "genes": [{"id": 28, "name": "IDH1", "primaryCoding": {"id": "hgnc:5382", "code": "HGNC:5382", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000138413", "code": "ENSG00000138413", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000138413"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3417", "code": "3417", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3417"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005896.4", "code": "NM_005896.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4"]}}], "extensions": [{"name": "location", "value": "2q34"}, {"name": "location_sortable", "value": "02q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "2"}, {"name": "start_position", "value": 209113112}, {"name": "end_position", "value": 209113112}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.395G>A"}, {"name": "protein_change", "value": "p.R132H"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "4"}, {"name": "rsid", "value": "rs121913500"}, {"name": "hgvsg", "value": "2:g.209113112C>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 1, "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "primaryCoding": {"id": "oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML"]}, "mappings": []}, "objectTherapeutic": {"id": 33, "membership_operator": "AND", "therapies": [{"id": 92, "conceptType": "Drug", "name": "Ivosidenib", "primaryCoding": {"id": "ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["IDH1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 91, "conceptType": "Drug", "name": "Azacitidine", "primaryCoding": {"id": "ncit:C288", "code": "C288", "name": "Azacitidine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Hypomethylating agent chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10358, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tibsovo:0", "indication": "Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Acute myeloid leukaemia", "raw_therapeutics": "Tibsovo (ivosidenib) in combination with azacitidine", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 183, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 77, "name": "IDH1 p.R132L", "genes": [{"id": 28, "name": "IDH1", "primaryCoding": {"id": "hgnc:5382", "code": "HGNC:5382", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000138413", "code": "ENSG00000138413", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000138413"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3417", "code": "3417", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3417"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005896.4", "code": "NM_005896.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4"]}}], "extensions": [{"name": "location", "value": "2q34"}, {"name": "location_sortable", "value": "02q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "2"}, {"name": "start_position", "value": 209113112}, {"name": "end_position", "value": 209113112}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "A"}, {"name": "cdna_change", "value": "c.385G>T"}, {"name": "protein_change", "value": "p.R132L"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "4"}, {"name": "rsid", "value": "rs121913500"}, {"name": "hgvsg", "value": "2:g.209113112C>A"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 1, "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "primaryCoding": {"id": "oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML"]}, "mappings": []}, "objectTherapeutic": {"id": 33, "membership_operator": "AND", "therapies": [{"id": 92, "conceptType": "Drug", "name": "Ivosidenib", "primaryCoding": {"id": "ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["IDH1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 91, "conceptType": "Drug", "name": "Azacitidine", "primaryCoding": {"id": "ncit:C288", "code": "C288", "name": "Azacitidine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Hypomethylating agent chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10359, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tibsovo:0", "indication": "Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Acute myeloid leukaemia", "raw_therapeutics": "Tibsovo (ivosidenib) in combination with azacitidine", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 184, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 78, "name": "IDH1 p.R132S", "genes": [{"id": 28, "name": "IDH1", "primaryCoding": {"id": "hgnc:5382", "code": "HGNC:5382", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000138413", "code": "ENSG00000138413", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000138413"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3417", "code": "3417", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3417"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005896.4", "code": "NM_005896.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4"]}}], "extensions": [{"name": "location", "value": "2q34"}, {"name": "location_sortable", "value": "02q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "2"}, {"name": "start_position", "value": 209113113}, {"name": "end_position", "value": 209113113}, {"name": "reference_allele", "value": "G"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.394C>A"}, {"name": "protein_change", "value": "p.R132S"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "4"}, {"name": "rsid", "value": "rs121913499"}, {"name": "hgvsg", "value": "2:g.209113113G>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 1, "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "primaryCoding": {"id": "oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML"]}, "mappings": []}, "objectTherapeutic": {"id": 33, "membership_operator": "AND", "therapies": [{"id": 92, "conceptType": "Drug", "name": "Ivosidenib", "primaryCoding": {"id": "ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["IDH1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 91, "conceptType": "Drug", "name": "Azacitidine", "primaryCoding": {"id": "ncit:C288", "code": "C288", "name": "Azacitidine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Hypomethylating agent chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10360, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tibsovo:1", "indication": "Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Cholangiocarcinoma", "raw_therapeutics": "Tibsovo (ivosidenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 190, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 74, "name": "IDH1 p.R132C", "genes": [{"id": 28, "name": "IDH1", "primaryCoding": {"id": "hgnc:5382", "code": "HGNC:5382", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000138413", "code": "ENSG00000138413", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000138413"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3417", "code": "3417", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3417"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005896.4", "code": "NM_005896.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4"]}}], "extensions": [{"name": "location", "value": "2q34"}, {"name": "location_sortable", "value": "02q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "2"}, {"name": "start_position", "value": 209113113}, {"name": "end_position", "value": 209113113}, {"name": "reference_allele", "value": "G"}, {"name": "alternate_allele", "value": "A"}, {"name": "cdna_change", "value": "c.394C>T"}, {"name": "protein_change", "value": "p.R132C"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "4"}, {"name": "rsid", "value": "rs121913499"}, {"name": "hgvsg", "value": "2:g.209113113G>A"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 11, "conceptType": "Disease", "name": "Cholangiocarcinoma", "primaryCoding": {"id": "oncotree:CHOL", "code": "CHOL", "name": "Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL"]}, "mappings": []}, "objectTherapeutic": {"id": 92, "conceptType": "Drug", "name": "Ivosidenib", "primaryCoding": {"id": "ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["IDH1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10361, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tibsovo:1", "indication": "Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Cholangiocarcinoma", "raw_therapeutics": "Tibsovo (ivosidenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 191, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 75, "name": "IDH1 p.R132G", "genes": [{"id": 28, "name": "IDH1", "primaryCoding": {"id": "hgnc:5382", "code": "HGNC:5382", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000138413", "code": "ENSG00000138413", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000138413"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3417", "code": "3417", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3417"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005896.4", "code": "NM_005896.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4"]}}], "extensions": [{"name": "location", "value": "2q34"}, {"name": "location_sortable", "value": "02q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "2"}, {"name": "start_position", "value": 209113113}, {"name": "end_position", "value": 209113113}, {"name": "reference_allele", "value": "G"}, {"name": "alternate_allele", "value": "C"}, {"name": "cdna_change", "value": "c.394C>G"}, {"name": "protein_change", "value": "p.R132G"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "4"}, {"name": "rsid", "value": "rs121913499"}, {"name": "hgvsg", "value": "2:g.209113113G>C"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 11, "conceptType": "Disease", "name": "Cholangiocarcinoma", "primaryCoding": {"id": "oncotree:CHOL", "code": "CHOL", "name": "Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL"]}, "mappings": []}, "objectTherapeutic": {"id": 92, "conceptType": "Drug", "name": "Ivosidenib", "primaryCoding": {"id": "ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["IDH1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10362, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tibsovo:1", "indication": "Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Cholangiocarcinoma", "raw_therapeutics": "Tibsovo (ivosidenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 192, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 76, "name": "IDH1 p.R132H", "genes": [{"id": 28, "name": "IDH1", "primaryCoding": {"id": "hgnc:5382", "code": "HGNC:5382", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000138413", "code": "ENSG00000138413", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000138413"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3417", "code": "3417", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3417"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005896.4", "code": "NM_005896.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4"]}}], "extensions": [{"name": "location", "value": "2q34"}, {"name": "location_sortable", "value": "02q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "2"}, {"name": "start_position", "value": 209113112}, {"name": "end_position", "value": 209113112}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.395G>A"}, {"name": "protein_change", "value": "p.R132H"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "4"}, {"name": "rsid", "value": "rs121913500"}, {"name": "hgvsg", "value": "2:g.209113112C>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 11, "conceptType": "Disease", "name": "Cholangiocarcinoma", "primaryCoding": {"id": "oncotree:CHOL", "code": "CHOL", "name": "Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL"]}, "mappings": []}, "objectTherapeutic": {"id": 92, "conceptType": "Drug", "name": "Ivosidenib", "primaryCoding": {"id": "ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["IDH1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10363, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tibsovo:1", "indication": "Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Cholangiocarcinoma", "raw_therapeutics": "Tibsovo (ivosidenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 193, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 77, "name": "IDH1 p.R132L", "genes": [{"id": 28, "name": "IDH1", "primaryCoding": {"id": "hgnc:5382", "code": "HGNC:5382", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000138413", "code": "ENSG00000138413", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000138413"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3417", "code": "3417", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3417"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005896.4", "code": "NM_005896.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4"]}}], "extensions": [{"name": "location", "value": "2q34"}, {"name": "location_sortable", "value": "02q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "2"}, {"name": "start_position", "value": 209113112}, {"name": "end_position", "value": 209113112}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "A"}, {"name": "cdna_change", "value": "c.385G>T"}, {"name": "protein_change", "value": "p.R132L"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "4"}, {"name": "rsid", "value": "rs121913500"}, {"name": "hgvsg", "value": "2:g.209113112C>A"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 11, "conceptType": "Disease", "name": "Cholangiocarcinoma", "primaryCoding": {"id": "oncotree:CHOL", "code": "CHOL", "name": "Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL"]}, "mappings": []}, "objectTherapeutic": {"id": 92, "conceptType": "Drug", "name": "Ivosidenib", "primaryCoding": {"id": "ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["IDH1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10364, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tibsovo:1", "indication": "Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ivosidenib as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 variant who were previously treated with at least one prior line of systemic therapy.", "raw_biomarkers": null, "raw_cancer_type": "Cholangiocarcinoma", "raw_therapeutics": "Tibsovo (ivosidenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tibsovo", "type": "Document", "subtype": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product information]. EMA.", "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.", "company": "", "drug_name_brand": "Tibsovo", "drug_name_generic": "ivosidenib", "first_published": "2023-05-12", "access_date": null, "publication_date": "2024-01-15", "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 194, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 78, "name": "IDH1 p.R132S", "genes": [{"id": 28, "name": "IDH1", "primaryCoding": {"id": "hgnc:5382", "code": "HGNC:5382", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000138413", "code": "ENSG00000138413", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000138413"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3417", "code": "3417", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3417"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005896.4", "code": "NM_005896.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4"]}}], "extensions": [{"name": "location", "value": "2q34"}, {"name": "location_sortable", "value": "02q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "2"}, {"name": "start_position", "value": 209113113}, {"name": "end_position", "value": 209113113}, {"name": "reference_allele", "value": "G"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.394C>A"}, {"name": "protein_change", "value": "p.R132S"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "4"}, {"name": "rsid", "value": "rs121913499"}, {"name": "hgvsg", "value": "2:g.209113113G>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 11, "conceptType": "Disease", "name": "Cholangiocarcinoma", "primaryCoding": {"id": "oncotree:CHOL", "code": "CHOL", "name": "Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL"]}, "mappings": []}, "objectTherapeutic": {"id": 92, "conceptType": "Drug", "name": "Ivosidenib", "primaryCoding": {"id": "ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["IDH1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10365, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tremelimumab astrazeneca", "type": "Document", "subtype": "Regulatory approval", "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.", "citation": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tremelimumab AstraZeneca", "drug_name_generic": "tremelimumab", "first_published": "2023-04-04", "access_date": null, "publication_date": "2023-09-11", "url": "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tremelimumab astrazeneca:0", "indication": "Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tremelimumab AstraZeneca (tremelimumab) in combination with durvalumab and platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tremelimumab astrazeneca", "type": "Document", "subtype": "Regulatory approval", "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.", "citation": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tremelimumab AstraZeneca", "drug_name_generic": "tremelimumab", "first_published": "2023-04-04", "access_date": null, "publication_date": "2023-09-11", "url": "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 104, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 20, "membership_operator": "AND", "therapies": [{"id": 45, "conceptType": "Drug", "name": "Tremelimumab", "primaryCoding": {"id": "ncit:C49085", "code": "C49085", "name": "Tremelimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10366, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tremelimumab astrazeneca", "type": "Document", "subtype": "Regulatory approval", "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.", "citation": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tremelimumab AstraZeneca", "drug_name_generic": "tremelimumab", "first_published": "2023-04-04", "access_date": null, "publication_date": "2023-09-11", "url": "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tremelimumab astrazeneca:0", "indication": "Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tremelimumab AstraZeneca (tremelimumab) in combination with durvalumab and platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tremelimumab astrazeneca", "type": "Document", "subtype": "Regulatory approval", "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.", "citation": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tremelimumab AstraZeneca", "drug_name_generic": "tremelimumab", "first_published": "2023-04-04", "access_date": null, "publication_date": "2023-09-11", "url": "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 105, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 21, "membership_operator": "AND", "therapies": [{"id": 45, "conceptType": "Drug", "name": "Tremelimumab", "primaryCoding": {"id": "ncit:C49085", "code": "C49085", "name": "Tremelimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10367, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tremelimumab astrazeneca", "type": "Document", "subtype": "Regulatory approval", "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.", "citation": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tremelimumab AstraZeneca", "drug_name_generic": "tremelimumab", "first_published": "2023-04-04", "access_date": null, "publication_date": "2023-09-11", "url": "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tremelimumab astrazeneca:0", "indication": "Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tremelimumab AstraZeneca (tremelimumab) in combination with durvalumab and platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tremelimumab astrazeneca", "type": "Document", "subtype": "Regulatory approval", "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.", "citation": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tremelimumab AstraZeneca", "drug_name_generic": "tremelimumab", "first_published": "2023-04-04", "access_date": null, "publication_date": "2023-09-11", "url": "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 107, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 23, "membership_operator": "AND", "therapies": [{"id": 45, "conceptType": "Drug", "name": "Tremelimumab", "primaryCoding": {"id": "ncit:C49085", "code": "C49085", "name": "Tremelimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 50, "conceptType": "Drug", "name": "Gemcitabine", "primaryCoding": {"id": "ncit:C66876", "code": "C66876", "name": "Gemcitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antimetabolite"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10368, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tremelimumab astrazeneca", "type": "Document", "subtype": "Regulatory approval", "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.", "citation": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tremelimumab AstraZeneca", "drug_name_generic": "tremelimumab", "first_published": "2023-04-04", "access_date": null, "publication_date": "2023-09-11", "url": "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tremelimumab astrazeneca:0", "indication": "Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tremelimumab AstraZeneca (tremelimumab) in combination with durvalumab and platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tremelimumab astrazeneca", "type": "Document", "subtype": "Regulatory approval", "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.", "citation": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tremelimumab AstraZeneca", "drug_name_generic": "tremelimumab", "first_published": "2023-04-04", "access_date": null, "publication_date": "2023-09-11", "url": "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 106, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 22, "membership_operator": "AND", "therapies": [{"id": 45, "conceptType": "Drug", "name": "Tremelimumab", "primaryCoding": {"id": "ncit:C49085", "code": "C49085", "name": "Tremelimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 50, "conceptType": "Drug", "name": "Gemcitabine", "primaryCoding": {"id": "ncit:C66876", "code": "C66876", "name": "Gemcitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antimetabolite"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10369, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tremelimumab astrazeneca", "type": "Document", "subtype": "Regulatory approval", "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.", "citation": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tremelimumab AstraZeneca", "drug_name_generic": "tremelimumab", "first_published": "2023-04-04", "access_date": null, "publication_date": "2023-09-11", "url": "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tremelimumab astrazeneca:0", "indication": "Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized tremelimumab in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations. This indication is based on POSEIDON, a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tremelimumab AstraZeneca (tremelimumab) in combination with durvalumab and platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tremelimumab astrazeneca", "type": "Document", "subtype": "Regulatory approval", "name": "Tremelimumab AstraZeneca (tremelimumab) [product information]. EMA.", "citation": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tremelimumab AstraZeneca", "drug_name_generic": "tremelimumab", "first_published": "2023-04-04", "access_date": null, "publication_date": "2023-09-11", "url": "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 108, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 24, "membership_operator": "AND", "therapies": [{"id": 45, "conceptType": "Drug", "name": "Tremelimumab", "primaryCoding": {"id": "ncit:C49085", "code": "C49085", "name": "Tremelimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 51, "conceptType": "Drug", "name": "Nab-paclitaxel", "primaryCoding": {"id": "ncit:C2688", "code": "C2688", "name": "Nab-paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2688"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10370, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized arsenic trioxide for induction of remission, and consolidation in adult patients with either newly diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) (white blood cell count, <= 10 x 10^3 / ul) in combination with all-trans-retinoic acid (ATRA) or relapsed / refractory acute promyelocytic leukemia (APL) (previous treatment should have included a retinoid and chemotherapy). Both contexts should be characterized by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukemia / retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.trisenox", "type": "Document", "subtype": "Regulatory approval", "name": "Trisenox (arsenic trioxide) [product information]. EMA.", "citation": "Teva B.V. Trisenox (arsenic trioxide) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trisenox-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Trisenox", "drug_name_generic": "arsenic trioxide", "first_published": "2009-10-08", "access_date": null, "publication_date": "2023-05-25", "url": "https://www.ema.europa.eu/en/documents/product-information/trisenox-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.trisenox:0", "indication": "RISENOX is indicated for induction of remission, and consolidation in adult patients with either newly diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) (white blood cell count, <= 10 x 10^3 / ul) in combination with all-trans-retinoic acid (ATRA) or relapsed / refractory acute promyelocytic leukemia (APL) (previous treatment should have included a retinoid and chemotherapy). Both contexts should be characterized by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukemia / retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized arsenic trioxide for induction of remission, and consolidation in adult patients with either newly diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) (white blood cell count, <= 10 x 10^3 / ul) in combination with all-trans-retinoic acid (ATRA) or relapsed / refractory acute promyelocytic leukemia (APL) (previous treatment should have included a retinoid and chemotherapy). Both contexts should be characterized by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukemia / retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.", "raw_biomarkers": null, "raw_cancer_type": "acute promyelocytic leukaemia", "raw_therapeutics": "Trisenox (arsenic trioxide)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.trisenox", "type": "Document", "subtype": "Regulatory approval", "name": "Trisenox (arsenic trioxide) [product information]. EMA.", "citation": "Teva B.V. Trisenox (arsenic trioxide) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trisenox-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Trisenox", "drug_name_generic": "arsenic trioxide", "first_published": "2009-10-08", "access_date": null, "publication_date": "2023-05-25", "url": "https://www.ema.europa.eu/en/documents/product-information/trisenox-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 28, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 79, "name": "PML::RARA", "genes": [{"id": 42, "name": "PML", "primaryCoding": {"id": "hgnc:9113", "code": "HGNC:9113", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9113"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000140464", "code": "ENSG00000140464", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000140464"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5371", "code": "5371", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5371"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_033238.3", "code": "NM_033238.3", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_033238.3"]}}], "extensions": [{"name": "location", "value": "15q24.1"}, {"name": "location_sortable", "value": "15q24.1"}]}, {"id": 48, "name": "RARA", "primaryCoding": {"id": "hgnc:9864", "code": "HGNC:9864", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9864"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000131759", "code": "ENSG00000131759", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000131759"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5914", "code": "5914", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5914"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000964.4", "code": "NM_000964.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000964.4"]}}], "extensions": [{"name": "location", "value": "17q21.2"}, {"name": "location_sortable", "value": "17q21.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 10, "conceptType": "Disease", "name": "APL with PML-RARA", "primaryCoding": {"id": "oncotree:APLPMLRARA", "code": "APLPMLRARA", "name": "APL with PML-RARA", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=APLPMLRARA"]}, "mappings": []}, "objectTherapeutic": {"id": 93, "conceptType": "Drug", "name": "Arsenic trioxide", "primaryCoding": {"id": "ncit:C1005", "code": "C1005", "name": "Arsenic Trioxide", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1005"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PML::RARA inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10371, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.trodelvy", "type": "Document", "subtype": "Regulatory approval", "name": "Trodelvy (sacituzumab govitecan) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Trodelvy (sacituzumab govitecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Trodelvy", "drug_name_generic": "sacituzumab govitecan", "first_published": "2021-11-24", "access_date": null, "publication_date": "2023-08-11", "url": "https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.trodelvy:0", "indication": "Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.", "raw_biomarkers": null, "raw_cancer_type": "unresectable or metastatic breast cancer", "raw_therapeutics": "Trodelvy (sacituzumab govitecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.trodelvy", "type": "Document", "subtype": "Regulatory approval", "name": "Trodelvy (sacituzumab govitecan) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Trodelvy (sacituzumab govitecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Trodelvy", "drug_name_generic": "sacituzumab govitecan", "first_published": "2021-11-24", "access_date": null, "publication_date": "2023-08-11", "url": "https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 403, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 43, "name": "ER negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 44, "name": "PR negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 94, "conceptType": "Drug", "name": "Sacituzumab govitecan", "primaryCoding": {"id": "ncit:C102783", "code": "C102783", "name": "Sacituzumab Govitecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102783"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10373, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.trodelvy", "type": "Document", "subtype": "Regulatory approval", "name": "Trodelvy (sacituzumab govitecan) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Trodelvy (sacituzumab govitecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Trodelvy", "drug_name_generic": "sacituzumab govitecan", "first_published": "2021-11-24", "access_date": null, "publication_date": "2023-08-11", "url": "https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.trodelvy:1", "indication": "Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Trodelvy (sacituzumab govitecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.trodelvy", "type": "Document", "subtype": "Regulatory approval", "name": "Trodelvy (sacituzumab govitecan) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Trodelvy (sacituzumab govitecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Trodelvy", "drug_name_generic": "sacituzumab govitecan", "first_published": "2021-11-24", "access_date": null, "publication_date": "2023-08-11", "url": "https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 404, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 94, "conceptType": "Drug", "name": "Sacituzumab govitecan", "primaryCoding": {"id": "ncit:C102783", "code": "C102783", "name": "Sacituzumab Govitecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102783"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10374, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.trodelvy", "type": "Document", "subtype": "Regulatory approval", "name": "Trodelvy (sacituzumab govitecan) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Trodelvy (sacituzumab govitecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Trodelvy", "drug_name_generic": "sacituzumab govitecan", "first_published": "2021-11-24", "access_date": null, "publication_date": "2023-08-11", "url": "https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.trodelvy:1", "indication": "Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Trodelvy (sacituzumab govitecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.trodelvy", "type": "Document", "subtype": "Regulatory approval", "name": "Trodelvy (sacituzumab govitecan) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Trodelvy (sacituzumab govitecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Trodelvy", "drug_name_generic": "sacituzumab govitecan", "first_published": "2021-11-24", "access_date": null, "publication_date": "2023-08-11", "url": "https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 405, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 94, "conceptType": "Drug", "name": "Sacituzumab govitecan", "primaryCoding": {"id": "ncit:C102783", "code": "C102783", "name": "Sacituzumab Govitecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102783"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10375, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.trodelvy", "type": "Document", "subtype": "Regulatory approval", "name": "Trodelvy (sacituzumab govitecan) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Trodelvy (sacituzumab govitecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Trodelvy", "drug_name_generic": "sacituzumab govitecan", "first_published": "2021-11-24", "access_date": null, "publication_date": "2023-08-11", "url": "https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.trodelvy:1", "indication": "Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized sacituzumab govitecan for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting (see section 5.1).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Trodelvy (sacituzumab govitecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.trodelvy", "type": "Document", "subtype": "Regulatory approval", "name": "Trodelvy (sacituzumab govitecan) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Trodelvy (sacituzumab govitecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Trodelvy", "drug_name_generic": "sacituzumab govitecan", "first_published": "2021-11-24", "access_date": null, "publication_date": "2023-08-11", "url": "https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 406, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 94, "conceptType": "Drug", "name": "Sacituzumab govitecan", "primaryCoding": {"id": "ncit:C102783", "code": "C102783", "name": "Sacituzumab Govitecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102783"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10376, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have at least 2 prior anti-HER2 treatment regimens.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tukysa", "type": "Document", "subtype": "Regulatory approval", "name": "Tukysa (tucatinib) [product information]. EMA.", "citation": "Seagen B.V. Tukysa (tucatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tukysa", "drug_name_generic": "tucatinib", "first_published": "2021-02-18", "access_date": null, "publication_date": "2023-08-21", "url": "https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tukysa:0", "indication": "TUKYSA is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have at least 2 prior anti-HER2 treatment regimens.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Tukysa (tucatinib) in combination with trastuzumab and capecitabine", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tukysa", "type": "Document", "subtype": "Regulatory approval", "name": "Tukysa (tucatinib) [product information]. EMA.", "citation": "Seagen B.V. Tukysa (tucatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tukysa", "drug_name_generic": "tucatinib", "first_published": "2021-02-18", "access_date": null, "publication_date": "2023-08-21", "url": "https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 425, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 84, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 38, "conceptType": "Drug", "name": "Capecitabine", "primaryCoding": {"id": "ncit:C1794", "code": "C1794", "name": "Capecitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 95, "conceptType": "Drug", "name": "Tucatinib", "primaryCoding": {"id": "ncit:C77896", "code": "C77896", "name": "Tucatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77896"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10378, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with capecitabine for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tyverb", "type": "Document", "subtype": "Regulatory approval", "name": "Tyverb (lapatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tyverb", "drug_name_generic": "lapatinib", "first_published": "2009-11-17", "access_date": null, "publication_date": "2023-05-10", "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tyverb:0", "indication": "Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with capecitabine for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Tyverb (lapatinib) in combination with capecitabine", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tyverb", "type": "Document", "subtype": "Regulatory approval", "name": "Tyverb (lapatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tyverb", "drug_name_generic": "lapatinib", "first_published": "2009-11-17", "access_date": null, "publication_date": "2023-05-10", "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 195, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 34, "membership_operator": "AND", "therapies": [{"id": 96, "conceptType": "Drug", "name": "Lapatinib", "primaryCoding": {"id": "ncit:C26653", "code": "C26653", "name": "Lapatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C26653"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 38, "conceptType": "Drug", "name": "Capecitabine", "primaryCoding": {"id": "ncit:C1794", "code": "C1794", "name": "Capecitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10379, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with trastuzumab for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tyverb", "type": "Document", "subtype": "Regulatory approval", "name": "Tyverb (lapatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tyverb", "drug_name_generic": "lapatinib", "first_published": "2009-11-17", "access_date": null, "publication_date": "2023-05-10", "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tyverb:1", "indication": "Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with trastuzumab for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Tyverb (lapatinib) in combination with trastuzumab and chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tyverb", "type": "Document", "subtype": "Regulatory approval", "name": "Tyverb (lapatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tyverb", "drug_name_generic": "lapatinib", "first_published": "2009-11-17", "access_date": null, "publication_date": "2023-05-10", "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 685, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 44, "name": "PR negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 139, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 96, "conceptType": "Drug", "name": "Lapatinib", "primaryCoding": {"id": "ncit:C26653", "code": "C26653", "name": "Lapatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C26653"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10380, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. This indication states that the patients in the registration study were not previosuly treated with trastuzumab or an aromatase inhibitor and that no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. This indication is based on the randomized, double-blind, and placebo controlled phase 3 study EGF30008, which used Letrozole as an aromatase inhibitor. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tyverb", "type": "Document", "subtype": "Regulatory approval", "name": "Tyverb (lapatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tyverb", "drug_name_generic": "lapatinib", "first_published": "2009-11-17", "access_date": null, "publication_date": "2023-05-10", "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tyverb:2", "indication": "Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. This indication states that the patients in the registration study were not previosuly treated with trastuzumab or an aromatase inhibitor and that no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. This indication is based on the randomized, double-blind, and placebo controlled phase 3 study EGF30008, which used Letrozole as an aromatase inhibitor. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Tyverb (lapatinib) in combination with an aromataste inhibitor", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tyverb", "type": "Document", "subtype": "Regulatory approval", "name": "Tyverb (lapatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tyverb", "drug_name_generic": "lapatinib", "first_published": "2009-11-17", "access_date": null, "publication_date": "2023-05-10", "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 198, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 20, "name": "HER2-positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 35, "membership_operator": "AND", "therapies": [{"id": 96, "conceptType": "Drug", "name": "Lapatinib", "primaryCoding": {"id": "ncit:C26653", "code": "C26653", "name": "Lapatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C26653"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10381, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with capecitabine for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tyverb", "type": "Document", "subtype": "Regulatory approval", "name": "Tyverb (lapatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tyverb", "drug_name_generic": "lapatinib", "first_published": "2009-11-17", "access_date": null, "publication_date": "2023-05-10", "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tyverb:0", "indication": "Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with capecitabine for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Tyverb (lapatinib) in combination with capecitabine", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tyverb", "type": "Document", "subtype": "Regulatory approval", "name": "Tyverb (lapatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tyverb", "drug_name_generic": "lapatinib", "first_published": "2009-11-17", "access_date": null, "publication_date": "2023-05-10", "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 687, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 34, "membership_operator": "AND", "therapies": [{"id": 96, "conceptType": "Drug", "name": "Lapatinib", "primaryCoding": {"id": "ncit:C26653", "code": "C26653", "name": "Lapatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C26653"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 38, "conceptType": "Drug", "name": "Capecitabine", "primaryCoding": {"id": "ncit:C1794", "code": "C1794", "name": "Capecitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10382, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with trastuzumab for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tyverb", "type": "Document", "subtype": "Regulatory approval", "name": "Tyverb (lapatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tyverb", "drug_name_generic": "lapatinib", "first_published": "2009-11-17", "access_date": null, "publication_date": "2023-05-10", "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tyverb:1", "indication": "Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with trastuzumab for the treatment of adult patients with breast cancer, whose tumors overexpress HER2 (ErbB2), with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy in combination with chemotherapy. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Tyverb (lapatinib) in combination with trastuzumab and chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tyverb", "type": "Document", "subtype": "Regulatory approval", "name": "Tyverb (lapatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tyverb", "drug_name_generic": "lapatinib", "first_published": "2009-11-17", "access_date": null, "publication_date": "2023-05-10", "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 688, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 44, "name": "PR negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 139, "membership_operator": "AND", "therapies": [{"id": 25, "conceptType": "Drug", "name": "Trastuzumab", "primaryCoding": {"id": "ncit:C1647", "code": "C1647", "name": "Trastuzumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 96, "conceptType": "Drug", "name": "Lapatinib", "primaryCoding": {"id": "ncit:C26653", "code": "C26653", "name": "Lapatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C26653"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10383, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. This indication states that the patients in the registration study were not previosuly treated with trastuzumab or an aromatase inhibitor and that no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. This indication is based on the randomized, double-blind, and placebo controlled phase 3 study EGF30008, which used Letrozole as an aromatase inhibitor. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tyverb", "type": "Document", "subtype": "Regulatory approval", "name": "Tyverb (lapatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tyverb", "drug_name_generic": "lapatinib", "first_published": "2009-11-17", "access_date": null, "publication_date": "2023-05-10", "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tyverb:2", "indication": "Tyverb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2) in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized laplatinib in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. This indication states that the patients in the registration study were not previosuly treated with trastuzumab or an aromatase inhibitor and that no data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. This indication is based on the randomized, double-blind, and placebo controlled phase 3 study EGF30008, which used Letrozole as an aromatase inhibitor. Lapatinib's product information sheet further defines HER2 (ErbB2) overexpressing tumors as IHC3+, or IHC2+ with gene amplification or gene amplification alone.", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Tyverb (lapatinib) in combination with an aromataste inhibitor", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tyverb", "type": "Document", "subtype": "Regulatory approval", "name": "Tyverb (lapatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Tyverb", "drug_name_generic": "lapatinib", "first_published": "2009-11-17", "access_date": null, "publication_date": "2023-05-10", "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 689, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 21, "name": "ERBB2 amplification", "genes": [{"id": 18, "name": "ERBB2", "primaryCoding": {"id": "hgnc:3430", "code": "HGNC:3430", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141736", "code": "ENSG00000141736", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141736"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2064", "code": "2064", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2064"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004448.4", "code": "NM_004448.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4"]}}], "extensions": [{"name": "location", "value": "17q12"}, {"name": "location_sortable", "value": "17q12"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 35, "membership_operator": "AND", "therapies": [{"id": 96, "conceptType": "Drug", "name": "Lapatinib", "primaryCoding": {"id": "ncit:C26653", "code": "C26653", "name": "Lapatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C26653"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["HER2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10384, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.vectibix", "type": "Document", "subtype": "Regulatory approval", "name": "Vectibix (panitumumab) [product information]. EMA.", "citation": "Amgen Europe B.V. Vectibix (panitumumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf. Revised July 2022. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Vectibix", "drug_name_generic": "panitumumab", "first_published": "2009-06-18", "access_date": null, "publication_date": "2022-07-06", "url": "https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.vectibix:0", "indication": "Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX or FOLFIRI.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Vectibix (panitumumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.vectibix", "type": "Document", "subtype": "Regulatory approval", "name": "Vectibix (panitumumab) [product information]. EMA.", "citation": "Amgen Europe B.V. Vectibix (panitumumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf. Revised July 2022. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Vectibix", "drug_name_generic": "panitumumab", "first_published": "2009-06-18", "access_date": null, "publication_date": "2022-07-06", "url": "https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 690, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 25, "name": "Wild type KRAS", "genes": [{"id": 31, "name": "KRAS", "primaryCoding": {"id": "hgnc:6407", "code": "HGNC:6407", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_004985.5", "code": "NM_004985.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000133703", "code": "ENSG00000133703", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000133703"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3845", "code": "3845", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3845"]}}], "extensions": [{"name": "location", "value": "12p12.1"}, {"name": "location_sortable", "value": "12p12.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 27, "name": "Wild type NRAS", "genes": [{"id": 33, "name": "NRAS", "primaryCoding": {"id": "hgnc:7989", "code": "HGNC:7989", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7989"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_002524.5", "code": "NM_002524.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_002524.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000213281", "code": "ENSG00000213281", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000213281"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4893", "code": "4893", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4893"]}}], "extensions": [{"name": "location", "value": "1p13.2"}, {"name": "location_sortable", "value": "01p13.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 50, "membership_operator": "AND", "therapies": [{"id": 97, "conceptType": "Drug", "name": "Panitumumab", "primaryCoding": {"id": "ncit:C1857", "code": "C1857", "name": "Panitumumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1857"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 28, "conceptType": "Drug", "name": "Oxaliplatin", "primaryCoding": {"id": "ncit:C1181", "code": "C1181", "name": "Oxaliplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10385, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.vectibix", "type": "Document", "subtype": "Regulatory approval", "name": "Vectibix (panitumumab) [product information]. EMA.", "citation": "Amgen Europe B.V. Vectibix (panitumumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf. Revised July 2022. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Vectibix", "drug_name_generic": "panitumumab", "first_published": "2009-06-18", "access_date": null, "publication_date": "2022-07-06", "url": "https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.vectibix:0", "indication": "Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX or FOLFIRI.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Vectibix (panitumumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.vectibix", "type": "Document", "subtype": "Regulatory approval", "name": "Vectibix (panitumumab) [product information]. EMA.", "citation": "Amgen Europe B.V. Vectibix (panitumumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf. Revised July 2022. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Vectibix", "drug_name_generic": "panitumumab", "first_published": "2009-06-18", "access_date": null, "publication_date": "2022-07-06", "url": "https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 691, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 25, "name": "Wild type KRAS", "genes": [{"id": 31, "name": "KRAS", "primaryCoding": {"id": "hgnc:6407", "code": "HGNC:6407", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_004985.5", "code": "NM_004985.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000133703", "code": "ENSG00000133703", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000133703"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3845", "code": "3845", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3845"]}}], "extensions": [{"name": "location", "value": "12p12.1"}, {"name": "location_sortable", "value": "12p12.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 27, "name": "Wild type NRAS", "genes": [{"id": 33, "name": "NRAS", "primaryCoding": {"id": "hgnc:7989", "code": "HGNC:7989", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7989"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_002524.5", "code": "NM_002524.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_002524.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000213281", "code": "ENSG00000213281", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000213281"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4893", "code": "4893", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4893"]}}], "extensions": [{"name": "location", "value": "1p13.2"}, {"name": "location_sortable", "value": "01p13.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 141, "membership_operator": "AND", "therapies": [{"id": 97, "conceptType": "Drug", "name": "Panitumumab", "primaryCoding": {"id": "ncit:C1857", "code": "C1857", "name": "Panitumumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1857"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 27, "conceptType": "Drug", "name": "Irinotecan", "primaryCoding": {"id": "ncit:C62040", "code": "C62040", "name": "Irinotecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62040"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase I inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10386, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFIRI for the second-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.vectibix", "type": "Document", "subtype": "Regulatory approval", "name": "Vectibix (panitumumab) [product information]. EMA.", "citation": "Amgen Europe B.V. Vectibix (panitumumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf. Revised July 2022. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Vectibix", "drug_name_generic": "panitumumab", "first_published": "2009-06-18", "access_date": null, "publication_date": "2022-07-06", "url": "https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.vectibix:1", "indication": "Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFIRI for the second-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Vectibix (panitumumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.vectibix", "type": "Document", "subtype": "Regulatory approval", "name": "Vectibix (panitumumab) [product information]. EMA.", "citation": "Amgen Europe B.V. Vectibix (panitumumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf. Revised July 2022. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Vectibix", "drug_name_generic": "panitumumab", "first_published": "2009-06-18", "access_date": null, "publication_date": "2022-07-06", "url": "https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 691, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 25, "name": "Wild type KRAS", "genes": [{"id": 31, "name": "KRAS", "primaryCoding": {"id": "hgnc:6407", "code": "HGNC:6407", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_004985.5", "code": "NM_004985.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000133703", "code": "ENSG00000133703", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000133703"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3845", "code": "3845", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3845"]}}], "extensions": [{"name": "location", "value": "12p12.1"}, {"name": "location_sortable", "value": "12p12.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 27, "name": "Wild type NRAS", "genes": [{"id": 33, "name": "NRAS", "primaryCoding": {"id": "hgnc:7989", "code": "HGNC:7989", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7989"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_002524.5", "code": "NM_002524.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_002524.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000213281", "code": "ENSG00000213281", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000213281"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4893", "code": "4893", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4893"]}}], "extensions": [{"name": "location", "value": "1p13.2"}, {"name": "location_sortable", "value": "01p13.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 141, "membership_operator": "AND", "therapies": [{"id": 97, "conceptType": "Drug", "name": "Panitumumab", "primaryCoding": {"id": "ncit:C1857", "code": "C1857", "name": "Panitumumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1857"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 27, "conceptType": "Drug", "name": "Irinotecan", "primaryCoding": {"id": "ncit:C62040", "code": "C62040", "name": "Irinotecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62040"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase I inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10387, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized panitumumab as a monotherapy for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.vectibix", "type": "Document", "subtype": "Regulatory approval", "name": "Vectibix (panitumumab) [product information]. EMA.", "citation": "Amgen Europe B.V. Vectibix (panitumumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf. Revised July 2022. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Vectibix", "drug_name_generic": "panitumumab", "first_published": "2009-06-18", "access_date": null, "publication_date": "2022-07-06", "url": "https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.vectibix:2", "indication": "Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized panitumumab as a monotherapy for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Vectibix (panitumumab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.vectibix", "type": "Document", "subtype": "Regulatory approval", "name": "Vectibix (panitumumab) [product information]. EMA.", "citation": "Amgen Europe B.V. Vectibix (panitumumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf. Revised July 2022. Accessed March 28, 2024.", "company": "", "drug_name_brand": "Vectibix", "drug_name_generic": "panitumumab", "first_published": "2009-06-18", "access_date": null, "publication_date": "2022-07-06", "url": "https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 692, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 25, "name": "Wild type KRAS", "genes": [{"id": 31, "name": "KRAS", "primaryCoding": {"id": "hgnc:6407", "code": "HGNC:6407", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_004985.5", "code": "NM_004985.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000133703", "code": "ENSG00000133703", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000133703"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:3845", "code": "3845", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/3845"]}}], "extensions": [{"name": "location", "value": "12p12.1"}, {"name": "location_sortable", "value": "12p12.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 27, "name": "Wild type NRAS", "genes": [{"id": 33, "name": "NRAS", "primaryCoding": {"id": "hgnc:7989", "code": "HGNC:7989", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7989"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_002524.5", "code": "NM_002524.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_002524.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000213281", "code": "ENSG00000213281", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000213281"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4893", "code": "4893", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4893"]}}], "extensions": [{"name": "location", "value": "1p13.2"}, {"name": "location_sortable", "value": "01p13.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 97, "conceptType": "Drug", "name": "Panitumumab", "primaryCoding": {"id": "ncit:C1857", "code": "C1857", "name": "Panitumumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1857"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10388, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.venclyxto", "type": "Document", "subtype": "Regulatory approval", "name": "Venclyxto (venetoclax) [product information]. EMA.", "citation": "AbbVie Deutschland GmbH Co. KG. Venclyxto (venetoclax) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Revised October 2022. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Venclyxto", "drug_name_generic": "venetoclax", "first_published": "2016-12-21", "access_date": null, "publication_date": "2023-10-31", "url": "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.venclyxto:0", "indication": "Venclyxto monotherapy is indicated for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)", "raw_therapeutics": "Venclyxto (venetoclax)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.venclyxto", "type": "Document", "subtype": "Regulatory approval", "name": "Venclyxto (venetoclax) [product information]. EMA.", "citation": "AbbVie Deutschland GmbH Co. KG. Venclyxto (venetoclax) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Revised October 2022. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Venclyxto", "drug_name_generic": "venetoclax", "first_published": "2016-12-21", "access_date": null, "publication_date": "2023-10-31", "url": "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 693, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 80, "name": "TP53 somatic variants", "genes": [{"id": 52, "name": "TP53", "primaryCoding": {"id": "hgnc:11998", "code": "HGNC:11998", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11998"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141510", "code": "ENSG00000141510", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141510"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:7157", "code": "7157", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/7157"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000546.6", "code": "NM_000546.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000546.6"]}}], "extensions": [{"name": "location", "value": "17p13.1"}, {"name": "location_sortable", "value": "17p13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 84, "conceptType": "Disease", "name": "Chronic Lymphocytic Leukemia", "primaryCoding": {"id": "ncit:C3163", "code": "C3163", "name": "Chronic Lymphocytic Leukemia", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3163"]}, "mappings": [{"relation": "broadMatch", "coding": {"id": "oncotree:CLLSLL", "code": "CLLSLL", "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CLLSLL"]}}]}, "objectTherapeutic": {"id": 98, "conceptType": "Drug", "name": "Venetoclax", "primaryCoding": {"id": "ncit:C103147", "code": "C103147", "name": "Venetoclax", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103147"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCL2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10389, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.venclyxto", "type": "Document", "subtype": "Regulatory approval", "name": "Venclyxto (venetoclax) [product information]. EMA.", "citation": "AbbVie Deutschland GmbH Co. KG. Venclyxto (venetoclax) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Revised October 2022. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Venclyxto", "drug_name_generic": "venetoclax", "first_published": "2016-12-21", "access_date": null, "publication_date": "2023-10-31", "url": "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.venclyxto:0", "indication": "Venclyxto monotherapy is indicated for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)", "raw_therapeutics": "Venclyxto (venetoclax)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.venclyxto", "type": "Document", "subtype": "Regulatory approval", "name": "Venclyxto (venetoclax) [product information]. EMA.", "citation": "AbbVie Deutschland GmbH Co. KG. Venclyxto (venetoclax) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Revised October 2022. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Venclyxto", "drug_name_generic": "venetoclax", "first_published": "2016-12-21", "access_date": null, "publication_date": "2023-10-31", "url": "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 694, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 81, "name": "TP53 deletion", "genes": [{"id": 52, "name": "TP53", "primaryCoding": {"id": "hgnc:11998", "code": "HGNC:11998", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11998"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141510", "code": "ENSG00000141510", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141510"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:7157", "code": "7157", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/7157"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000546.6", "code": "NM_000546.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000546.6"]}}], "extensions": [{"name": "location", "value": "17p13.1"}, {"name": "location_sortable", "value": "17p13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Deletion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 84, "conceptType": "Disease", "name": "Chronic Lymphocytic Leukemia", "primaryCoding": {"id": "ncit:C3163", "code": "C3163", "name": "Chronic Lymphocytic Leukemia", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3163"]}, "mappings": [{"relation": "broadMatch", "coding": {"id": "oncotree:CLLSLL", "code": "CLLSLL", "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CLLSLL"]}}]}, "objectTherapeutic": {"id": 98, "conceptType": "Drug", "name": "Venetoclax", "primaryCoding": {"id": "ncit:C103147", "code": "C103147", "name": "Venetoclax", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103147"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCL2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10390, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.venclyxto", "type": "Document", "subtype": "Regulatory approval", "name": "Venclyxto (venetoclax) [product information]. EMA.", "citation": "AbbVie Deutschland GmbH Co. KG. Venclyxto (venetoclax) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Revised October 2022. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Venclyxto", "drug_name_generic": "venetoclax", "first_published": "2016-12-21", "access_date": null, "publication_date": "2023-10-31", "url": "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.venclyxto:0", "indication": "Venclyxto monotherapy is indicated for the treatment of CLL in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)", "raw_therapeutics": "Venclyxto (venetoclax)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.venclyxto", "type": "Document", "subtype": "Regulatory approval", "name": "Venclyxto (venetoclax) [product information]. EMA.", "citation": "AbbVie Deutschland GmbH Co. KG. Venclyxto (venetoclax) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Revised October 2022. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Venclyxto", "drug_name_generic": "venetoclax", "first_published": "2016-12-21", "access_date": null, "publication_date": "2023-10-31", "url": "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 695, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 84, "name": "17p deletion", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number (arm level)"}, {"name": "chromosome", "value": "17"}, {"name": "direction", "value": "Deletion"}, {"name": "arm", "value": "p"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 84, "conceptType": "Disease", "name": "Chronic Lymphocytic Leukemia", "primaryCoding": {"id": "ncit:C3163", "code": "C3163", "name": "Chronic Lymphocytic Leukemia", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3163"]}, "mappings": [{"relation": "broadMatch", "coding": {"id": "oncotree:CLLSLL", "code": "CLLSLL", "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CLLSLL"]}}]}, "objectTherapeutic": {"id": 98, "conceptType": "Drug", "name": "Venetoclax", "primaryCoding": {"id": "ncit:C103147", "code": "C103147", "name": "Venetoclax", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103147"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCL2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10391, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.venclyxto", "type": "Document", "subtype": "Regulatory approval", "name": "Venclyxto (venetoclax) [product information]. EMA.", "citation": "AbbVie Deutschland GmbH Co. KG. Venclyxto (venetoclax) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Revised October 2022. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Venclyxto", "drug_name_generic": "venetoclax", "first_published": "2016-12-21", "access_date": null, "publication_date": "2023-10-31", "url": "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.venclyxto:1", "indication": "Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed chemoimmunotherapy and a B-cell receptor pathway inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)", "raw_therapeutics": "Venclyxto (venetoclax)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.venclyxto", "type": "Document", "subtype": "Regulatory approval", "name": "Venclyxto (venetoclax) [product information]. EMA.", "citation": "AbbVie Deutschland GmbH Co. KG. Venclyxto (venetoclax) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Revised October 2022. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Venclyxto", "drug_name_generic": "venetoclax", "first_published": "2016-12-21", "access_date": null, "publication_date": "2023-10-31", "url": "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 696, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 83, "name": "Wild type TP53", "genes": [{"id": 52, "name": "TP53", "primaryCoding": {"id": "hgnc:11998", "code": "HGNC:11998", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11998"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141510", "code": "ENSG00000141510", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141510"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:7157", "code": "7157", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/7157"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000546.6", "code": "NM_000546.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000546.6"]}}], "extensions": [{"name": "location", "value": "17p13.1"}, {"name": "location_sortable", "value": "17p13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 84, "conceptType": "Disease", "name": "Chronic Lymphocytic Leukemia", "primaryCoding": {"id": "ncit:C3163", "code": "C3163", "name": "Chronic Lymphocytic Leukemia", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3163"]}, "mappings": [{"relation": "broadMatch", "coding": {"id": "oncotree:CLLSLL", "code": "CLLSLL", "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CLLSLL"]}}]}, "objectTherapeutic": {"id": 98, "conceptType": "Drug", "name": "Venetoclax", "primaryCoding": {"id": "ncit:C103147", "code": "C103147", "name": "Venetoclax", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103147"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCL2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10392, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.venclyxto", "type": "Document", "subtype": "Regulatory approval", "name": "Venclyxto (venetoclax) [product information]. EMA.", "citation": "AbbVie Deutschland GmbH Co. KG. Venclyxto (venetoclax) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Revised October 2022. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Venclyxto", "drug_name_generic": "venetoclax", "first_published": "2016-12-21", "access_date": null, "publication_date": "2023-10-31", "url": "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.venclyxto:1", "indication": "Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed chemoimmunotherapy and a B-cell receptor pathway inhibitor.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)", "raw_therapeutics": "Venclyxto (venetoclax)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.venclyxto", "type": "Document", "subtype": "Regulatory approval", "name": "Venclyxto (venetoclax) [product information]. EMA.", "citation": "AbbVie Deutschland GmbH Co. KG. Venclyxto (venetoclax) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Revised October 2022. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Venclyxto", "drug_name_generic": "venetoclax", "first_published": "2016-12-21", "access_date": null, "publication_date": "2023-10-31", "url": "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 695, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 84, "name": "17p deletion", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number (arm level)"}, {"name": "chromosome", "value": "17"}, {"name": "direction", "value": "Deletion"}, {"name": "arm", "value": "p"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 84, "conceptType": "Disease", "name": "Chronic Lymphocytic Leukemia", "primaryCoding": {"id": "ncit:C3163", "code": "C3163", "name": "Chronic Lymphocytic Leukemia", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3163"]}, "mappings": [{"relation": "broadMatch", "coding": {"id": "oncotree:CLLSLL", "code": "CLLSLL", "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CLLSLL"]}}]}, "objectTherapeutic": {"id": 98, "conceptType": "Drug", "name": "Venetoclax", "primaryCoding": {"id": "ncit:C103147", "code": "C103147", "name": "Venetoclax", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103147"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCL2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10396, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:1", "indication": "Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 3, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 1, "membership_operator": "AND", "therapies": [{"id": 36, "conceptType": "Drug", "name": "Anastrozole", "primaryCoding": {"id": "ncit:C1607", "code": "C1607", "name": "Anastrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10397, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:1", "indication": "Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 4, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 1, "membership_operator": "AND", "therapies": [{"id": 36, "conceptType": "Drug", "name": "Anastrozole", "primaryCoding": {"id": "ncit:C1607", "code": "C1607", "name": "Anastrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10398, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:1", "indication": "Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 5, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 1, "membership_operator": "AND", "therapies": [{"id": 36, "conceptType": "Drug", "name": "Anastrozole", "primaryCoding": {"id": "ncit:C1607", "code": "C1607", "name": "Anastrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10402, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:1", "indication": "Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 6, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 2, "membership_operator": "AND", "therapies": [{"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10403, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:1", "indication": "Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 7, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 2, "membership_operator": "AND", "therapies": [{"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10404, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:1", "indication": "Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 8, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 2, "membership_operator": "AND", "therapies": [{"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10408, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:1", "indication": "Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 9, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 3, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10409, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:1", "indication": "Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 10, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 3, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10410, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:1", "indication": "Verzenios is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy and an aromatase inhibitor or fulvestrant as an initial endocrine-based therapy, or in women who have received prior endocrine therapy, for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Abemaciclib's product information further states that in pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. This indication is based on the randomized, double-blind, placebo-controlled phase 3 study MONARCH 3 that used either anastrozole or letrozole as an aromatase inhibitor.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 11, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 3, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10414, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.vitrakvi", "type": "Document", "subtype": "Regulatory approval", "name": "Vitrakvi (larotrectinib) [product information]. EMA.", "citation": "Bayer AG. Vitrakvi (larotrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Vitrakvi", "drug_name_generic": "larotrectinib", "first_published": "2019-10-24", "access_date": null, "publication_date": "2023-09-22", "url": "https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.vitrakvi:0", "indication": "VITRAKVI as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.", "raw_biomarkers": null, "raw_cancer_type": "Any solid tumor", "raw_therapeutics": "Vitrakvi (larotrectinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.vitrakvi", "type": "Document", "subtype": "Regulatory approval", "name": "Vitrakvi (larotrectinib) [product information]. EMA.", "citation": "Bayer AG. Vitrakvi (larotrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Vitrakvi", "drug_name_generic": "larotrectinib", "first_published": "2019-10-24", "access_date": null, "publication_date": "2023-09-22", "url": "https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 199, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 63, "name": "v::NTRK1", "genes": [{"id": 35, "name": "NTRK1", "primaryCoding": {"id": "hgnc:8031", "code": "HGNC:8031", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8031"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_002529.4", "code": "NM_002529.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_002529.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000198400", "code": "ENSG00000198400", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000198400"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4914", "code": "4914", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4914"]}}], "extensions": [{"name": "location", "value": "1q23.1"}, {"name": "location_sortable", "value": "01q23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 5, "conceptType": "Disease", "name": "Any solid tumor", "primaryCoding": {"id": "ncit:C132146", "code": "C132146", "name": "Malignant Solid Neoplasm", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146"]}, "mappings": []}, "objectTherapeutic": {"id": 100, "conceptType": "Drug", "name": "Larotrectinib", "primaryCoding": {"id": "ncit:C115977", "code": "C115977", "name": "Larotrectinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115977"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["NTRK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10415, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.vitrakvi", "type": "Document", "subtype": "Regulatory approval", "name": "Vitrakvi (larotrectinib) [product information]. EMA.", "citation": "Bayer AG. Vitrakvi (larotrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Vitrakvi", "drug_name_generic": "larotrectinib", "first_published": "2019-10-24", "access_date": null, "publication_date": "2023-09-22", "url": "https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.vitrakvi:0", "indication": "VITRAKVI as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.", "raw_biomarkers": null, "raw_cancer_type": "Any solid tumor", "raw_therapeutics": "Vitrakvi (larotrectinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.vitrakvi", "type": "Document", "subtype": "Regulatory approval", "name": "Vitrakvi (larotrectinib) [product information]. EMA.", "citation": "Bayer AG. Vitrakvi (larotrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Vitrakvi", "drug_name_generic": "larotrectinib", "first_published": "2019-10-24", "access_date": null, "publication_date": "2023-09-22", "url": "https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 200, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 64, "name": "v::NTRK2", "genes": [{"id": 36, "name": "NTRK2", "primaryCoding": {"id": "hgnc:8032", "code": "HGNC:8032", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8032"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000148053", "code": "ENSG00000148053", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000148053"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4915", "code": "4915", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4915"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_006180.6", "code": "NM_006180.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_006180.6"]}}], "extensions": [{"name": "location", "value": "9q21.33"}, {"name": "location_sortable", "value": "09q21.33"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 5, "conceptType": "Disease", "name": "Any solid tumor", "primaryCoding": {"id": "ncit:C132146", "code": "C132146", "name": "Malignant Solid Neoplasm", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146"]}, "mappings": []}, "objectTherapeutic": {"id": 100, "conceptType": "Drug", "name": "Larotrectinib", "primaryCoding": {"id": "ncit:C115977", "code": "C115977", "name": "Larotrectinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115977"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["NTRK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10416, "type": "Statement", "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.vitrakvi", "type": "Document", "subtype": "Regulatory approval", "name": "Vitrakvi (larotrectinib) [product information]. EMA.", "citation": "Bayer AG. Vitrakvi (larotrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Vitrakvi", "drug_name_generic": "larotrectinib", "first_published": "2019-10-24", "access_date": null, "publication_date": "2023-09-22", "url": "https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.vitrakvi:0", "indication": "VITRAKVI as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has conditionally authorized larotrectinib for the treatment of adult and pediatric patients with solid tumors that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity. It is also indicated for the treatment of adult and pediatric patients with solid tumors that display an NTRK gene fusion who have no satisfactory treatment options.", "raw_biomarkers": null, "raw_cancer_type": "Any solid tumor", "raw_therapeutics": "Vitrakvi (larotrectinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.vitrakvi", "type": "Document", "subtype": "Regulatory approval", "name": "Vitrakvi (larotrectinib) [product information]. EMA.", "citation": "Bayer AG. Vitrakvi (larotrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Vitrakvi", "drug_name_generic": "larotrectinib", "first_published": "2019-10-24", "access_date": null, "publication_date": "2023-09-22", "url": "https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 201, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 65, "name": "v::NTRK3", "genes": [{"id": 37, "name": "NTRK3", "primaryCoding": {"id": "hgnc:8033", "code": "HGNC:8033", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8033"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_001012338.3", "code": "NM_001012338.3", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_001012338.3"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000140538", "code": "ENSG00000140538", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000140538"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:4916", "code": "4916", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/4916"]}}], "extensions": [{"name": "location", "value": "15q25.3"}, {"name": "location_sortable", "value": "15q25.3"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 5, "conceptType": "Disease", "name": "Any solid tumor", "primaryCoding": {"id": "ncit:C132146", "code": "C132146", "name": "Malignant Solid Neoplasm", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146"]}, "mappings": []}, "objectTherapeutic": {"id": 100, "conceptType": "Drug", "name": "Larotrectinib", "primaryCoding": {"id": "ncit:C115977", "code": "C115977", "name": "Larotrectinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115977"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["NTRK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10417, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dacomitinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating variants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.vizimpro", "type": "Document", "subtype": "Regulatory approval", "name": "Vizimpro (dacomitinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Vizimpro (dacomitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf. Revised February 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Vizimpro", "drug_name_generic": "dacomitinib", "first_published": "2019-06-05", "access_date": null, "publication_date": "2024-02-21", "url": "https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.vizimpro:0", "indication": "Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized dacomitinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating variants.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Vizimpro (dacomitinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.vizimpro", "type": "Document", "subtype": "Regulatory approval", "name": "Vizimpro (dacomitinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Vizimpro (dacomitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf. Revised February 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Vizimpro", "drug_name_generic": "dacomitinib", "first_published": "2019-06-05", "access_date": null, "publication_date": "2024-02-21", "url": "https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 708, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 19, "name": "EGFR oncogenic variants", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 101, "conceptType": "Drug", "name": "Dacomitinib", "primaryCoding": {"id": "ncit:C53398", "code": "C53398", "name": "Dacomitinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C53398"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10418, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized crizotinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.xalkori", "type": "Document", "subtype": "Regulatory approval", "name": "Xalkori (crizotinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Xalkori (crizotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Xalkori", "drug_name_generic": "crizotinib", "first_published": "2012-11-14", "access_date": null, "publication_date": "2024-09-24", "url": "https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.xalkori:0", "indication": "XALKORI as monotherapy is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized crizotinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Xalkori (crizotinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.xalkori", "type": "Document", "subtype": "Regulatory approval", "name": "Xalkori (crizotinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Xalkori (crizotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Xalkori", "drug_name_generic": "crizotinib", "first_published": "2012-11-14", "access_date": null, "publication_date": "2024-09-24", "url": "https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 84, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 102, "conceptType": "Drug", "name": "Crizotinib", "primaryCoding": {"id": "ncit:C74061", "code": "C74061", "name": "Crizotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C74061"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition", "MET inhibition", "ROS1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10419, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.xalkori", "type": "Document", "subtype": "Regulatory approval", "name": "Xalkori (crizotinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Xalkori (crizotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Xalkori", "drug_name_generic": "crizotinib", "first_published": "2012-11-14", "access_date": null, "publication_date": "2024-09-24", "url": "https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.xalkori:1", "indication": "XALKORI as monotherapy is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Xalkori (crizotinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.xalkori", "type": "Document", "subtype": "Regulatory approval", "name": "Xalkori (crizotinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Xalkori (crizotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Xalkori", "drug_name_generic": "crizotinib", "first_published": "2012-11-14", "access_date": null, "publication_date": "2024-09-24", "url": "https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 84, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 102, "conceptType": "Drug", "name": "Crizotinib", "primaryCoding": {"id": "ncit:C74061", "code": "C74061", "name": "Crizotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C74061"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition", "MET inhibition", "ROS1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10420, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.xalkori", "type": "Document", "subtype": "Regulatory approval", "name": "Xalkori (crizotinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Xalkori (crizotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Xalkori", "drug_name_generic": "crizotinib", "first_published": "2012-11-14", "access_date": null, "publication_date": "2024-09-24", "url": "https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.xalkori:2", "indication": "XALKORI as monotherapy is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Xalkori (crizotinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.xalkori", "type": "Document", "subtype": "Regulatory approval", "name": "Xalkori (crizotinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Xalkori (crizotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Xalkori", "drug_name_generic": "crizotinib", "first_published": "2012-11-14", "access_date": null, "publication_date": "2024-09-24", "url": "https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 85, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 62, "name": "v::ROS1", "genes": [{"id": 50, "name": "ROS1", "primaryCoding": {"id": "hgnc:10261", "code": "HGNC:10261", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000047936", "code": "ENSG00000047936", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000047936"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:6098", "code": "6098", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/6098"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_001378902.1", "code": "NM_001378902.1", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1"]}}], "extensions": [{"name": "location", "value": "6q22.1"}, {"name": "location_sortable", "value": "06q22.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 102, "conceptType": "Drug", "name": "Crizotinib", "primaryCoding": {"id": "ncit:C74061", "code": "C74061", "name": "Crizotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C74061"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition", "MET inhibition", "ROS1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10421, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.xalkori", "type": "Document", "subtype": "Regulatory approval", "name": "Xalkori (crizotinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Xalkori (crizotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Xalkori", "drug_name_generic": "crizotinib", "first_published": "2012-11-14", "access_date": null, "publication_date": "2024-09-24", "url": "https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.xalkori:3", "indication": "XALKORI as monotherapy is indicated for the treatment of paediatric patients (age >= 1 to <18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).", "raw_biomarkers": null, "raw_cancer_type": "anaplastic large cell lymphoma", "raw_therapeutics": "Xalkori (crizotinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.xalkori", "type": "Document", "subtype": "Regulatory approval", "name": "Xalkori (crizotinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Xalkori (crizotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Xalkori", "drug_name_generic": "crizotinib", "first_published": "2012-11-14", "access_date": null, "publication_date": "2024-09-24", "url": "https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 86, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 3, "conceptType": "Disease", "name": "Anaplastic Large Cell Lymphoma", "primaryCoding": {"id": "oncotree:ALCL", "code": "ALCL", "name": "Anaplastic Large Cell Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALCL"]}, "mappings": []}, "objectTherapeutic": {"id": 102, "conceptType": "Drug", "name": "Crizotinib", "primaryCoding": {"id": "ncit:C74061", "code": "C74061", "name": "Crizotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C74061"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition", "MET inhibition", "ROS1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10422, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumor (IMT).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.xalkori", "type": "Document", "subtype": "Regulatory approval", "name": "Xalkori (crizotinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Xalkori (crizotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Xalkori", "drug_name_generic": "crizotinib", "first_published": "2012-11-14", "access_date": null, "publication_date": "2024-09-24", "url": "https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.xalkori:4", "indication": "XALKORI as monotherapy is indicated for the treatment of paediatric patients (age >= 1 to <18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumour (IMT).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized crizotinib for the treatment of pediatric patients (age >= 1 to < 18 years) with recurrent or refractory anaplastic lymphoma kinase (ALK)-positive unresectable inflammatory myofibroblastic tumor (IMT).", "raw_biomarkers": null, "raw_cancer_type": "Inflammatory myofibroblastic tumour (IMT)", "raw_therapeutics": "Xalkori (crizotinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.xalkori", "type": "Document", "subtype": "Regulatory approval", "name": "Xalkori (crizotinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Xalkori (crizotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Xalkori", "drug_name_generic": "crizotinib", "first_published": "2012-11-14", "access_date": null, "publication_date": "2024-09-24", "url": "https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 87, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 28, "conceptType": "Disease", "name": "Inflammatory Myofibroblastic Tumor", "primaryCoding": {"id": "oncotree:IMT", "code": "IMT", "name": "Inflammatory Myofibroblastic Tumor", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=IMT"]}, "mappings": []}, "objectTherapeutic": {"id": 102, "conceptType": "Drug", "name": "Crizotinib", "primaryCoding": {"id": "ncit:C74061", "code": "C74061", "name": "Crizotinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C74061"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition", "MET inhibition", "ROS1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10423, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib's product information states that, before taking gilteritinib, relapsed or refactory AML patients must have confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test. The product information describes the mechanism of action for gilteritinib as inhibiting FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and that it induces apoptosis in leukemic cells expressing FLT3-ITD.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.xospata", "type": "Document", "subtype": "Regulatory approval", "name": "Xospata (gilteritinib) [product information]. EMA.", "citation": "Astellas Pharma Europe B.V. Xospata (gilteritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf. Revised November 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Xospata", "drug_name_generic": "gilteritinib", "first_published": "2019-11-08", "access_date": null, "publication_date": "2023-11-07", "url": "https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.xospata:0", "indication": "Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib's product information states that, before taking gilteritinib, relapsed or refactory AML patients must have confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test. The product information describes the mechanism of action for gilteritinib as inhibiting FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and that it induces apoptosis in leukemic cells expressing FLT3-ITD.", "raw_biomarkers": null, "raw_cancer_type": "Acute myeloid leukaemia", "raw_therapeutics": "Xospata (gilteritinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.xospata", "type": "Document", "subtype": "Regulatory approval", "name": "Xospata (gilteritinib) [product information]. EMA.", "citation": "Astellas Pharma Europe B.V. Xospata (gilteritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf. Revised November 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Xospata", "drug_name_generic": "gilteritinib", "first_published": "2019-11-08", "access_date": null, "publication_date": "2023-11-07", "url": "https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 709, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 66, "name": "FLT3-ITD", "genes": [{"id": 26, "name": "FLT3", "primaryCoding": {"id": "hgnc:3765", "code": "HGNC:3765", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000122025", "code": "ENSG00000122025", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000122025"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2322", "code": "2322", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2322"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004119.3", "code": "NM_004119.3", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3"]}}], "extensions": [{"name": "location", "value": "13q12.2"}, {"name": "location_sortable", "value": "13q12.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "variant_annotation", "value": "Internal Tandem Duplication (ITD)"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 1, "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "primaryCoding": {"id": "oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML"]}, "mappings": []}, "objectTherapeutic": {"id": 104, "conceptType": "Drug", "name": "Gilteritinib", "primaryCoding": {"id": "ncit:C116722", "code": "C116722", "name": "Gilteritinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FLT3 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10424, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib's product information states that, before taking gilteritinib, relapsed or refactory AML patients must have confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test. The product information describes the mechanism of action for gilteritinib as inhibiting FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and that it induces apoptosis in leukemic cells expressing FLT3-ITD.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.xospata", "type": "Document", "subtype": "Regulatory approval", "name": "Xospata (gilteritinib) [product information]. EMA.", "citation": "Astellas Pharma Europe B.V. Xospata (gilteritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf. Revised November 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Xospata", "drug_name_generic": "gilteritinib", "first_published": "2019-11-08", "access_date": null, "publication_date": "2023-11-07", "url": "https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.xospata:0", "indication": "Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Gilteritinib's product information states that, before taking gilteritinib, relapsed or refactory AML patients must have confirmation of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] or tyrosine kinase domain [TKD]) using a validated test. The product information describes the mechanism of action for gilteritinib as inhibiting FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and that it induces apoptosis in leukemic cells expressing FLT3-ITD.", "raw_biomarkers": null, "raw_cancer_type": "Acute myeloid leukaemia", "raw_therapeutics": "Xospata (gilteritinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.xospata", "type": "Document", "subtype": "Regulatory approval", "name": "Xospata (gilteritinib) [product information]. EMA.", "citation": "Astellas Pharma Europe B.V. Xospata (gilteritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf. Revised November 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Xospata", "drug_name_generic": "gilteritinib", "first_published": "2019-11-08", "access_date": null, "publication_date": "2023-11-07", "url": "https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 710, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 85, "name": "FLT3 p.D835Y", "genes": [{"id": 26, "name": "FLT3", "primaryCoding": {"id": "hgnc:3765", "code": "HGNC:3765", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000122025", "code": "ENSG00000122025", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000122025"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2322", "code": "2322", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2322"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004119.3", "code": "NM_004119.3", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3"]}}], "extensions": [{"name": "location", "value": "13q12.2"}, {"name": "location_sortable", "value": "13q12.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "13"}, {"name": "start_position", "value": 28592642}, {"name": "end_position", "value": 28592642}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "A"}, {"name": "cdna_change", "value": "c.2503G>T"}, {"name": "protein_change", "value": "p.D835Y"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "20"}, {"name": "rsid", "value": "rs121913488"}, {"name": "hgvsg", "value": "13:g.28592642C>A"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 1, "conceptType": "Disease", "name": "Acute Myeloid Leukemia", "primaryCoding": {"id": "oncotree:AML", "code": "AML", "name": "Acute Myeloid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML"]}, "mappings": []}, "objectTherapeutic": {"id": 104, "conceptType": "Drug", "name": "Gilteritinib", "primaryCoding": {"id": "ncit:C116722", "code": "C116722", "name": "Gilteritinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FLT3 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10425, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.yervoy", "type": "Document", "subtype": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Yervoy", "drug_name_generic": "ipilimumab", "first_published": "2011-07-25", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.yervoy:0", "indication": "YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.yervoy", "type": "Document", "subtype": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Yervoy", "drug_name_generic": "ipilimumab", "first_published": "2011-07-25", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 172, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 30, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": {"id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10426, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.yervoy", "type": "Document", "subtype": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Yervoy", "drug_name_generic": "ipilimumab", "first_published": "2011-07-25", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.yervoy:0", "indication": "YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.yervoy", "type": "Document", "subtype": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Yervoy", "drug_name_generic": "ipilimumab", "first_published": "2011-07-25", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 173, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 31, "membership_operator": "AND", "therapies": [{"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": {"id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10427, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.yervoy", "type": "Document", "subtype": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Yervoy", "drug_name_generic": "ipilimumab", "first_published": "2011-07-25", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.yervoy:0", "indication": "YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing EGFR mutations or ALK translocations. This indication is based on CA2099LA, a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.yervoy", "type": "Document", "subtype": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Yervoy", "drug_name_generic": "ipilimumab", "first_published": "2011-07-25", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 174, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 32, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": {"id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10428, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.yervoy", "type": "Document", "subtype": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Yervoy", "drug_name_generic": "ipilimumab", "first_published": "2011-07-25", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.yervoy:1", "indication": "YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.yervoy", "type": "Document", "subtype": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Yervoy", "drug_name_generic": "ipilimumab", "first_published": "2011-07-25", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 169, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 38, "name": "MSI-H", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Microsatellite Stability"}, {"name": "present", "value": true}, {"name": "status", "value": "Microsatellite instability-high (MSI-H)"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 29, "membership_operator": "AND", "therapies": [{"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": {"id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10429, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.yervoy", "type": "Document", "subtype": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Yervoy", "drug_name_generic": "ipilimumab", "first_published": "2011-07-25", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.yervoy:1", "indication": "YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Colorectal cancer", "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.yervoy", "type": "Document", "subtype": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Yervoy", "drug_name_generic": "ipilimumab", "first_published": "2011-07-25", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 507, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 36, "name": "dMMR", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Mismatch Repair"}, {"name": "present", "value": true}, {"name": "status", "value": "Deficient"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 15, "conceptType": "Disease", "name": "Colorectal Adenocarcinoma", "primaryCoding": {"id": "oncotree:COADREAD", "code": "COADREAD", "name": "Colorectal Adenocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD"]}, "mappings": []}, "objectTherapeutic": {"id": 29, "membership_operator": "AND", "therapies": [{"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": {"id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10430, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.yervoy", "type": "Document", "subtype": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Yervoy", "drug_name_generic": "ipilimumab", "first_published": "2011-07-25", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.yervoy:2", "indication": "YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression >= 1%.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ipilimumab in combination with nivolumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression >= 1%.", "raw_biomarkers": null, "raw_cancer_type": "Oesophageal squamous cell carcinoma", "raw_therapeutics": "Yervoy (ipilimumab) in combination with nivolumab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.yervoy", "type": "Document", "subtype": "Regulatory approval", "name": "Yervoy (ipilimumab) [product information]. EMA.", "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Yervoy", "drug_name_generic": "ipilimumab", "first_published": "2011-07-25", "access_date": null, "publication_date": "2024-03-21", "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 642, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 33, "name": "PD-L1 >= 1%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.01"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 82, "conceptType": "Disease", "name": "Esophageal Squamous Cell Carcinoma", "primaryCoding": {"id": "oncotree:ESCC", "code": "ESCC", "name": "Esophageal Squamous Cell Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCC"]}, "mappings": []}, "objectTherapeutic": {"id": 29, "membership_operator": "AND", "therapies": [{"id": 72, "conceptType": "Drug", "name": "Nivolumab", "primaryCoding": {"id": "ncit:C68814", "code": "C68814", "name": "Nivolumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 71, "conceptType": "Drug", "name": "Ipilimumab", "primaryCoding": {"id": "ncit:C2654", "code": "C2654", "name": "Ipilimumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CTLA-4 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10431, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Vemurafenib's product information states the special warning and caution that the efficacy and safety of vemurafenib in patients with tumors expressing rare BRAF V600 mutations other than V600E and V600K have not been convincingly established.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.zelboraf", "type": "Document", "subtype": "Regulatory approval", "name": "Zelboraf (vemurafenib) [product information]. EMA.", "citation": "Roche Registration GmbH. Zelboraf (vemurafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf. Revised July 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zelboraf", "drug_name_generic": "vemurafenib", "first_published": "2012-03-19", "access_date": null, "publication_date": "2023-07-18", "url": "https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.zelboraf:0", "indication": "Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF V600 mutation- positive unresectable or metastatic melanoma.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Vemurafenib's product information states the special warning and caution that the efficacy and safety of vemurafenib in patients with tumors expressing rare BRAF V600 mutations other than V600E and V600K have not been convincingly established.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Zelboraf (vemurafenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.zelboraf", "type": "Document", "subtype": "Regulatory approval", "name": "Zelboraf (vemurafenib) [product information]. EMA.", "citation": "Roche Registration GmbH. Zelboraf (vemurafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf. Revised July 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zelboraf", "drug_name_generic": "vemurafenib", "first_published": "2012-03-19", "access_date": null, "publication_date": "2023-07-18", "url": "https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 426, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 16, "name": "BRAF p.V600E", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453136}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1799T>A"}, {"name": "protein_change", "value": "p.V600E"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs113488022"}, {"name": "hgvsg", "value": "7:g.140453136A>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 22, "conceptType": "Drug", "name": "Vemurafenib", "primaryCoding": {"id": "ncit:C64768", "code": "C64768", "name": "Vemurafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10432, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Vemurafenib's product information states the special warning and caution that the efficacy and safety of vemurafenib in patients with tumors expressing rare BRAF V600 mutations other than V600E and V600K have not been convincingly established.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.zelboraf", "type": "Document", "subtype": "Regulatory approval", "name": "Zelboraf (vemurafenib) [product information]. EMA.", "citation": "Roche Registration GmbH. Zelboraf (vemurafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf. Revised July 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zelboraf", "drug_name_generic": "vemurafenib", "first_published": "2012-03-19", "access_date": null, "publication_date": "2023-07-18", "url": "https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.zelboraf:0", "indication": "Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF V600 mutation- positive unresectable or metastatic melanoma.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Vemurafenib's product information states the special warning and caution that the efficacy and safety of vemurafenib in patients with tumors expressing rare BRAF V600 mutations other than V600E and V600K have not been convincingly established.", "raw_biomarkers": null, "raw_cancer_type": "Melanoma", "raw_therapeutics": "Zelboraf (vemurafenib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.zelboraf", "type": "Document", "subtype": "Regulatory approval", "name": "Zelboraf (vemurafenib) [product information]. EMA.", "citation": "Roche Registration GmbH. Zelboraf (vemurafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf. Revised July 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zelboraf", "drug_name_generic": "vemurafenib", "first_published": "2012-03-19", "access_date": null, "publication_date": "2023-07-18", "url": "https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 711, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 17, "name": "BRAF p.V600K", "genes": [{"id": 8, "name": "BRAF", "primaryCoding": {"id": "hgnc:1097", "code": "HGNC:1097", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000157764", "code": "ENSG00000157764", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000157764"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:673", "code": "673", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/673"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004333.6", "code": "NM_004333.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6"]}}], "extensions": [{"name": "location", "value": "7q34"}, {"name": "location_sortable", "value": "07q34"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 140453136}, {"name": "end_position", "value": 140453137}, {"name": "reference_allele", "value": "AC"}, {"name": "alternate_allele", "value": "TT"}, {"name": "cdna_change", "value": "c.1798_1799GT>AA"}, {"name": "protein_change", "value": "p.V600K"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "15"}, {"name": "rsid", "value": "rs121913227"}, {"name": "hgvsg", "value": "7:g.140453136_140453137delinsTT"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 40, "conceptType": "Disease", "name": "Melanoma", "primaryCoding": {"id": "oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL"]}, "mappings": []}, "objectTherapeutic": {"id": 22, "conceptType": "Drug", "name": "Vemurafenib", "primaryCoding": {"id": "ncit:C64768", "code": "C64768", "name": "Vemurafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["B-RAF inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10433, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.zydelig", "type": "Document", "subtype": "Regulatory approval", "name": "Zydelig (idelalisib) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Zydelig (idelalisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf. Revised June 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zydelig", "drug_name_generic": "idelalisib", "first_published": "2014-10-14", "access_date": null, "publication_date": "2023-06-23", "url": "https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.zydelig:0", "indication": "Zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.", "raw_biomarkers": null, "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)", "raw_therapeutics": "Zydelig (idelalisib) in combination with rituximab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.zydelig", "type": "Document", "subtype": "Regulatory approval", "name": "Zydelig (idelalisib) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Zydelig (idelalisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf. Revised June 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zydelig", "drug_name_generic": "idelalisib", "first_published": "2014-10-14", "access_date": null, "publication_date": "2023-06-23", "url": "https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 712, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 81, "name": "TP53 deletion", "genes": [{"id": 52, "name": "TP53", "primaryCoding": {"id": "hgnc:11998", "code": "HGNC:11998", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11998"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141510", "code": "ENSG00000141510", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141510"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:7157", "code": "7157", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/7157"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000546.6", "code": "NM_000546.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000546.6"]}}], "extensions": [{"name": "location", "value": "17p13.1"}, {"name": "location_sortable", "value": "17p13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Deletion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 84, "conceptType": "Disease", "name": "Chronic Lymphocytic Leukemia", "primaryCoding": {"id": "ncit:C3163", "code": "C3163", "name": "Chronic Lymphocytic Leukemia", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3163"]}, "mappings": [{"relation": "broadMatch", "coding": {"id": "oncotree:CLLSLL", "code": "CLLSLL", "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CLLSLL"]}}]}, "objectTherapeutic": {"id": 145, "membership_operator": "AND", "therapies": [{"id": 105, "conceptType": "Drug", "name": "Idelalisib", "primaryCoding": {"id": "ncit:C78825", "code": "C78825", "name": "Idelalisib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C78825"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 60, "conceptType": "Drug", "name": "Rituximab", "primaryCoding": {"id": "ncit:C1702", "code": "C1702", "name": "Rituximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD20 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10434, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.zydelig", "type": "Document", "subtype": "Regulatory approval", "name": "Zydelig (idelalisib) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Zydelig (idelalisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf. Revised June 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zydelig", "drug_name_generic": "idelalisib", "first_published": "2014-10-14", "access_date": null, "publication_date": "2023-06-23", "url": "https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.zydelig:0", "indication": "Zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.", "raw_biomarkers": null, "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)", "raw_therapeutics": "Zydelig (idelalisib) in combination with rituximab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.zydelig", "type": "Document", "subtype": "Regulatory approval", "name": "Zydelig (idelalisib) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Zydelig (idelalisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf. Revised June 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zydelig", "drug_name_generic": "idelalisib", "first_published": "2014-10-14", "access_date": null, "publication_date": "2023-06-23", "url": "https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 713, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 80, "name": "TP53 somatic variants", "genes": [{"id": 52, "name": "TP53", "primaryCoding": {"id": "hgnc:11998", "code": "HGNC:11998", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11998"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000141510", "code": "ENSG00000141510", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000141510"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:7157", "code": "7157", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/7157"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000546.6", "code": "NM_000546.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000546.6"]}}], "extensions": [{"name": "location", "value": "17p13.1"}, {"name": "location_sortable", "value": "17p13.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "17"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 84, "conceptType": "Disease", "name": "Chronic Lymphocytic Leukemia", "primaryCoding": {"id": "ncit:C3163", "code": "C3163", "name": "Chronic Lymphocytic Leukemia", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3163"]}, "mappings": [{"relation": "broadMatch", "coding": {"id": "oncotree:CLLSLL", "code": "CLLSLL", "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CLLSLL"]}}]}, "objectTherapeutic": {"id": 145, "membership_operator": "AND", "therapies": [{"id": 105, "conceptType": "Drug", "name": "Idelalisib", "primaryCoding": {"id": "ncit:C78825", "code": "C78825", "name": "Idelalisib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C78825"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 60, "conceptType": "Drug", "name": "Rituximab", "primaryCoding": {"id": "ncit:C1702", "code": "C1702", "name": "Rituximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD20 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10435, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.zydelig", "type": "Document", "subtype": "Regulatory approval", "name": "Zydelig (idelalisib) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Zydelig (idelalisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf. Revised June 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zydelig", "drug_name_generic": "idelalisib", "first_published": "2014-10-14", "access_date": null, "publication_date": "2023-06-23", "url": "https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.zydelig:0", "indication": "Zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized idelalisib in combination with rituximab for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or a TP53 mutation who are not eligible for any other therapies.", "raw_biomarkers": null, "raw_cancer_type": "Chronic lymphocytic leukemia (CLL)", "raw_therapeutics": "Zydelig (idelalisib) in combination with rituximab", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.zydelig", "type": "Document", "subtype": "Regulatory approval", "name": "Zydelig (idelalisib) [product information]. EMA.", "citation": "Gilead Sciences Ireland UC. Zydelig (idelalisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf. Revised June 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zydelig", "drug_name_generic": "idelalisib", "first_published": "2014-10-14", "access_date": null, "publication_date": "2023-06-23", "url": "https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 714, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 84, "name": "17p deletion", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number (arm level)"}, {"name": "chromosome", "value": "17"}, {"name": "direction", "value": "Deletion"}, {"name": "arm", "value": "p"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 84, "conceptType": "Disease", "name": "Chronic Lymphocytic Leukemia", "primaryCoding": {"id": "ncit:C3163", "code": "C3163", "name": "Chronic Lymphocytic Leukemia", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3163"]}, "mappings": [{"relation": "broadMatch", "coding": {"id": "oncotree:CLLSLL", "code": "CLLSLL", "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CLLSLL"]}}]}, "objectTherapeutic": {"id": 145, "membership_operator": "AND", "therapies": [{"id": 105, "conceptType": "Drug", "name": "Idelalisib", "primaryCoding": {"id": "ncit:C78825", "code": "C78825", "name": "Idelalisib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C78825"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 60, "conceptType": "Drug", "name": "Rituximab", "primaryCoding": {"id": "ncit:C1702", "code": "C1702", "name": "Rituximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD20 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10436, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ceritinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.zykadia", "type": "Document", "subtype": "Regulatory approval", "name": "Zykadia (ceritinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Zykadia (ceritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf. Revised December 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zykadia", "drug_name_generic": "ceritinib", "first_published": "2015-06-04", "access_date": null, "publication_date": "2023-12-07", "url": "https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.zykadia:0", "indication": "Zykadia as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ceritinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Zykadia (ceritinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.zykadia", "type": "Document", "subtype": "Regulatory approval", "name": "Zykadia (ceritinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Zykadia (ceritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf. Revised December 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zykadia", "drug_name_generic": "ceritinib", "first_published": "2015-06-04", "access_date": null, "publication_date": "2023-12-07", "url": "https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 77, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 106, "conceptType": "Drug", "name": "Ceritinib", "primaryCoding": {"id": "ncit:C115112", "code": "C115112", "name": "Ceritinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115112"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10437, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized ceritinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.zykadia", "type": "Document", "subtype": "Regulatory approval", "name": "Zykadia (ceritinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Zykadia (ceritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf. Revised December 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zykadia", "drug_name_generic": "ceritinib", "first_published": "2015-06-04", "access_date": null, "publication_date": "2023-12-07", "url": "https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.zykadia:1", "indication": "Zykadia as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized ceritinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Zykadia (ceritinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.zykadia", "type": "Document", "subtype": "Regulatory approval", "name": "Zykadia (ceritinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Zykadia (ceritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf. Revised December 2023. Accessed March 26, 2024.", "company": "", "drug_name_brand": "Zykadia", "drug_name_generic": "ceritinib", "first_published": "2015-06-04", "access_date": null, "publication_date": "2023-12-07", "url": "https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 77, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 8, "name": "v::ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 106, "conceptType": "Drug", "name": "Ceritinib", "primaryCoding": {"id": "ncit:C115112", "code": "C115112", "name": "Ceritinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115112"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["ALK inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10438, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized tislelizumab in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% of tumor cells with no EGFR or ALK positive mutations and who have either (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC. This indication is based on BGB-A317-304, a randomized, open-label, and multicenter phase 3 study where patients were randomized (2:1) to receive tislelizumab in combination with pemetrexed and carboplatin or cisplatin (n=223) or pemetrexed and carboplatin or cisplatin (n=111), where the choice of platinum (cisplatin or carboplatin) was the investigator's choice. Tislelizumab's product information further states that the study excluded patients with active brain or leptomeningeal metastases, known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids or other immunosuppressants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tevimbra", "type": "Document", "subtype": "Regulatory approval", "name": "Tevimbra (tislelizumab) [product information]. EMA.", "citation": "BeiGene Ireland Ltd. Tevimbra (tislelizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tevimbra", "drug_name_generic": "tislelizumab", "first_published": "2023-10-02", "access_date": null, "publication_date": "2024-07-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tevimbra:0", "indication": "Tevimbra in combination with pemetrexed and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous NSCLC whose tumors have PD-L1 expression on >= 50% of tumor cells with no EGFR or ALK positive mutations and who have (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized tislelizumab in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% of tumor cells with no EGFR or ALK positive mutations and who have either (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC. This indication is based on BGB-A317-304, a randomized, open-label, and multicenter phase 3 study where patients were randomized (2:1) to receive tislelizumab in combination with pemetrexed and carboplatin or cisplatin (n=223) or pemetrexed and carboplatin or cisplatin (n=111), where the choice of platinum (cisplatin or carboplatin) was the investigator's choice. Tislelizumab's product information further states that the study excluded patients with active brain or leptomeningeal metastases, known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids or other immunosuppressants.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tevimbra (tislelizumab) in combination with pemetrexed and platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tevimbra", "type": "Document", "subtype": "Regulatory approval", "name": "Tevimbra (tislelizumab) [product information]. EMA.", "citation": "BeiGene Ireland Ltd. Tevimbra (tislelizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tevimbra", "drug_name_generic": "tislelizumab", "first_published": "2023-10-02", "access_date": null, "publication_date": "2024-07-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 715, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 39, "name": "PD-L1 >= 50%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.5"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 146, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 107, "conceptType": "Drug", "name": "Tislelizumab", "primaryCoding": {"id": "ncit:C121775", "code": "C121775", "name": "Tislelizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121775"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10439, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized tislelizumab in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% of tumor cells with no EGFR or ALK positive mutations and who have either (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC. This indication is based on BGB-A317-304, a randomized, open-label, and multicenter phase 3 study where patients were randomized (2:1) to receive tislelizumab in combination with pemetrexed and carboplatin or cisplatin (n=223) or pemetrexed and carboplatin or cisplatin (n=111), where the choice of platinum (cisplatin or carboplatin) was the investigator's choice. Tislelizumab's product information further states that the study excluded patients with active brain or leptomeningeal metastases, known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids or other immunosuppressants.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.tevimbra", "type": "Document", "subtype": "Regulatory approval", "name": "Tevimbra (tislelizumab) [product information]. EMA.", "citation": "BeiGene Ireland Ltd. Tevimbra (tislelizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tevimbra", "drug_name_generic": "tislelizumab", "first_published": "2023-10-02", "access_date": null, "publication_date": "2024-07-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.tevimbra:0", "indication": "Tevimbra in combination with pemetrexed and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous NSCLC whose tumors have PD-L1 expression on >= 50% of tumor cells with no EGFR or ALK positive mutations and who have (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized tislelizumab in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% of tumor cells with no EGFR or ALK positive mutations and who have either (i) locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or (ii) metastatic NSCLC. This indication is based on BGB-A317-304, a randomized, open-label, and multicenter phase 3 study where patients were randomized (2:1) to receive tislelizumab in combination with pemetrexed and carboplatin or cisplatin (n=223) or pemetrexed and carboplatin or cisplatin (n=111), where the choice of platinum (cisplatin or carboplatin) was the investigator's choice. Tislelizumab's product information further states that the study excluded patients with active brain or leptomeningeal metastases, known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids or other immunosuppressants.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Tevimbra (tislelizumab) in combination with pemetrexed and platinum-based chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.tevimbra", "type": "Document", "subtype": "Regulatory approval", "name": "Tevimbra (tislelizumab) [product information]. EMA.", "citation": "BeiGene Ireland Ltd. Tevimbra (tislelizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.", "company": "", "drug_name_brand": "Tevimbra", "drug_name_generic": "tislelizumab", "first_published": "2023-10-02", "access_date": null, "publication_date": "2024-07-25", "url": "https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 716, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 39, "name": "PD-L1 >= 50%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "PD-L1"}, {"name": "unit", "value": "Tumor Proportion Score (TPS)"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.5"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 147, "membership_operator": "AND", "therapies": [{"id": 107, "conceptType": "Drug", "name": "Tislelizumab", "primaryCoding": {"id": "ncit:C121775", "code": "C121775", "name": "Tislelizumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121775"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10440, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.rybrevant", "type": "Document", "subtype": "Regulatory approval", "name": "Rybrevant (amivantamab) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Rybrevant (amivantamab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf. Revised July 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Rybrevant", "drug_name_generic": "amivantamab", "first_published": "2022-02-01", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.rybrevant:0", "indication": "Rybrevant is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Rybrevant (amivantamab) in combination with carboplatin and pemetrexed", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.rybrevant", "type": "Document", "subtype": "Regulatory approval", "name": "Rybrevant (amivantamab) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Rybrevant (amivantamab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf. Revised July 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Rybrevant", "drug_name_generic": "amivantamab", "first_published": "2022-02-01", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 26, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 86, "name": "EGFR Exon 20 (Insertion)", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "variant_annotation", "value": "Insertion"}, {"name": "exon", "value": "20"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 6, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 108, "conceptType": "Drug", "name": "Amivantamab", "primaryCoding": {"id": "ncit:C124993", "code": "C124993", "name": "Amivantamab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10441, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized amivantamab as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations, after failure of platinum-based chemotherapy.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.rybrevant", "type": "Document", "subtype": "Regulatory approval", "name": "Rybrevant (amivantamab) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Rybrevant (amivantamab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf. Revised July 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Rybrevant", "drug_name_generic": "amivantamab", "first_published": "2022-02-01", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.rybrevant:1", "indication": "Rybrevant is indicated as monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum-based chemotherapy.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized amivantamab as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations, after failure of platinum-based chemotherapy.", "raw_biomarkers": null, "raw_cancer_type": "Non-small cell lung cancer", "raw_therapeutics": "Rybrevant (amivantamab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.rybrevant", "type": "Document", "subtype": "Regulatory approval", "name": "Rybrevant (amivantamab) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Rybrevant (amivantamab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf. Revised July 2024. Accessed August 25, 2024.", "company": "", "drug_name_brand": "Rybrevant", "drug_name_generic": "amivantamab", "first_published": "2022-02-01", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 27, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 86, "name": "EGFR Exon 20 (Insertion)", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "variant_annotation", "value": "Insertion"}, {"name": "exon", "value": "20"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 108, "conceptType": "Drug", "name": "Amivantamab", "primaryCoding": {"id": "ncit:C124993", "code": "C124993", "name": "Amivantamab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["EGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10442, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.truqap:0", "indication": "TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Truqap (capivasertib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 717, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 87, "name": "PIK3CA somatic variants", "genes": [{"id": 41, "name": "PIK3CA", "primaryCoding": {"id": "hgnc:8975", "code": "HGNC:8975", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_006218.4", "code": "NM_006218.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000121879", "code": "ENSG00000121879", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000121879"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5290", "code": "5290", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5290"]}}], "extensions": [{"name": "location", "value": "3q26.32"}, {"name": "location_sortable", "value": "03q26.32"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 12, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 109, "conceptType": "Drug", "name": "Capivasertib", "primaryCoding": {"id": "ncit:C102564", "code": "C102564", "name": "Capivasertib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10443, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.truqap:0", "indication": "TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Truqap (capivasertib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 718, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 88, "name": "PIK3CA amplification", "genes": [{"id": 41, "name": "PIK3CA", "primaryCoding": {"id": "hgnc:8975", "code": "HGNC:8975", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_006218.4", "code": "NM_006218.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000121879", "code": "ENSG00000121879", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000121879"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5290", "code": "5290", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5290"]}}], "extensions": [{"name": "location", "value": "3q26.32"}, {"name": "location_sortable", "value": "03q26.32"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 12, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 109, "conceptType": "Drug", "name": "Capivasertib", "primaryCoding": {"id": "ncit:C102564", "code": "C102564", "name": "Capivasertib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10444, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.truqap:0", "indication": "TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Truqap (capivasertib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 58, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 89, "name": "AKT1 amplification", "genes": [{"id": 1, "name": "AKT1", "primaryCoding": {"id": "hgnc:391", "code": "HGNC:391", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_001382430.1", "code": "NM_001382430.1", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000142208", "code": "ENSG00000142208", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000142208"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:207", "code": "207", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/207"]}}], "extensions": [{"name": "location", "value": "14q32.33"}, {"name": "location_sortable", "value": "14q32.33"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Amplification"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 12, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 109, "conceptType": "Drug", "name": "Capivasertib", "primaryCoding": {"id": "ncit:C102564", "code": "C102564", "name": "Capivasertib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10445, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.truqap:0", "indication": "TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Truqap (capivasertib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 55, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 90, "name": "AKT1 somatic variants", "genes": [{"id": 1, "name": "AKT1", "primaryCoding": {"id": "hgnc:391", "code": "HGNC:391", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_001382430.1", "code": "NM_001382430.1", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000142208", "code": "ENSG00000142208", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000142208"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:207", "code": "207", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/207"]}}], "extensions": [{"name": "location", "value": "14q32.33"}, {"name": "location_sortable", "value": "14q32.33"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "14"}, {"name": "requires_oncogenic", "value": true}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 12, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 109, "conceptType": "Drug", "name": "Capivasertib", "primaryCoding": {"id": "ncit:C102564", "code": "C102564", "name": "Capivasertib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10446, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.truqap:0", "indication": "TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Truqap (capivasertib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 61, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 91, "name": "PTEN nonsense variants", "genes": [{"id": 43, "name": "PTEN", "primaryCoding": {"id": "hgnc:9588", "code": "HGNC:9588", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_000314.8", "code": "NM_000314.8", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171862", "code": "ENSG00000171862", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171862"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5728", "code": "5728", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5728"]}}], "extensions": [{"name": "location", "value": "10q23.31"}, {"name": "location_sortable", "value": "10q23.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "10"}, {"name": "variant_annotation", "value": "Nonsense"}, {"name": "requires_oncogenic", "value": true}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 12, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 109, "conceptType": "Drug", "name": "Capivasertib", "primaryCoding": {"id": "ncit:C102564", "code": "C102564", "name": "Capivasertib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10447, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.truqap:0", "indication": "TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Truqap (capivasertib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 64, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 92, "name": "PTEN frameshift variants", "genes": [{"id": 43, "name": "PTEN", "primaryCoding": {"id": "hgnc:9588", "code": "HGNC:9588", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_000314.8", "code": "NM_000314.8", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171862", "code": "ENSG00000171862", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171862"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5728", "code": "5728", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5728"]}}], "extensions": [{"name": "location", "value": "10q23.31"}, {"name": "location_sortable", "value": "10q23.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "10"}, {"name": "variant_annotation", "value": "Frameshift"}, {"name": "requires_oncogenic", "value": true}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 12, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 109, "conceptType": "Drug", "name": "Capivasertib", "primaryCoding": {"id": "ncit:C102564", "code": "C102564", "name": "Capivasertib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10448, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.truqap:0", "indication": "TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Truqap (capivasertib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 67, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 93, "name": "PTEN splice site variants", "genes": [{"id": 43, "name": "PTEN", "primaryCoding": {"id": "hgnc:9588", "code": "HGNC:9588", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_000314.8", "code": "NM_000314.8", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171862", "code": "ENSG00000171862", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171862"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5728", "code": "5728", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5728"]}}], "extensions": [{"name": "location", "value": "10q23.31"}, {"name": "location_sortable", "value": "10q23.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "10"}, {"name": "variant_annotation", "value": "Splice Site"}, {"name": "requires_oncogenic", "value": true}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 12, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 109, "conceptType": "Drug", "name": "Capivasertib", "primaryCoding": {"id": "ncit:C102564", "code": "C102564", "name": "Capivasertib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10449, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.truqap:0", "indication": "TRUQAP is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, TRUQAP plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practices should be considered.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized capivasertib in combination with fulvestrant for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. Capivasertib's product information further states that in pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. The product information further states that, for men, administration of LHRH agonist according to current clinical practices should be considered. This indication is based on CAPItello-291, a randomized, double-blind, placebo-controlled trial, where HER2-negative status was defined as either IHC 0 or 1+, or IHC 2+/ISH-, and qualifying alterations were activating mutations in PIK3CA and AKT1 and inactivating mutations in PTEN.", "raw_biomarkers": null, "raw_cancer_type": "locally advanced or metastatic breast cancer", "raw_therapeutics": "Truqap (capivasertib) in combination with fulvestrant", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.truqap", "type": "Document", "subtype": "Regulatory approval", "name": "Truqap (capivasertib) [product information]. EMA.", "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.", "company": "", "drug_name_brand": "Truqap", "drug_name_generic": "capivasertib", "first_published": "2024-07-11", "access_date": null, "publication_date": "2024-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 70, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 94, "name": "PTEN deletion", "genes": [{"id": 43, "name": "PTEN", "primaryCoding": {"id": "hgnc:9588", "code": "HGNC:9588", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_000314.8", "code": "NM_000314.8", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171862", "code": "ENSG00000171862", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171862"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:5728", "code": "5728", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/5728"]}}], "extensions": [{"name": "location", "value": "10q23.31"}, {"name": "location_sortable", "value": "10q23.31"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Copy Number"}, {"name": "present", "value": true}, {"name": "direction", "value": "Deletion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 12, "membership_operator": "AND", "therapies": [{"id": 30, "conceptType": "Drug", "name": "Fulvestrant", "primaryCoding": {"id": "ncit:C1379", "code": "C1379", "name": "Fulvestrant", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 109, "conceptType": "Drug", "name": "Capivasertib", "primaryCoding": {"id": "ncit:C102564", "code": "C102564", "name": "Capivasertib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PI3K/AKT/mTOR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10458, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.balversa:0", "indication": "Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "raw_biomarkers": null, "raw_cancer_type": "urothelial carcinoma", "raw_therapeutics": "Balversa (erdafitinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 719, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 95, "name": "FGFR2::BICC1", "genes": [{"id": 7, "name": "BICC1", "primaryCoding": {"id": "hgnc:19351", "code": "HGNC:19351", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19351"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_001080512.3", "code": "NM_001080512.3", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_001080512.3"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000122870", "code": "ENSG00000122870", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000122870"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:80114", "code": "80114", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/80114"]}}], "extensions": [{"name": "location", "value": "10q21.1"}, {"name": "location_sortable", "value": "10q21.1"}]}, {"id": 23, "name": "FGFR2", "primaryCoding": {"id": "hgnc:3689", "code": "HGNC:3689", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_000141.5", "code": "NM_000141.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000141.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000066468", "code": "ENSG00000066468", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000066468"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2263", "code": "2263", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2263"]}}], "extensions": [{"name": "location", "value": "10q26.13"}, {"name": "location_sortable", "value": "10q26.13"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 8, "conceptType": "Disease", "name": "Bladder Urothelial Carcinoma", "primaryCoding": {"id": "oncotree:BLCA", "code": "BLCA", "name": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"]}, "mappings": []}, "objectTherapeutic": {"id": 110, "conceptType": "Drug", "name": "Erdafitinib", "primaryCoding": {"id": "ncit:C103273", "code": "C103273", "name": "Erdafitinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10459, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.balversa:0", "indication": "Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "raw_biomarkers": null, "raw_cancer_type": "urothelial carcinoma", "raw_therapeutics": "Balversa (erdafitinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 720, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 96, "name": "FGFR2::CASP7", "genes": [{"id": 12, "name": "CASP7", "primaryCoding": {"id": "hgnc:1508", "code": "HGNC:1508", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1508"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000165806", "code": "ENSG00000165806", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000165806"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:840", "code": "840", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/840"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_001227.5", "code": "NM_001227.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_001227.5"]}}], "extensions": [{"name": "location", "value": "10q25.3"}, {"name": "location_sortable", "value": "10q25.3"}]}, {"id": 23, "name": "FGFR2", "primaryCoding": {"id": "hgnc:3689", "code": "HGNC:3689", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_000141.5", "code": "NM_000141.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000141.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000066468", "code": "ENSG00000066468", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000066468"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2263", "code": "2263", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2263"]}}], "extensions": [{"name": "location", "value": "10q26.13"}, {"name": "location_sortable", "value": "10q26.13"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 8, "conceptType": "Disease", "name": "Bladder Urothelial Carcinoma", "primaryCoding": {"id": "oncotree:BLCA", "code": "BLCA", "name": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"]}, "mappings": []}, "objectTherapeutic": {"id": 110, "conceptType": "Drug", "name": "Erdafitinib", "primaryCoding": {"id": "ncit:C103273", "code": "C103273", "name": "Erdafitinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10460, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.balversa:0", "indication": "Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "raw_biomarkers": null, "raw_cancer_type": "urothelial carcinoma", "raw_therapeutics": "Balversa (erdafitinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 128, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 97, "name": "FGFR3::TACC3", "genes": [{"id": 24, "name": "FGFR3", "primaryCoding": {"id": "hgnc:3690", "code": "HGNC:3690", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000068078", "code": "ENSG00000068078", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000068078"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2261", "code": "2261", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2261"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000142.5", "code": "NM_000142.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5"]}}], "extensions": [{"name": "location", "value": "4p16.3"}, {"name": "location_sortable", "value": "04p16.3"}]}, {"id": 51, "name": "TACC3", "primaryCoding": {"id": "hgnc:11524", "code": "HGNC:11524", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11524"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_006342.3", "code": "NM_006342.3", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_006342.3"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000013810", "code": "ENSG00000013810", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000013810"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:10460", "code": "10460", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/10460"]}}], "extensions": [{"name": "location", "value": "4p16.3"}, {"name": "location_sortable", "value": "04p16.3"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 8, "conceptType": "Disease", "name": "Bladder Urothelial Carcinoma", "primaryCoding": {"id": "oncotree:BLCA", "code": "BLCA", "name": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"]}, "mappings": []}, "objectTherapeutic": {"id": 110, "conceptType": "Drug", "name": "Erdafitinib", "primaryCoding": {"id": "ncit:C103273", "code": "C103273", "name": "Erdafitinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10461, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.balversa:0", "indication": "Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "raw_biomarkers": null, "raw_cancer_type": "urothelial carcinoma", "raw_therapeutics": "Balversa (erdafitinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 721, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 98, "name": "FGFR3::BAIAP2L1", "genes": [{"id": 4, "name": "BAIAP2L1", "primaryCoding": {"id": "hgnc:21649", "code": "HGNC:21649", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21649"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000006453", "code": "ENSG00000006453", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000006453"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:55971", "code": "55971", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/55971"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_018842.5", "code": "NM_018842.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_018842.5"]}}], "extensions": [{"name": "location", "value": "7q21.3-q22.1"}, {"name": "location_sortable", "value": "07q21.3-q22.1"}]}, {"id": 24, "name": "FGFR3", "primaryCoding": {"id": "hgnc:3690", "code": "HGNC:3690", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000068078", "code": "ENSG00000068078", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000068078"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2261", "code": "2261", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2261"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000142.5", "code": "NM_000142.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5"]}}], "extensions": [{"name": "location", "value": "4p16.3"}, {"name": "location_sortable", "value": "04p16.3"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 8, "conceptType": "Disease", "name": "Bladder Urothelial Carcinoma", "primaryCoding": {"id": "oncotree:BLCA", "code": "BLCA", "name": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"]}, "mappings": []}, "objectTherapeutic": {"id": 110, "conceptType": "Drug", "name": "Erdafitinib", "primaryCoding": {"id": "ncit:C103273", "code": "C103273", "name": "Erdafitinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10462, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.balversa:0", "indication": "Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "raw_biomarkers": null, "raw_cancer_type": "urothelial carcinoma", "raw_therapeutics": "Balversa (erdafitinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 124, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 99, "name": "FGFR3 p.R248C", "genes": [{"id": 24, "name": "FGFR3", "primaryCoding": {"id": "hgnc:3690", "code": "HGNC:3690", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000068078", "code": "ENSG00000068078", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000068078"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2261", "code": "2261", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2261"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000142.5", "code": "NM_000142.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5"]}}], "extensions": [{"name": "location", "value": "4p16.3"}, {"name": "location_sortable", "value": "04p16.3"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "4"}, {"name": "start_position", "value": 1803564}, {"name": "end_position", "value": 1803564}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.742C>T"}, {"name": "protein_change", "value": "p.R248C"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "6"}, {"name": "rsid", "value": "rs121913482"}, {"name": "hgvsg", "value": "4:g.1803564C>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 8, "conceptType": "Disease", "name": "Bladder Urothelial Carcinoma", "primaryCoding": {"id": "oncotree:BLCA", "code": "BLCA", "name": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"]}, "mappings": []}, "objectTherapeutic": {"id": 110, "conceptType": "Drug", "name": "Erdafitinib", "primaryCoding": {"id": "ncit:C103273", "code": "C103273", "name": "Erdafitinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10463, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.balversa:0", "indication": "Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "raw_biomarkers": null, "raw_cancer_type": "urothelial carcinoma", "raw_therapeutics": "Balversa (erdafitinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 125, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 100, "name": "FGFR3 p.S249C", "genes": [{"id": 24, "name": "FGFR3", "primaryCoding": {"id": "hgnc:3690", "code": "HGNC:3690", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000068078", "code": "ENSG00000068078", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000068078"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2261", "code": "2261", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2261"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000142.5", "code": "NM_000142.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5"]}}], "extensions": [{"name": "location", "value": "4p16.3"}, {"name": "location_sortable", "value": "04p16.3"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "4"}, {"name": "start_position", "value": 1803568}, {"name": "end_position", "value": 1803568}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "G"}, {"name": "cdna_change", "value": "c.746C>G"}, {"name": "protein_change", "value": "p.S249C"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "6"}, {"name": "rsid", "value": "rs121913483"}, {"name": "hgvsg", "value": "4:g.1803568C>G"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 8, "conceptType": "Disease", "name": "Bladder Urothelial Carcinoma", "primaryCoding": {"id": "oncotree:BLCA", "code": "BLCA", "name": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"]}, "mappings": []}, "objectTherapeutic": {"id": 110, "conceptType": "Drug", "name": "Erdafitinib", "primaryCoding": {"id": "ncit:C103273", "code": "C103273", "name": "Erdafitinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10464, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.balversa:0", "indication": "Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "raw_biomarkers": null, "raw_cancer_type": "urothelial carcinoma", "raw_therapeutics": "Balversa (erdafitinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 126, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 101, "name": "FGFR3 p.G370C", "genes": [{"id": 24, "name": "FGFR3", "primaryCoding": {"id": "hgnc:3690", "code": "HGNC:3690", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000068078", "code": "ENSG00000068078", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000068078"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2261", "code": "2261", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2261"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000142.5", "code": "NM_000142.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5"]}}], "extensions": [{"name": "location", "value": "4p16.3"}, {"name": "location_sortable", "value": "04p16.3"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "4"}, {"name": "start_position", "value": 1806089}, {"name": "end_position", "value": 1806089}, {"name": "reference_allele", "value": "G"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.1108G>T"}, {"name": "protein_change", "value": "p.G370C"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "8"}, {"name": "rsid", "value": "rs121913479"}, {"name": "hgvsg", "value": "4:g.1806089G>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 8, "conceptType": "Disease", "name": "Bladder Urothelial Carcinoma", "primaryCoding": {"id": "oncotree:BLCA", "code": "BLCA", "name": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"]}, "mappings": []}, "objectTherapeutic": {"id": 110, "conceptType": "Drug", "name": "Erdafitinib", "primaryCoding": {"id": "ncit:C103273", "code": "C103273", "name": "Erdafitinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10465, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.balversa:0", "indication": "Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.", "raw_biomarkers": null, "raw_cancer_type": "urothelial carcinoma", "raw_therapeutics": "Balversa (erdafitinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.balversa", "type": "Document", "subtype": "Regulatory approval", "name": "Balversa (erdafitinib) [product information]. EMA.", "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.", "company": "", "drug_name_brand": "Balversa", "drug_name_generic": "erdafitinib", "first_published": "2024-08-29", "access_date": null, "publication_date": "2024-08-29", "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 127, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 102, "name": "FGFR3 p.Y373C", "genes": [{"id": 24, "name": "FGFR3", "primaryCoding": {"id": "hgnc:3690", "code": "HGNC:3690", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000068078", "code": "ENSG00000068078", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000068078"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:2261", "code": "2261", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/2261"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_000142.5", "code": "NM_000142.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5"]}}], "extensions": [{"name": "location", "value": "4p16.3"}, {"name": "location_sortable", "value": "04p16.3"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "4"}, {"name": "start_position", "value": 1806099}, {"name": "end_position", "value": 1806099}, {"name": "reference_allele", "value": "A"}, {"name": "alternate_allele", "value": "G"}, {"name": "cdna_change", "value": "c.1118A>G"}, {"name": "protein_change", "value": "p.Y373C"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "8"}, {"name": "rsid", "value": "rs121913485"}, {"name": "hgvsg", "value": "4:g.1806099A>G"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 8, "conceptType": "Disease", "name": "Bladder Urothelial Carcinoma", "primaryCoding": {"id": "oncotree:BLCA", "code": "BLCA", "name": "Bladder Urothelial Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"]}, "mappings": []}, "objectTherapeutic": {"id": 110, "conceptType": "Drug", "name": "Erdafitinib", "primaryCoding": {"id": "ncit:C103273", "code": "C103273", "name": "Erdafitinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["FGFR inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10466, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocracinoma whose tumors are Claudin (CLDN) 18.2 positive. The product information states that eligible patients should have CLDN18.2 positive tumor defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining, assessed by a CE-marked IVD with the corresponding intended purpose. The product information further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.vyloy", "type": "Document", "subtype": "Regulatory approval", "name": "Vyloy (zolbetuximab) [product information]. EMA.", "citation": "Astellas Pharma Europe B.V. Vyloy (zolbetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Vyloy", "drug_name_generic": "zolbetuximab", "first_published": "2024-09-23", "access_date": null, "publication_date": "2024-09-23", "url": "https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.vyloy:0", "indication": "Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocracinoma whose tumors are Claudin (CLDN) 18.2 positive. The product information states that eligible patients should have CLDN18.2 positive tumor defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining, assessed by a CE-marked IVD with the corresponding intended purpose. The product information further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).", "raw_biomarkers": null, "raw_cancer_type": "Gastric or gastroesophageal junction (GEJ) adenocarcinoma", "raw_therapeutics": "Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.vyloy", "type": "Document", "subtype": "Regulatory approval", "name": "Vyloy (zolbetuximab) [product information]. EMA.", "citation": "Astellas Pharma Europe B.V. Vyloy (zolbetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Vyloy", "drug_name_generic": "zolbetuximab", "first_published": "2024-09-23", "access_date": null, "publication_date": "2024-09-23", "url": "https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 513, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 103, "name": "CLDN18.2 >= 75%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CLDN18.2"}, {"name": "unit", "value": "Percentage of tumor cells"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.75"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 2, "conceptType": "Disease", "name": "Adenocarcinoma of the Gastroesophageal Junction", "primaryCoding": {"id": "oncotree:GEJ", "code": "GEJ", "name": "Adenocarcinoma of the Gastroesophageal Junction", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ"]}, "mappings": []}, "objectTherapeutic": {"id": 96, "membership_operator": "AND", "therapies": [{"id": 28, "conceptType": "Drug", "name": "Oxaliplatin", "primaryCoding": {"id": "ncit:C1181", "code": "C1181", "name": "Oxaliplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 29, "conceptType": "Drug", "name": "Fluorouracil", "primaryCoding": {"id": "ncit:C505", "code": "C505", "name": "Fluorouracil", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 111, "conceptType": "Drug", "name": "Zolbetuximab", "primaryCoding": {"id": "ncit:C85475", "code": "C85475", "name": "Zolbetuximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C85475"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CLDN18.2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10467, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocracinoma whose tumors are Claudin (CLDN) 18.2 positive. The product information states that eligible patients should have CLDN18.2 positive tumor defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining, assessed by a CE-marked IVD with the corresponding intended purpose. The product information further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.vyloy", "type": "Document", "subtype": "Regulatory approval", "name": "Vyloy (zolbetuximab) [product information]. EMA.", "citation": "Astellas Pharma Europe B.V. Vyloy (zolbetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Vyloy", "drug_name_generic": "zolbetuximab", "first_published": "2024-09-23", "access_date": null, "publication_date": "2024-09-23", "url": "https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.vyloy:0", "indication": "Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocracinoma whose tumors are Claudin (CLDN) 18.2 positive. The product information states that eligible patients should have CLDN18.2 positive tumor defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining, assessed by a CE-marked IVD with the corresponding intended purpose. The product information further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).", "raw_biomarkers": null, "raw_cancer_type": "Gastric or gastroesophageal junction (GEJ) adenocarcinoma", "raw_therapeutics": "Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.vyloy", "type": "Document", "subtype": "Regulatory approval", "name": "Vyloy (zolbetuximab) [product information]. EMA.", "citation": "Astellas Pharma Europe B.V. Vyloy (zolbetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.", "company": "", "drug_name_brand": "Vyloy", "drug_name_generic": "zolbetuximab", "first_published": "2024-09-23", "access_date": null, "publication_date": "2024-09-23", "url": "https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 514, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 103, "name": "CLDN18.2 >= 75%", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CLDN18.2"}, {"name": "unit", "value": "Percentage of tumor cells"}, {"name": "equality", "value": ">="}, {"name": "value", "value": "0.75"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 2, "conceptType": "Disease", "name": "Adenocarcinoma of the Gastroesophageal Junction", "primaryCoding": {"id": "oncotree:GEJ", "code": "GEJ", "name": "Adenocarcinoma of the Gastroesophageal Junction", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ"]}, "mappings": []}, "objectTherapeutic": {"id": 97, "membership_operator": "AND", "therapies": [{"id": 28, "conceptType": "Drug", "name": "Oxaliplatin", "primaryCoding": {"id": "ncit:C1181", "code": "C1181", "name": "Oxaliplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 111, "conceptType": "Drug", "name": "Zolbetuximab", "primaryCoding": {"id": "ncit:C85475", "code": "C85475", "name": "Zolbetuximab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C85475"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CLDN18.2 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 38, "conceptType": "Drug", "name": "Capecitabine", "primaryCoding": {"id": "ncit:C1794", "code": "C1794", "name": "Capecitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Thymidylate synthase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10869, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:0", "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 0, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 0, "membership_operator": "AND", "therapies": [{"id": 119, "conceptType": "Drug", "name": "Tamoxifen", "primaryCoding": {"id": "ncit:C62078", "code": "C62078", "name": "Tamoxifen", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62078"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10870, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:0", "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 1, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 0, "membership_operator": "AND", "therapies": [{"id": 119, "conceptType": "Drug", "name": "Tamoxifen", "primaryCoding": {"id": "ncit:C62078", "code": "C62078", "name": "Tamoxifen", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62078"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10871, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:0", "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 2, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 0, "membership_operator": "AND", "therapies": [{"id": 119, "conceptType": "Drug", "name": "Tamoxifen", "primaryCoding": {"id": "ncit:C62078", "code": "C62078", "name": "Tamoxifen", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62078"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Estrogen receptor inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10872, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:0", "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 3, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 1, "membership_operator": "AND", "therapies": [{"id": 36, "conceptType": "Drug", "name": "Anastrozole", "primaryCoding": {"id": "ncit:C1607", "code": "C1607", "name": "Anastrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10873, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:0", "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 4, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 1, "membership_operator": "AND", "therapies": [{"id": 36, "conceptType": "Drug", "name": "Anastrozole", "primaryCoding": {"id": "ncit:C1607", "code": "C1607", "name": "Anastrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10874, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:0", "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 5, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 1, "membership_operator": "AND", "therapies": [{"id": 36, "conceptType": "Drug", "name": "Anastrozole", "primaryCoding": {"id": "ncit:C1607", "code": "C1607", "name": "Anastrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10875, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:0", "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 6, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 2, "membership_operator": "AND", "therapies": [{"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10876, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:0", "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 7, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 2, "membership_operator": "AND", "therapies": [{"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10877, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:0", "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 8, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 2, "membership_operator": "AND", "therapies": [{"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 40, "conceptType": "Drug", "name": "Letrozole", "primaryCoding": {"id": "ncit:C1527", "code": "C1527", "name": "Letrozole", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10878, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:0", "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 792, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 165, "membership_operator": "AND", "therapies": [{"id": 5, "conceptType": "Drug", "name": "Exemestane", "primaryCoding": {"id": "ncit:C1097", "code": "C1097", "name": "Exemestane", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10879, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:0", "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 793, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 165, "membership_operator": "AND", "therapies": [{"id": 5, "conceptType": "Drug", "name": "Exemestane", "primaryCoding": {"id": "ncit:C1097", "code": "C1097", "name": "Exemestane", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10880, "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone.", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.verzenios:0", "indication": "Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. Abemaciclib's product information further states that in pre- or perimenopausal women, aromatase inhibitor endrocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. The product information further states that this indication was approved based on results from the monarchE study, a randomized, open label, two cohort, phase 3 study which enrolled a total of 5,637 patients who were randomized in a 1:1 ratio to receive 2 years of abemaciclib plus physician's choice of standard endocrine therapy, or standard endocrine therapy alone. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).", "raw_biomarkers": null, "raw_cancer_type": "Breast cancer", "raw_therapeutics": "Verzenios (abemaciclib) in combination with endocrine therapy", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.verzenios", "type": "Document", "subtype": "Regulatory approval", "name": "Verzenios (abemaciclib) [product information]. EMA.", "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.", "company": "", "drug_name_brand": "Verzenios", "drug_name_generic": "abemaciclib", "first_published": "2018-10-29", "access_date": null, "publication_date": "2024-03-12", "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 794, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 3, "name": "PR positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Progesterone receptor (PR)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}, {"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 165, "membership_operator": "AND", "therapies": [{"id": 5, "conceptType": "Drug", "name": "Exemestane", "primaryCoding": {"id": "ncit:C1097", "code": "C1097", "name": "Exemestane", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Aromatase inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Hormone therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 99, "conceptType": "Drug", "name": "Abemaciclib", "primaryCoding": {"id": "ncit:C97660", "code": "C97660", "name": "Abemaciclib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CDK4/6 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10881, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.blincyto", "type": "Document", "subtype": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Blincyto", "drug_name_generic": "blinatumomab", "first_published": "2015-12-07", "access_date": null, "publication_date": "2025-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.blincyto:4", "indication": "BLINCYTO is indicated as monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome negative CD19 positive B-cell precusor acute lymphoblastic leukaemia (ALL).", "initial_approval_date": "2025-02-10", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0056-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy for the treatment of pediatric patients aged 1 month or older with high-risk first relapsed Philidelphia chromosome negative CD19 positive B-cell precursor ALL as part of the consolidation therapy.", "raw_biomarkers": "Philadelphia chromosome negative CD19 positive", "raw_cancer_type": "Acute lymphoblastic leukemia (ALL)", "raw_therapeutics": "Blincyto (blinatumomab)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.blincyto", "type": "Document", "subtype": "Regulatory approval", "name": "Blincyto (blinatumomab) [product information]. EMA.", "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Blincyto", "drug_name_generic": "blinatumomab", "first_published": "2015-12-07", "access_date": null, "publication_date": "2025-07-23", "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 46, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}, {"id": 14, "name": "CD19 +", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "CD19"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 0, "conceptType": "Disease", "name": "Acute Lymphoid Leukemia", "primaryCoding": {"id": "oncotree:ALL", "code": "ALL", "name": "Acute Lymphoid Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL"]}, "mappings": []}, "objectTherapeutic": {"id": 15, "conceptType": "Drug", "name": "Blinatumomab", "primaryCoding": {"id": "ncit:C62528", "code": "C62528", "name": "Blinatumomab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62528"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["CD19 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10882, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.bosulif", "type": "Document", "subtype": "Regulatory approval", "name": "Bosulif (bosutinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Bosulif", "drug_name_generic": "bosutinib", "first_published": "2013-04-09", "access_date": null, "publication_date": "2025-08-26", "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.bosulif:2", "indication": "Bosulif is indicated for the treatment of adult and paediatric patients aged 6 years and older with CP Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.", "initial_approval_date": "2025-08-26", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult and pediatric patients aged 6 years and older with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options.", "raw_biomarkers": "Philadelphia chromosome-positive", "raw_cancer_type": "Chronic Myelogenous Leukemia", "raw_therapeutics": "Bosulif (bosutinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.bosulif", "type": "Document", "subtype": "Regulatory approval", "name": "Bosulif (bosutinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Bosulif", "drug_name_generic": "bosutinib", "first_published": "2013-04-09", "access_date": null, "publication_date": "2025-08-26", "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 47, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 12, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 16, "conceptType": "Drug", "name": "Bosutinib", "primaryCoding": {"id": "ncit:C60809", "code": "C60809", "name": "Bosutinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C60809"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10883, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.bosulif", "type": "Document", "subtype": "Regulatory approval", "name": "Bosulif (bosutinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Bosulif", "drug_name_generic": "bosutinib", "first_published": "2013-04-09", "access_date": null, "publication_date": "2025-08-26", "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.bosulif:0", "indication": "Bosulif is indicated for the treatment of adult and paediatric patients aged 6 years and older with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).", "initial_approval_date": "2025-08-26", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult and pediatric patients aged 6 years and older with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).", "raw_biomarkers": "Philadelphia chromosome-positive", "raw_cancer_type": "Chronic Myelogenous Leukemia", "raw_therapeutics": "Bosulif (bosutinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.bosulif", "type": "Document", "subtype": "Regulatory approval", "name": "Bosulif (bosutinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Bosulif", "drug_name_generic": "bosutinib", "first_published": "2013-04-09", "access_date": null, "publication_date": "2025-08-26", "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 545, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 16, "conceptType": "Drug", "name": "Bosutinib", "primaryCoding": {"id": "ncit:C60809", "code": "C60809", "name": "Bosutinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C60809"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10884, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.bosulif", "type": "Document", "subtype": "Regulatory approval", "name": "Bosulif (bosutinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Bosulif", "drug_name_generic": "bosutinib", "first_published": "2013-04-09", "access_date": null, "publication_date": "2025-08-26", "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.bosulif:1", "indication": "Bosulif is indicated for the treatment of adult patients with accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.", "initial_approval_date": "2025-08-26", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with accelerated phase, and blast phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options.", "raw_biomarkers": "Philadelphia chromosome-positive", "raw_cancer_type": "Chronic Myelogenous Leukemia", "raw_therapeutics": "Bosulif (bosutinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.bosulif", "type": "Document", "subtype": "Regulatory approval", "name": "Bosulif (bosutinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Bosulif", "drug_name_generic": "bosutinib", "first_published": "2013-04-09", "access_date": null, "publication_date": "2025-08-26", "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 545, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 16, "conceptType": "Drug", "name": "Bosutinib", "primaryCoding": {"id": "ncit:C60809", "code": "C60809", "name": "Bosutinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C60809"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10885, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.bosulif", "type": "Document", "subtype": "Regulatory approval", "name": "Bosulif (bosutinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Bosulif", "drug_name_generic": "bosutinib", "first_published": "2013-04-09", "access_date": null, "publication_date": "2025-08-26", "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.bosulif:2", "indication": "Bosulif is indicated for the treatment of adult and paediatric patients aged 6 years and older with CP Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.", "initial_approval_date": "2025-08-26", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/bosulif-h-c-002373-x-0058-g-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult and pediatric patients aged 6 years and older with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options.", "raw_biomarkers": "Philadelphia chromosome-positive", "raw_cancer_type": "Chronic Myelogenous Leukemia", "raw_therapeutics": "Bosulif (bosutinib)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.bosulif", "type": "Document", "subtype": "Regulatory approval", "name": "Bosulif (bosutinib) [product information]. EMA.", "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised August 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Bosulif", "drug_name_generic": "bosutinib", "first_published": "2013-04-09", "access_date": null, "publication_date": "2025-08-26", "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 545, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 15, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 13, "conceptType": "Disease", "name": "Chronic Myelogenous Leukemia", "primaryCoding": {"id": "oncotree:CML", "code": "CML", "name": "Chronic Myelogenous Leukemia", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML"]}, "mappings": []}, "objectTherapeutic": {"id": 16, "conceptType": "Drug", "name": "Bosutinib", "primaryCoding": {"id": "ncit:C60809", "code": "C60809", "name": "Bosutinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C60809"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["BCR-ABL inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10886, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:4", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.", "initial_approval_date": "2025-04-28", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0048-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.", "raw_biomarkers": "Hormone receptor (HR)-positive, HER2-low or HER2-ultralow", "raw_cancer_type": "breast cancer", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 849, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 72, "name": "EGFR somatic variants", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 153, "conceptType": "Drug", "name": "Datopotamab deruxtecan", "primaryCoding": {"id": "ncit:C151967", "code": "C151967", "name": "Datopotamab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition", "Trop-2 directed antibody"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10887, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:4", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.", "initial_approval_date": "2025-04-28", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0048-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.", "raw_biomarkers": "Hormone receptor (HR)-positive, HER2-low or HER2-ultralow", "raw_cancer_type": "breast cancer", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 850, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 10, "name": "EGFR Exon 19 (Deletion)", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "variant_annotation", "value": "Deletion"}, {"name": "exon", "value": "19"}, {"name": "requires_oncogenic", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 153, "conceptType": "Drug", "name": "Datopotamab deruxtecan", "primaryCoding": {"id": "ncit:C151967", "code": "C151967", "name": "Datopotamab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition", "Trop-2 directed antibody"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10888, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:4", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.", "initial_approval_date": "2025-04-28", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0048-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.", "raw_biomarkers": "Hormone receptor (HR)-positive, HER2-low or HER2-ultralow", "raw_cancer_type": "breast cancer", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 851, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 9, "name": "EGFR p.L858R", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 55259515}, {"name": "end_position", "value": 55259515}, {"name": "reference_allele", "value": "T"}, {"name": "alternate_allele", "value": "G"}, {"name": "cdna_change", "value": "c.2573T>G"}, {"name": "protein_change", "value": "p.L858R"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "21"}, {"name": "rsid", "value": "rs121434568"}, {"name": "hgvsg", "value": "7:g.55259515T>G"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 153, "conceptType": "Drug", "name": "Datopotamab deruxtecan", "primaryCoding": {"id": "ncit:C151967", "code": "C151967", "name": "Datopotamab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition", "Trop-2 directed antibody"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10889, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:4", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.", "initial_approval_date": "2025-04-28", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0048-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.", "raw_biomarkers": "Hormone receptor (HR)-positive, HER2-low or HER2-ultralow", "raw_cancer_type": "breast cancer", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 852, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 70, "name": "EGFR p.T790M", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "start_position", "value": 55249071}, {"name": "end_position", "value": 55249071}, {"name": "reference_allele", "value": "C"}, {"name": "alternate_allele", "value": "T"}, {"name": "cdna_change", "value": "c.2369C>T"}, {"name": "protein_change", "value": "p.T790M"}, {"name": "variant_annotation", "value": "Missense"}, {"name": "exon", "value": "20"}, {"name": "rsid", "value": "rs121434569"}, {"name": "hgvsg", "value": "7:g.55249071C>T"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 153, "conceptType": "Drug", "name": "Datopotamab deruxtecan", "primaryCoding": {"id": "ncit:C151967", "code": "C151967", "name": "Datopotamab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition", "Trop-2 directed antibody"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10890, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:4", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.", "initial_approval_date": "2025-04-28", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0048-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.", "raw_biomarkers": "Hormone receptor (HR)-positive, HER2-low or HER2-ultralow", "raw_cancer_type": "breast cancer", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 853, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 86, "name": "EGFR Exon 20 (Insertion)", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Somatic Variant"}, {"name": "present", "value": true}, {"name": "chromosome", "value": "7"}, {"name": "variant_annotation", "value": "Insertion"}, {"name": "exon", "value": "20"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 153, "conceptType": "Drug", "name": "Datopotamab deruxtecan", "primaryCoding": {"id": "ncit:C151967", "code": "C151967", "name": "Datopotamab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition", "Trop-2 directed antibody"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10891, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.enhertu:4", "indication": "Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.", "initial_approval_date": "2025-04-28", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/enhertu-h-c-005124-ii-0048-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized trastuzumab deruxtecan as a monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regime.", "raw_biomarkers": "Hormone receptor (HR)-positive, HER2-low or HER2-ultralow", "raw_cancer_type": "breast cancer", "raw_therapeutics": "Enhertu (trastuzumab deruxtecan)", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.enhertu", "type": "Document", "subtype": "Regulatory approval", "name": "Enhertu (trastuzumab deruxtecan) [product information]. EMA.", "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised April 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Enhertu", "drug_name_generic": "trastuzumab deruxtecan", "first_published": "2021-02-08", "access_date": null, "publication_date": "2025-04-28", "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 854, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 2, "name": "HER2-negative", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Negative"}]}, {"id": 1, "name": "ER positive", "genes": [], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Protein expression"}, {"name": "present", "value": true}, {"name": "marker", "value": "Estrogen receptor (ER)"}, {"name": "unit", "value": "status"}, {"name": "equality", "value": "="}, {"name": "value", "value": "Positive"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 9, "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "primaryCoding": {"id": "oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA"]}, "mappings": []}, "objectTherapeutic": {"id": 153, "conceptType": "Drug", "name": "Datopotamab deruxtecan", "primaryCoding": {"id": "ncit:C151967", "code": "C151967", "name": "Datopotamab Deruxtecan", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Topoisomerase inhibition", "Trop-2 directed antibody"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10892, "type": "Statement", "description": "", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:0", "indication": "Glivec is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.", "raw_biomarkers": null, "raw_cancer_type": "Chronic Myeloid Leukemia", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 159, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 12, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 71, "conceptType": "Disease", "name": "Chronic Myeloid Leukemia, BCR-ABL1+", "primaryCoding": {"id": "oncotree:CMLBCRABL1", "code": "CMLBCRABL1", "name": "Chronic Myeloid Leukemia, BCR-ABL1+", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CMLBCRABL1"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10893, "type": "Statement", "description": "", "contributions": [{"id": 10, "type": "Contribution", "agent": {"id": 0, "type": "Agent", "subtype": "organization", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute"}, "description": "The US FDA approved datopotamab deruxtecan for the treatment of adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.", "date": "2025-09-02"}], "reportedIn": [{"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.glivec:1", "indication": "Glivec is indicated for the treatment of adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.", "initial_approval_date": null, "initial_approval_url": null, "description": "The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult and pediatric patients with Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia (CML) in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.", "raw_biomarkers": null, "raw_cancer_type": "Chronic Myeloid Leukemia", "raw_therapeutics": "Imatinib", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.glivec", "type": "Document", "subtype": "Regulatory approval", "name": "Glivec (imatinib) [product information]. EMA.", "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.", "company": "", "drug_name_brand": "Glivec", "drug_name_generic": "imatinib", "first_published": "2009-08-18", "access_date": null, "publication_date": "2023-11-20", "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 159, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 12, "name": "BCR::ABL1", "genes": [{"id": 0, "name": "ABL1", "primaryCoding": {"id": "hgnc:76", "code": "HGNC:76", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000097007", "code": "ENSG00000097007", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000097007"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:25", "code": "25", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/25"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_005157.6", "code": "NM_005157.6", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6"]}}], "extensions": [{"name": "location", "value": "9q34.12"}, {"name": "location_sortable", "value": "09q34.12"}]}, {"id": 6, "name": "BCR", "primaryCoding": {"id": "hgnc:1014", "code": "HGNC:1014", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000186716", "code": "ENSG00000186716", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000186716"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:613", "code": "613", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/613"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004327.4", "code": "NM_004327.4", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4"]}}], "extensions": [{"name": "location", "value": "22q11.23"}, {"name": "location_sortable", "value": "22q11.23"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Rearrangement"}, {"name": "present", "value": true}, {"name": "rearrangement_type", "value": "Fusion"}]}], "subjectVariant": {}, "conditionQualifier": {"id": 71, "conceptType": "Disease", "name": "Chronic Myeloid Leukemia, BCR-ABL1+", "primaryCoding": {"id": "oncotree:CMLBCRABL1", "code": "CMLBCRABL1", "name": "Chronic Myeloid Leukemia, BCR-ABL1+", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CMLBCRABL1"]}, "mappings": []}, "objectTherapeutic": {"id": 41, "conceptType": "Drug", "name": "Imatinib", "primaryCoding": {"id": "ncit:C62035", "code": "C62035", "name": "Imatinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Bcr-Abl inhibition", "c-Kit inhibition", "PDGF-R inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}}}, {"id": 10894, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.imfinzi:3", "indication": "IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements.", "initial_approval_date": "2025-06-18", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-004771-ii-0064-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and no EGFR mutations or ALK rearrangements. This indication is based on AEGEAN (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.", "raw_biomarkers": "no EGFR mutations or ALK rearrangements", "raw_cancer_type": "NSCLC", "raw_therapeutics": "IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 474, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 25, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 35, "conceptType": "Drug", "name": "Paclitaxel", "primaryCoding": {"id": "ncit:C1411", "code": "C1411", "name": "Paclitaxel", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Taxane-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10895, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.imfinzi:3", "indication": "IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements.", "initial_approval_date": "2025-06-18", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-004771-ii-0064-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and no EGFR mutations or ALK rearrangements. This indication is based on AEGEAN (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.", "raw_biomarkers": "no EGFR mutations or ALK rearrangements", "raw_cancer_type": "NSCLC", "raw_therapeutics": "IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 475, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 87, "membership_operator": "AND", "therapies": [{"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 50, "conceptType": "Drug", "name": "Gemcitabine", "primaryCoding": {"id": "ncit:C66876", "code": "C66876", "name": "Gemcitabine", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antimetabolite"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10896, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.imfinzi:3", "indication": "IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements.", "initial_approval_date": "2025-06-18", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-004771-ii-0064-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and no EGFR mutations or ALK rearrangements. This indication is based on AEGEAN (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.", "raw_biomarkers": "no EGFR mutations or ALK rearrangements", "raw_cancer_type": "NSCLC", "raw_therapeutics": "IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 476, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 88, "membership_operator": "AND", "therapies": [{"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 39, "conceptType": "Drug", "name": "Cisplatin", "primaryCoding": {"id": "ncit:C376", "code": "C376", "name": "Cisplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}, {"id": 10897, "type": "Statement", "description": "", "contributions": [], "reportedIn": [{"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}], "direction": "supports", "indication": {"id": "ind:ema.imfinzi:3", "indication": "IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements.", "initial_approval_date": "2025-06-18", "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-004771-ii-0064-epar-assessment-report-variation_en.pdf", "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and no EGFR mutations or ALK rearrangements. This indication is based on AEGEAN (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.", "raw_biomarkers": "no EGFR mutations or ALK rearrangements", "raw_cancer_type": "NSCLC", "raw_therapeutics": "IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment", "icd10": null, "regimen_code": null, "reimbursement_category": null, "reimbursement_date": null, "reimbursement_details": null, "date_regular_approval": null, "date_accelerated_approval": null, "document": {"id": "doc:ema.imfinzi", "type": "Document", "subtype": "Regulatory approval", "name": "Imfinzi (durvalumab) [product information]. EMA.", "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.", "company": "", "drug_name_brand": "Imfinzi", "drug_name_generic": "durvalumab", "first_published": "2018-10-30", "access_date": null, "publication_date": "2025-07-11", "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf", "url_drug": null, "application_number": null, "organization": {"id": "ema", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union.", "url": "https://www.ema.europa.eu/en/medicines", "last_updated": "2024-10-20"}}}, "proposition": {"id": 477, "type": "VariantTherapeuticResponseProposition", "predicate": "predictSensitivityTo", "biomarkers": [{"id": 35, "name": "Wild type EGFR", "genes": [{"id": 17, "name": "EGFR", "primaryCoding": {"id": "hgnc:3236", "code": "HGNC:3236", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236"]}, "mappings": [{"relation": "relatedMatch", "coding": {"id": "refseq:NM_005228.5", "code": "NM_005228.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5"]}}, {"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000146648", "code": "ENSG00000146648", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000146648"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:1956", "code": "1956", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/1956"]}}], "extensions": [{"name": "location", "value": "7p11.2"}, {"name": "location_sortable", "value": "07p11.2"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}, {"id": 34, "name": "Wild type ALK", "genes": [{"id": 2, "name": "ALK", "primaryCoding": {"id": "hgnc:427", "code": "HGNC:427", "name": null, "system": "https://genenames.org", "systemVersion": null, "iris": ["https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"]}, "mappings": [{"relation": "exactMatch", "coding": {"id": "ensembl:ensg00000171094", "code": "ENSG00000171094", "name": null, "system": "https://www.ensembl.org", "systemVersion": null, "iris": ["https://www.ensembl.org/id/ENSG00000171094"]}}, {"relation": "exactMatch", "coding": {"id": "ncbi:238", "code": "238", "name": null, "system": "https://www.ncbi.nlm.nih.gov/gene", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/gene/238"]}}, {"relation": "relatedMatch", "coding": {"id": "refseq:NM_004304.5", "code": "NM_004304.5", "name": null, "system": "https://www.ncbi.nlm.nih.gov/nuccore", "systemVersion": null, "iris": ["https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"]}}], "extensions": [{"name": "location", "value": "2p23.2-p23.1"}, {"name": "location_sortable", "value": "02p23.2-p23.1"}]}], "type": "CategoricalVariant", "extensions": [{"name": "biomarker_type", "value": "Wild type"}, {"name": "present", "value": true}]}], "subjectVariant": {}, "conditionQualifier": {"id": 47, "conceptType": "Disease", "name": "Non-Small Cell Lung Cancer", "primaryCoding": {"id": "oncotree:NSCLC", "code": "NSCLC", "name": "Non-Small Cell Lung Cancer", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2021_11_02", "iris": ["https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC"]}, "mappings": []}, "objectTherapeutic": {"id": 89, "membership_operator": "AND", "therapies": [{"id": 37, "conceptType": "Drug", "name": "Carboplatin", "primaryCoding": {"id": "ncit:C1282", "code": "C1282", "name": "Carboplatin", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Platinum-based chemotherapy"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 44, "conceptType": "Drug", "name": "Durvalumab", "primaryCoding": {"id": "ncit:C103194", "code": "C103194", "name": "Durvalumab", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["PD-1/PD-L1 inhibition"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Immunotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}, {"id": 49, "conceptType": "Drug", "name": "Pemetrexed", "primaryCoding": {"id": "ncit:C61614", "code": "C61614", "name": "Pemetrexed", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": ["https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614"]}, "mappings": [], "extensions": [{"name": "therapy_strategy", "value": ["Antifolate"], "description": "Associated therapeutic strategy or mechanism of action of the therapy."}, {"name": "therapy_type", "value": "Chemotherapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"}]}]}}}]